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Abstract 
Peptide natural products have diverse, elaborate scaffolds and are important leads in the 
development of new drugs.  A complete understanding of the natural biosynthetic 
pathways of these compounds can improve chemical syntheses and boost bioengineering 
efforts.  There are two classes of peptide natural products: ribosomal and nonribosomal 
peptides.  Ribosomally produced and posttranslationally modified peptides (RiPPs) are 
produced by the ribosome using the 20 canonical amino acids and undergo extensive 
tailoring to yield the active natural products.  Nonribosomal peptides (NRPs) are 
assembled through an enzyme dependent system and can incorporate over 500 different 
amino and acyl building blocks to impart complexity.  These peptides can also undergo 
additional tailoring to further modify the core peptide.   
 The microviridins are a class of RiPPs that are modified by two ATP dependent 
ligases to create a total of three macrocyclic bonds.  We have solved the three 
dimensional protein structures of each of these ligases to establish the mechanism of 
substrate recognition and cyclization.  Vancomycin is a NRP that contains five 
nonproteinogenic aromatic amino acids that are necessary for biological activity.  One of 
these amino acids is derived from a polyketide pathway and undergoes a four-electron 
oxidation by a cofactor independent dioxygenase, DpgC.  We have solved the structure of 
this enzyme and have established a radical mechanism.  We have investigated this 
mechanism using synthetic probes and mutagenesis.  We have examined O2 binding 
using molecular dynamics and mutagenesis.  NRPs are synthesized by the multidomain, 
modular nonribosomal peptide synthetases (NRPSs) in an enzyme templated, ATP-
dependent manner.  We have synthesized domain specific probes to study the structures 
and mechanisms of these pathways.  Our continued work will provide the insight 
necessary to manipulate these pathways to provide biologically active compounds.   
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Chapter 1:  Informal Introduction to this Thesis 
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 As a member of the Bruner lab I have had the opportunity to work on a wide 
variety of projects.  As such, this introduction will be more of an overview of the skills 
and techniques I have mastered rather than containing extensive background on all my 
projects.  Sufficient background information to introduce each project will be located at 
the beginning of each chapter, with one chapter per project.    
 One of the main reasons I was attracted to the lab was because of the 
interdisciplinary nature of much of work performed.  I came to graduate school with only 
minimal undergraduate research experience solely in the field of organic synthesis.  
Every lab member I spoke with before joining the group wooed me with stories of their 
projects investigating the biosynthesis of antibiotics and anticancer compounds using 
synthetic chemistry, microbiology, and enzymology.   I joined the lab excited to learn 
new things and I haven’t been disappointed. 
 The overall theme of my research over the past several years has been 
investigating the biosynthesis of peptide natural products. The goal of my work has been 
to use synthetic chemistry, structural biology, and biochemistry to understand the 
biosynthetic mechanisms used by bacteria and fungi to construct natural products.  Our 
hope is that with a clear understanding of the proteins involved, we can engineer these 
pathways to create novel compounds and aid in the discovery of new therapeutics.   
I have had the opportunity to work on a well established project investigating the 
mechanism of cofactor independent dioxygenation by DpgC.  When I joined the lab, two 
papers had recently been published by other lab members, which discussed the complete 
protein-inhibitor structure and kinetic parameters for wild-type protein, mutants, and 
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alternate substrates.  This allowed me to use the insight gained from this data to target 
specific questions regarding the mechanism of this unique protein.   
 I also began work early on in my graduate studies investigating the interdomain 
interactions and multidomain structure of nonribosomal peptide syntheases (NRPS).  
Initial work in the lab had provided the protein construct and diffraction quality crystals, 
but phase information had not been obtained to solve the structure. We knew other labs 
were working on similar projects so I initially sought to solve the phases using a simple 
method of heavy atom incorporation, but had little success.   In mid-2008, the group of 
Prof. M. Marahiel published a structure of a complete NRPS termination module in 
Science and this project was pushed to the backburner.  When I came back to this project 
it was with renewed focus and a design that would allow us to obtain the structure of our 
NRPS protein, but also would ensure that we could get more detailed information from 
this structure that had been lacking from the first structure.   
 The final project I will discuss in this thesis involves the investigation of a pair of 
proteins that are involved in the biosynthesis of the microviridins, which are the only 
tricyclic ribosomally derived peptides identified to date.  I was brought on to this project 
most recently when structural studies of these proteins suffered due to poor quality 
crystals.  I was able to solve this problem by co-crystallizing each protein with its peptide 
substrate.  I performed other experiments to investigate questions that have arisen in the 
literature surrounding the role of these proteins in the biosynthesis of the microviridins.   
 Each of these projects has allowed me to become a well-rounded scientist.  I have 
mastered DNA manipulation techniques including PCR cloning and site directed 
mutagenesis.  I have learned the techniques that are most important to ensure success in 
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these areas, and the tricks of the trade to use in difficult cases.  I can quickly utilitze the 
bioinformatic tools available to design and create different gene constructs to suit our 
research goals.   
 I have gained experience in protein expression using E. coli as a host.  I have used 
vectors designed for protein expression under control of the lac and ara operons which 
also contain a hexa histidine tag for easy purification. I have optimized expression levels 
by varying growth media, induction cell density, induction temperature, inductant 
concentration, and protein sequence.   I have also expressed native proteins directly, 
which lack any affinity tag for use in detecting protein complexes. 
 Inclusion of the hexa histidine tag in the protein sequence allows for purification 
of the desired protein using immobilized metal affinity chromatography (IMAC).  
Specifically we use nickel-nitrilotriacetic acid (Ni-NTA) that is bound to resin.  The 
mobile histidines of the tag in the protein of interest can coordinate to the Ni within the 
resin with low nonspecific binding by other E. coli proteins.  This step can result in 
protein that is greater than 90% pure.  For X-ray crystallography protein purity is 
essential, so I have optimized further steps of ion exchange and size exclusion 
chromatography to yield the highest purity protein possible which retains its active 
conformation necessary for successful crystallization.  I have also used LC-MS to 
determine protein purity and to verify protein sequence. 
 Once large amounts of pure protein have been produced, crystal screening can 
occur.  I have screened proteins for crystallization using commercial and homemade 
screens at 4 °C and 20 °C by manual setup and also using the Phoenix crystallization 
robot.  I have learned to identify promising crystal hits and optimize those hits by varying 
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the crystallization buffer condition and using micro- and macroseeding and co-
crystallization with ligands.  I can also use the techniques of reductive methylation and 
partial proteolysis to promote improved crystal packing interactions.  When high quality 
crystals are obtained, I have developed successful cryoprotectant conditions for X-ray 
diffraction data collection at cryogenic temperatures on both home and synchrotron 
radiation sources.  I can process raw data images easily and identify data of the highest 
quality for structure solution.  I have mastered the use of Phenix for structure solution and 
refinement and Coot for manual model building.   
 In addition to experimentally determined protein structures, I have also used 
Rosetta and PyRosetta to build de novo protein models and to model alternate loop 
positions.  Additional features of Rosettta software suite include simple energy 
minimizations and protein-protein and protein-ligand docking.   
 I have used the tools of organic chemistry to design and synthesize protein 
substrates for use in assays and inhibitors to specifically target enzyme active sites for use 
in crystallography.  I have gained experience with synthetic design using available 
resources.  I can track reaction progress using TLC and LC-MS.  I have optimized 
synthetic steps for highest yield and conducted normal and reverse phase chromatography 
to yield pure samples.  I have analyzed samples by NMR and MS to obtain data to direct 
further research efforts.   
 Finally, I have developed and modified existing enzyme assay methodologies to 
suit our specific needs.  I have used reporter assays to allow for spectroscopic detection 
of reaction progress to determine initial rates necessary to determine Michaelis-Menten 
kinetic parameters.  I have adapted a simple HPLC assay meant only to detect the 
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presence of products to allow for time dependent detection to determine kinetic 
parameters.  I have also developed LC-MS methologies to detect reaction products and to 
direct HPLC assays.  I have used ITC to determine substrate and inhibitor binding 
affinities, protein-protein interactions, and also to determine kinetic parameters.   
 I hope this short introduction provides an overview of the kind of work that will 
be discussed in the coming chapters.  I have learned many techniques over the last few 
years, but the most important thing I’ve learned in graduate school is how to use the tools 
at hand to solve any problem.  Though my formal education is nearing the end, I look 
forward to all the possibilities the future holds and know that I will spend my life trying 
to satisfy my scientific curiosity.    
  
 
 
 
 
Chapter 2:  Structural and Functional Studies of the ATP 
Grasp ligases, MdnJB and MdnJC, involved in the 
biosynthesis of Microviridin J 
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2.1  Introduction to Ribosomal Natural Products 
Natural products produced as secondary metabolites by bacteria, fungi, plants and 
other organisms have found clinical use as drugs for a variety of human ailments (Figure 
1).1 Extracts of willow bark, which contain salicylic acid, have been used since antiquity 
to treat pain and fever.  Acetylsalicyclic acid was first synthesized by French and German 
chemists in the mid 1800s and later developed by Bayer and marketed as Asprin in 
1897.2-5 Alexander Flemming is often acknowledged as the first person to discover 
penicillin in 1929.  He noticed that a petri dish containing Staphylococcus had been 
contaminated by a blue mold, which had caused a halo of inhibition surrounding it.6  It 
took many years and many other scientists of the day, but penicillin was eventually mass-
produced from a related strain of Penicillium in sufficient quantities to make a huge 
impact on the health of wounded soldiers during World War II.7  Lovastatin was the first 
statin marketed as a cholesterol-lowering drug by Merck in 1987.8  It was originally 
isolated from Aspergillus terreus and launched further research into HMG-CoA reductase 
inhibitors, which today include the synthetic statin Lipitor (Pfizer), which is the best 
selling drug in pharmaceutical history.9   
It is clear that natural products remain an important lead for drug development 
efforts.  Their activities range from antibiotic, antifungal, anticancer, immunosuppressive, 
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Figure 1:  Structures of medically relevant natural products isolated from bacteria and plants 
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anti-inflammatory, and others.  The chemical structures of these products are diverse and 
intricate.  Major classes of natural products include ribosomal peptides (RiPP), 
nonribosomal peptides (NRP), polyketides (PK), alkaloids, and terpenes.1  Numerous 
total syntheses have been completed, but often in low efficiency.10-12  As such, 
investigations into the biosynthetic routes used by the producing organisms have value 
for several reasons.  First, such investigations can lead to improving chemical methods to 
adopt so-called “bio-mimetic” syntheses.  Second, these pathways may reveal 
opportunities to improve production of the natural product by the producing organism.  
And finally, these pathways may reveal even better opportunities to modify the existing 
pathways to produce an array of analogs that could provide improved pharmaceutical 
properties.   
Ribosomal peptides (RiPPs) are no different.  In recent years, many RiPPs with 
various core architectures and interesting activities have been identified.13,14,15  The long-
standing idea that peptides would not be suitable drugs owing to their fast metabolism in 
humans has been disproven.  Simple modifications of the peptides have been shown to 
afford protection against proteases responsible for the natural metabolism.  RiPPs provide 
a tremendous opportunity for bioengineering efforts as the primary amino acid sequence 
of the products can be altered by using simple genetic approaches to produce to a library 
of altered peptide backbones.  The limitation lies with the fact that only 20 amino acids 
are commonly available for incorporation by the ribosome.  As a comparison, more than 
300 monomers are available in NRP pathways.  However, this limitation has not inhibited 
RiPPs from reaching wide structural diversity.  Post-translational modifications to the 
core peptide have allowed RiPPs to reach vast chemical space and have created a wide 
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array of scaffolds suitable for use in drug design.  These easily produced and engineered 
peptides may be helpful in perturbing protein-protein interactions involved in signaling 
pathways that are often considered “undruggable.”  The best way to take advantage of 
RiPP pathways is to gain a full understanding of the structural diversity possible in these 
systems. 
 
2.2  Structural Diversity in Ribosomal Peptides 
RiPP pathways are often, but not always, contained in fairly small gene clusters.  
The main requirement is a gene representing the precursor peptide that will encode for 
both the core peptide that will become the natural product and a leader or follower 
peptide to help direct the subsequent tailoring steps.16-20  These precursor peptides range 
in length from ~20-110 amino acids in length.15  Once the peptide is translated by the 
ribosome it is acted on by a wide variety of enzymes that can modify the main chain and 
side chains to increase structural rigidity and increase affinity for its target.  Many 
bacterial systems have been studied to date and an overview of each type of modification 
will be given. 
 Dehydration of serine and threonine residues to 2,3-didehydroalanine and (Z)-2,3-
didehydrobutyrine is common among RiPPs and proteins.21-24  Introduction of the 
electrophilic olefin is accomplished by a class of enzymes characterized by LanB, the 
dehydratase involved in lantibiotic biosynthesis (Figure 2).  LctM is the dehydratase in 
the pathway to lacticin 481 and, after recombinant expression in E. coli, was found to 
utilize Mg2+ and ATP to phosphorylate the side chain hydroxyls on the peptide as a 
means towards dehydration.25  Later, attack by a cysteine thiol results in creation of the 
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lanthionine moiety.26  The precursor peptide in this pathway has four possible 
dehydrations and mutagenesis revealed that not only does LctM accept shorter substrates, 
but when a cysteine residue was mutated to serine, LctM also dehydrated that residue. In 
this case dehydration is followed by nucleophilic attack of a cysteine thiol to form a 
lanthionine only requiring LctM.25  In other instances, two enzymes LanB and LanC may 
be necessary to first dehydrate and then direct the regiospecificty of the cyclization.26  A 
similar motif is created when the Cys is the C-terminal residue.  In mersacidin 
biosynthesis (Figure 2), decarboxylation occurs followed by sulphur mediated attack of a 
dehydrated residue.  This modification, known as an aminovinylcysteine, is thought to 
prevent carboxypeptidase degradation.27-30  The simplicity of the LctM system and the 
apparent substrate promiscuity make it a suitable system for engineering efforts. 
 
Figure 2:  Lantibiotics containing thioether bonds derived from cysteine and dehydrated serine or 
threonine.  Naming designation based on structure, coloring based on origin (blue=cysteine, green=serine, 
red=threonine).  Mersacidin also contains an aminovinylcysteine at its C-terminus. 
 Serine and threonine residues are again used to aid in complexity generation, 
along with cysteine residues, through heterocyclization reactions.31,32  The pathway to 
these heterocycles was originally proposed to require three separate domains to elicit 
heterocyclization activity.  Cyclization of microcin B17 (Figure 3) requires a Zn-binding 
protein McdB, an ATPase McdD, and a flavin-dependant oxidase McdC.  Inactiviation of 
any individual protein results in loss of heterocyclization activity suggesting that an intact 
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complex is necessary for activity.  McdB is the predicted heterocyclase while McdD is 
known to require several equivalents of ATP, which suggests that it functions as a motor 
protein to direct the peptide to the active site.  McdC is thought to oxidize thiazolines and 
oxazolines to the corresponding thiazoles and oxazoles.33  In contrast, recent work 
studying the heterocyclization in the pathways to the cyanobactins patellamide and 
trunkamide (figure 3) identified single enzymes PatD and TruD, which are composed of 
only Zn-binding and ATPase domains and are sufficient for heterocyclization.  An 
oxidase domain, in this case, is fused to the protease PatG to complete the final oxidation 
steps and cleave the leader peptide.34,35  Formation of heterocycles by all of these 
enzymes has been shown to increase structural rigidity, protect against proteolytic 
degradation, and be essential for bioactivity.31,36-40   
!
Figure 3:  RiPPS containing various heterocycles !
 Cysteine residues can also help create structural rigidity of RiPPs through 
intramolecular disulfide bonds.41   Mutagenesis has revealed disulfide bonds to be 
essential for bioactivity.42-44  The chemical synthesis of RiPPs containing disulfides is 
complicated by the facile formation of mismatched bonds and the difficultly in directing 
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desired disulfide formation.45  Many pathways, such as that of the bacteriocin thermopilin 
9, contain disulfide oxidase enzymes, disruption of which result in loss of activity.46  
However, not all pathways contain a dedicated disulfide oxidase and in the case of 
ulithiacyclamide, disulfide bond formation is thought to occur based on close proximity 
alone.47  Understanding the determinants for disulfide bond formation will allow for their 
use as a simple means to stabilize peptide scaffolds.   
 Another way to inhibit proteolytic degradation, which is used much more 
commonly in NRPs, is through epimerization of select amino acids.  The mechanism of 
epimerization in RiPPs is quite different from that proposed in the NRPS pathways.  In 
the case of the polytheonamides, a single epimerase, PoyD, is responsible for the 
conversion of most if not all of the 18 D-residues.  PoyD is homologous to the radical 
SAM superfamily, but with very few homologs listed in GenBank.  The epimerization is 
unidirectional and the mechanism is likely achieved through !-proton extraction to form 
a stabilized radical followed by hydrogen transfer from an unknown donor.48 The 
dehydration and reduction of L-Ser to form D-Ala found in the pathway of the bacteriocin 
gassericin A also results in a net change in stereochemistry.49  A change in 
stereochemistry can also been seen in amino acids adjacent to thiazole and thiazoline 
moieties, but this transformation is likely non-enzymatic.50  During the total synthesis of 
trunkamide A, after incorporation of L-Phe spontaneous epimerization to the D-conformer 
was apparent.51 
 A common modification across all types of peptides and proteins is 
prenylation.52"54  Introduction of isoprene-derived units imparts RiPPs with a lipophilic 
face, which can aid in targeting the peptides to the membrane.  In the case of the ComX 
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signaling peptides (Figure 4), prenylation is achieved through carbon-carbon bond 
formation between Trp C-3 and C-1 of the isoprenyl phosphate.  An additional 
cyclization is then possible between Trp N and C-2 creating a third ring on the Trp 
residue.55  Study of the biosynthesis of these peptides revealed that the prepeptide 
determines if farnesyl or geranyl groups are added.56  Prenylation is also common in the 
cyanobactins where Ser, Thr, and Tyr side chain hydroxyls are modified with DMAPP.  
Recently, the first tyrosine prenyl transferase (PT) LynF was examined in vitro and found 
to preferentially prenylate the Tyr hydroxyl of cyclic peptides over linear versions, 
hinting that these proteins prefer preprocessed peptides and do not require the prepeptide 
to direct prenylation.  Incubation of the enzymatic products at 37 °C allowed for a 
spontaneous Claisen rearrangement to yield ortho-C prenylated Tyr, lending evidence 
that O- and C-prenylated tyrosine residues arise from the same class of PTs.57    
 Formylation is exceedingly common in bacteria as well as in chloroplasts and 
mitochrondria where each initiating methionine residue bears the modification.58,59  Most 
often its existence is brief due to deformylase activity, but in the case of several RiPPs, 
the N-formylmethionine residue remains intact and is actually necessary for directing the 
peptide to its target cells.60-63  In the case of microcin C7, which is a heptapeptide 
inhibitor of bacterial translation, the formyl group is required to direct entry of the 
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Figure 4:  ComX Signalling peptide containing a prenylated tryptophan 
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peptide into susceptible cells.64 The host deformylase removes the formyl group in a rate-
limiting step followed by step-wise trimming of the N-terminus by a series of non-
specific peptidases that then results in an active inhibitor of translation, which causes cell 
death.65  Interestingly, this potent activity of microcin C7 is due to a unique modification, 
which gives rise to an nonhydrolyzable adenylated aspartate found to inhibit aspartyl 
tRNA synthetase.66  The enzyme MccB carries out this transformation and has been 
characterized in vitro. Incubation of the prepeptide MccA with MccB in the presence of 
Mg2+ and two equivalents of ATP resulted in conversion of the terminal asparagine 
residue into a phosphoramide adenylate linked asparate through a succinimde-containing 
intermediate.67   
!
Figure 5: Glycosylated, disufide-containing peptide Sublancin 
 Glycosylation is also ubiquitous among eukaryotes and slightly less so among 
prokaryotic proteins.68  Very few examples of glycosylation in RiPPs are known, but in 
all cases the sugar serves an essential function.  In the case of the antimicrobial peptide 
sublancin, SunS selectively S-glucosylates only Cys22 of the prepeptide SunA in the 
presence of four other Cys residues (Figure 5).69  Though the peptide is found to retain its 
antimicrobial activity in the absence of glycosylation in an agar-well diffusion assay, the 
sugar moiety has been found to be important for self-immunity.  Another bacteriocin, 
!"#
$%& !"#
$#' (") !"*
+#'
(") (")
$%& ,-. $%& !"*
+#'
(") /%-
!"# !"# ,0-
1"%
(-2
+#'
30% !"* (-2 ,#- ('*
!"*
+#'
(") 4)" (") !"#
!"#
!"#
!"#
+#'
/
/
/
/
567
85
8
58
85
85
85
/
Sublancin
! 16!
glycocin F, was recently found to contain a Cys S-linked N-acetylhexosamine and a Ser 
O-linked N-acetylglucosamine, which were determined to be essential for its antibiotic 
activity.70  The final and most distinctive example of glycosylation lies with microcin 
E492m.71  In this case two glycosyltransferases are responsible for linking the carboxyl of 
the C-terminal Ser of the MccE prepeptide to the C5 of DHB on the linearized version of 
the NRP enterobactin.  This unique linkage results in a Trojan horse style compound 
where the natural siderophore import system is responsible for drawing the conjugate into 
the cell, where the siderophore is processed and the peptide toxin released.72-74  Other 
siderophore containing antimicrobial compounds have been isolated and described, 
providing further evidence for the validity of using this mechanism to selectively target 
the often virulent siderophore-utilizing bacteria.75 
 Many amino acid side chain modifications can be found in the pathways to the 
lantibiotics microbisporicin, cypemycin, and cinnamycin (Figure 6).  Recent 
reconstitution and gene knockout experiments in the microbisporicin pathway have 
revealed MibH and MibS to be responsible for chlorinating a Trp residue at the 5 
position.76  MibH is homologous to flavin dependent tryptophan halogenases while MibS 
is related to flavin reductases, which can supply the FADH2 necessary for chlorination.   
Knockout of MibH revealed loss of chlorine by MS analysis but the resulting extract 
retained its antibiotic activity.  The microbisporicins also contain mono- and 
dihydroxyproline residues postulated to be incorporated by the heme-containing P450 
homolog MibO, though further studies are necessary to verify this role.  Cypemycin is of 
interest due to its potent activity against mouse leukemia cells.77  It is a linear peptide 
with several dehydrated residues, an aminovinylcysteine, two allo-isoleucines, and a 
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dimethylated N-terminus.  CypI is a candidate for the isoleucine isomerase activity as 
knockout mutant retained the activity and MS of the natural product.  CypI is 
homologous to the DUF255 family, which contain a thioredoxin domain and have 
homology to the N-acetyl-D-glucosamine epimerase superfamily.  CypM was identified 
as the SAM-dependent methyl transferase responsible for dimethylation of the released 
N-terminus of the active product.  Knockout of the gene resulted in loss of activity and a 
change in mass corresponding to loss of both methyl groups.  Cinnamycin and its closest 
structural analogues have been studied extensively as their binding to 
phosphtidylethanolamine (PE) causes secretion of chloride, which is misregulated in 
cystic fibrosis.78  Cinnamycin contains a hydroxylated Asp residue and linkage between a 
Lys !-amino and a dehydrated Ser.  CinX is an "-ketogluterate dependent/Fe(II)-
hydroxylase responsible for hydroxylation of Asp on the #-carbon.  This modification has 
been shown to be specifically important for interaction with the ammonium group of PE.  
In vitro investigations of proteins proposed to be involved in lysinoalanine formation 
failed to yield any visible product. As some lanthionine moieties have been shown to be 
nonenzymatically generated, it is postulated that lysinoalanine formation may also 
happen spontaneously in solution.  Partial reconstitution of the pathway including 
dehydration, hydroxylation, and leader peptide removal, followed by treatment under 
alkaline conditions, resulted in lysinoalanine formation, which was verified by MS 
analysis, though the stereoselectivity could not be established.  All of these modifications 
are rare, and only some have been shown to drastically effect activity.  Implementation of 
these modifications can therefore not only be used to change activity but also to provide 
improved pharmokinetic properties independent of activity.   
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2.3  Macrocyclization in Ribosomal Peptides 
 In addition to heterocycles, lanthionines, and disulfides, structural rigidity can 
also be imparted through other means of cyclization.79,80  A very common motif among 
RiPPs is macrocyclization between the N- and C- termini.  This modification results in a 
range of cyclic peptides from 6-12 amino acids in length, such as the cyanobactins,81 to 
more than 70 amino acids in length, such as the bacteriocins uberolysin82 and gassericin 
A.83  For example, in the pathway to the patellamides, two serine proteases act to create 
the mature cyclic peptide product.35,84  First, PatA trims away the N-terminal leader 
peptide.  Then PatG trims off the C-terminal sequence and, while the peptide is still 
linked to the active site Ser, PatG also orients the peptide such that the N-terminus is in 
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Figure 6:  Peptides containing side chain halogenation, hydroxylation, and C-terminal cyclizations 
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close proximity and amide bond formation out competes hydrolysis.  This cyclization is 
in contrast to the pathways to the head to tail cyclized bacteriocins which lack any extra 
C-terminal residues to be cleaved.  In this case, the carboxylate must somehow be 
activated before macrocyclization can occur; however no biochemical evidence of this 
mechanism or the responsible gene exists to date. 
 Cyclization between the N-terminus and a side chain carboxylic acid is also 
common (Figure 7).85  The gene cluster has been identified and in vitro assays performed 
to determine the biosynthesis of the lasso peptide microcin J25.86-89  Only four proteins 
are necessary for lasso peptide maturation and export:  the prepeptide McjA, a protease 
McjB, a cyclization enzyme McjC, and a transporter McjD.  McjB and McjC were found 
to both be necessary for any activity.  Using an E. coli reconstitution system, assays of 
the isolated membrane and McjA showed complete conversion to microcin J25 while 
assays with the soluble protein fraction showed no activity.  These results suggest that a 
complex may be formed between the two maturation enzymes and the exporter to ensure 
efficient synthesis and release from the cell.  In all assays ATP was necessary for product 
formation.  
Figure 7:  Lasso peptide microcin J25 with cyclization between the N-terminal glycine amino group and 
aspartic acid side chain. PDB ID: 1PP5 
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 A few instances of cyclization between the C-terminus and a side chain 
nucleophile have also been described.  A class of quorum sensing peptides known as the 
auto-inducing peptides (AIPs) contain either a thiolactone or lactone linkage between 
their C-terminus and a Cys or Ser residue five amino acids away.90-93  Cyclization is 
proposed to be analogous to the head-to-tail cyclization, but in this case a membrane 
bound cysteine protease AgrB cleaves the C-terminal end of the peptide and, while the 
peptide is still attached as a thioester to the active site Cys, the Cys/Ser residue five 
amino acids away on the peptide acts as a nucleophile releasing the peptide from the 
protease.  LamD558 is a pentapeptide thiolactone involved in the regulation of adherence 
in Lactobacillis plantarum WCFS1.94  This pathway was reconstituted with the use of 
only two genes and the product isolated was similar to the AIPs, but lacking a N-terminal 
tail.   
 The marinostatins and microviridins represent the only ribosomal peptides known 
to have multiple macrocyclizations between carboxylate and nucleophilic side chains.  
The compounds are produced by cyanobacteria and have diverse activities from protease 
inhibition to cytotoxic effects on neighboring organisms.95,96 
 
2.4  Microviridin Discovery and Biological Activity 
 In 1990, during the course of analyzing samples known to contain the 
nonribosomal peptide hepatotoxins, the microcystins produced by the cyanobacteria 
Microcystis viridis (NIES-102), a novel class of ribosomal peptides, was identified.97  The 
microviridins represent the first tricyclic depsipeptide natural products.  The structure of 
microviridin A was determined by NMR and amino acid analysis.  The peptide was 
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found to consist of 14 amino acids with the primary sequence YGGTFKYPSDWEEY.  
Two lactone bonds connect the side chains of Thr4/Asp10 and Ser9/Glu12 and a lactam 
bond connects the side chains of Lys6/Glu13.  The N-terminal Tyr residue was also 
found to be acetylated.  Over the next several years, additional variants of this class of 
compounds were isolated and found to have varied stability and bioactivity (Figure 8).98-
101  In 2003, microviridin J was isolated and characterized after the producing organism 
was found to be toxic to Daphnia.102,103 
 Daphnia are filter-feeding microcrustaceans that live in fresh water systems and 
are responsible for keeping algae levels low to prevent bloom formation.102,103  Algal 
blooms are harmful for two main reasons.  Algae typically produce an array of toxins that 
can directly harm other species including humans.  Algae also indirectly harm the 
environment as their decomposition drastically decreases dissolved oxygen levels, which 
puts stress on the entire ecosystem.  Toxins that disrupt Daphnia had been known for 
years; the structure and mechanism of action had not been established until isolation, 
structure elucidation, and study of microviridin J. 102,103   
 Feeding of Daphnia with Microcystis UWOCC MRC led to lethal molting, a 
symptom that had not been established for any other cyanobacteria at the time.  A peptide 
was the likely culprit and this hypothesis was confirmed when isolation and feeding of 
the peptide resulted in the same molting pattern.  Further studies were possible once large 
quantities of the protein were isolated and its structure determined.103  The peptide toxin 
was found to be a member of the microviridins and the new activity postulated to be due 
to the presence of an Arg residue located between conserved macrocyclized residues 
Thr4 and Lys6.   This residue was typically aromatic or hydrophobic and the resulting 
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microviridins showed chymotrypsin or elastase inhibition respectively, switching this 
residue to Arg was suggestive of microviridin J being a trypsin inhibitor.  Microviridin J 
was assayed for inhibitory activity against porcine trypsin, porcine elastase, bovine 
chymotrypsin, and trypsin-like proteases isolated directly from Daphnia.  Microviridin J 
showed inhibition is all cases but elastase.102 
 
2.5  Microviridin Biosynthesis 
 The first microviridin gene cluster was found in 2008.104  Genomic scans for the 
peptide sequences of the microviridin core identified Anabaena PCC7120 as containing 
three repeats of the conserved KYPSD motif.  However, this strain was not found to be a 
microviridin producer suggesting that these genes were silent.  A closer look at the genes 
surrounding the postulated precursor peptide revealed two genes that had homology to 
ATP-Grasp enzymes responsible for ATP-dependent condensation reactions.  These 
sequences were successfully used to scour genomic fosmid libraries of the known 
microviridin B and microviridin J producers, M. aeruginosa NIES298 and Microcystis 
UOWOCC MRC respectively, for possible gene clusters responsible for producing these 
compounds (Figure 9). 
! 23!
!
Figure 8:  Structures of the known Microviridins !
 The cluster in M. aeruginosa NIES298 contains five genes.  MdnA is the 
precursor peptide, which contains a leader peptide and is 50 amino acids in length, the C-
terminus of which corresponds exactly to the sequence found in microviridin B.  MdnB 
and MdnC are predicted ATP-Grasp ligases of 325 and 324 amino acids, respectively.  
This cluster also contains McaD, a 177 amino acid predicted N-acetyltransferase (NAT), 
and MdnE, a 687 amino acid predicted ABC transporter.  Successful reconstitution of this 
pathway in E. coli verified that these 5 enzymes were exclusively required for 
microviridin B production.   
 The cluster identified in Microcystis UOWOCC MRC, however, only contains the 
genes for the precursor peptide and ligases and lacks a dedicated NAT and transporter.  
Attempted reconstitution of this pathway in E. coli yielded completely cyclized, but 
improperly processed peptides that retained much of the leader peptide.  These 
experiments point to the ligases acting on the intact peptide followed by leader peptide 
cleavage and acetylation.  Knockout mutagenesis was performed to verify the identities 
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of each enzyme and also showed that in the absence of the ligases, the precursor peptide 
could not be detected, most likely due to degradation by E. coli proteases. 
!
Figure 9: Representative microviridin gene clusters with prepeptide genes indicted in blue and ligase genes 
responsible for cyclization in red.  Additional NAT and ABC transporter genes not present in all clusters 
are also shown. !
 Around the same time in 2008, a second microviridin gene cluster from 
Planktothrix agardhii NIVA-CYA 126/8 was found through an extensive search of the 
organisms unannotated DNA sequence using all 256 possible DNA sequences that could 
yield the expected amino acid sequence of the peptide microviridin K.105  The cluster 
contained the five coding regions analogous to the M. aeruginosa pathway, but with 
different gene organization and containing a second possible precursor peptide, though 
the corresponding processed peptide has not been isolated.  In this case, both ligases and 
NAT were produced as N-terminal His6-fusion proteins in E. coli and studied in vitro to 
verify their role in microviridin biosynthesis.  The ligases MvdC and MvdD were only 
provided in minimal yield with the majority of protein being found in the insoluble 
fraction.  Further work by this group established the order of lactone bond formation 
through the use of mutant prepeptides lacking either the Thr or Ser used in these 
processes.106  In vitro assays of these mutants with the lactone bond forming enzyme 
MvdD, showed only one cyclization with the Ser mutant and none with the Thr mutant 
suggesting that first the Thr acts as a nucleophile to form the first macrocycle, then the 
Ser residue creates the second.  The mechanism of macrocyclization was found to be 
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achieved through a phosphate activation pathway as opposed adenylation.  The group 
also determined that the monocyclized peptide was not a substrate for the lactam bond-
forming enzyme, MvdC.    Extensive alanine scanning mutagenesis on the core peptide 
showed that in some cases up to six residues could be altered and still cyclized by both 
ligases proving the potential of these peptides as scaffolds for drug design.   
 An improved E. coli expression system was developed that necessitated inclusion 
of a long promoter region located before MdnA to obtain microviridin production.107  
This system allowed for a directed mutagenesis study to determine the importance of 
conserved areas of the leader peptide.108  Alignment of the precursor peptides from 
known and predicted microviridin pathways revealed two sections in the leader peptide 
that show highly conserved sequences. All of the known microviridin prepetides contain 
a completely conserved region in leader peptide.  Surprisingly, single mutants of this 
region were still substrates for MdnC, the lactone bond forming enzyme, but not 
substrates for the lactam bond-forming enzyme MdnB.  Combined mutation of three of 
these residues was necessary to prevent cyclization by MdnC.  Located just before the 
core peptide is a proline rich region that is similar to the recognition sequences of proline 
endopeptidases.  A double mutant in this region retained its ability to be processed by 
MdnB and MdnC, however the triple mutant resulted in only bicyclic products.  This 
expression system also allowed for further studies into the role of the ABC transporter.  
Without a dedicated peptidase, it has been suggested that this transporter also controls 
cleavage of the leader peptide.  Reconstitution of the pathway lacking MdnE resulted in 
accumulation of tricyclic microviridins that were improperly processed at the N-terminus.  
However, this construct also showed significantly lower levels of MdnB.  The group 
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hypothesizes that these effects are due to disruption of the native membrane scaffolding 
of MdnE.  This would mean that all enzymes form a complex anchored to the membrane 
by MdnE.  However, it is also possible that MdnB alone is responsible for recruiting a 
peptidase for cleavage.  It would be interesting to see the effects of an ABC transporter 
knockout in the P. agardhii system.   
2.6  Structure and Mechanism of ATP Grasp Ligases 
 The ligases described in the remainder of the chapter will be denoted MdnJB and 
MdnJC to specify that these belong to the pathway to microviridin J from Microcystis 
UOWOCC MRC now classified as M. aeruginosa MRC.  These proteins share 40% 
sequence similarity and 60% sequence identity.  BLAST results show that these proteins 
belong to the ATP-Grasp superfamily, which share a similar ATP binding motif.109  
Crystal structures for several ATP-Grasp superfamily members show a similar fold even 
given the extremely low primary sequence homology (Figure 10).  There are now over 
100 superfamily members that all use ATP to activate a carboxylate through an 
acylphosphate, more than 20 of which have been structurally characterized.109   
The ATP binding pocket of these systems is made up of two " + # domains often 
referred to as the A and B domains that “grasp” ATP between them.  The B domain acts 
as a lid to anchor the ATP in place and is often mobile in the absence of ATP.   The P 
loop, which links the domains, provides for recognition of the adenosine moiety, while 
mostly acidic residues recognize the triphosphate motif, ribose ring, and any coordinated 
Mg2+ ions.109   
Though the ATP binding residues provide a 13 amino acid fingerprint of the 
superfamily, the majority of the sequence is dissimilar amoung family members as a 
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result of the varied chemical substrates used by each enzyme.   Besides the requirement 
for ATP and possibly Mg2+ or Ca2+, each ligase also requires a carboxylate to be activated 
and a nuclephile for bond formation.  The identity and size of each of these partners 
varies within the superfamily.  The carboxylate can be as small as formic acid, as is the 
case in PurT,110 or as large as a carboxylic side chain on "-tubulin in the case of tubulin 
tyrosine ligase.111  The nucleophile also varies from ammonia in carbamoyl phosphate 
synthetase112 to a biotin-linked enzyme in biotin carboxylase.113  The structural features 
will be described using D-Ala-D-Ala ligase,114-116 glutathione synthetase,117 biotin 
carboxylase,113 and ribosomal protein S6 kinase118 as respresentatives of this class.   
The first structure of a D-Ala-D-Ala ligase (DDlig) was reported in 1994.116  
DDlig is responsible for the incorporation of the D-Ala-D-Ala motif in the peptidoglycan 
layer in bacteria cell wall biosynthesis.  Vancomycin recognizes and binds to this motif, 
blocking transpeptidase catalyzed cross-linking of the peptidoglycan layer, which is 
necessary for structural stability of the cell wall.  In this case, the carboxylate to be 
activated by ATP comes from D-alanine and the nucleophile is the amino group of a 
second equivalent of D-alanine.  DDlig was crystallized in the presence of ATP and a 
phosphinate transition state analog.  The structure shows a compact protein with ADP 
sandwiched in an extended conformation by the antiparallel # sheets of the A and B 
domains and the phosphorylated analog positioned adjacent with two Mg2+ atoms 
bridging the phosphate groups.  This structure was found to be similar to the glutathione 
synthetase (GSHase) structure.117 
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Figure 10:  Overall fold of ATP-Grasp Superfamily members with bound ligands. From right to left: DDlig 
(PDB ID: 3DHV), GSH (PDB ID: 1GSA), BC (PDB ID: 3G8C), RimK (PDB ID: 4IWX). !
 Glutathione is a small peptide used to control the redox environment in all living 
things.117  It is synthesized by two successive peptide couplings the first of which occurs 
by amide bond formation between Cys amino group and the $-carboxyl of Glu.  The 
second step involves in the ATP-grasp member GSHase, which activates the C-terminus 
of the Cys residue then directs nucleophilic attack by the glycine amino group.  A co-
crystal structure was determined by soaking native crystals with ADP and GSH.  This 
soaking not only identified the binding pockets for the two substrates, but also allowed 
for restricted the motion of two loop regions that were not visible in the electron density 
maps of the native structure and allowed these loops to be completely modeled in.  When 
this structure is aligned with that of DDlig the RMSD is only 2.8 Å for main chain atoms, 
despite a sequence identity of only 13%.  The major structural difference is due to the 
presence of two # sheets inserted in the GSHase structure that are not present in the 
DDlig structure.  These sheets are located on the surface of the protein more than 20 Å 
away from the active site.117 
Biotin carboxylase (BC) is a much larger protein then either DDlig (306aa) or 
GSHase (316aa) at 449 amino acids.113  These extra residues make up a second C domain, 
which is necessary to create an active site large enough to accommodate the biotin-carrier 
protein (BCCP).  The BCCP acts as the nucleophile in the ligase reaction with activated 
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bicarbonate.  The carboxybiotin-carrier protein then transfers the carboxyl group to 
acetyl-CoA to create malonyl-CoA in fatty acid synthesis.  In 2009, a co-crystal structure 
of BC was solved in the presence of ADP, bicarbonate, and free biotin.119  The C2 
domain contains four antiparallel # strands that align with those of the A domain to form 
a larger active site base.  The presence of both substrates allowed the group to propose a 
mechanism where a Glu residue is responsible for removal of the bicarbonate proton 
followed by attack of the $-phosphate to release ADP; next, decomposition of the 
carboxyphosphate to carbon dioxide and phosphate allows for attack by the biotin to 
complete the reaction.  Recently, a structure was solved of BC with BCCP without 
ATP/ADP, which showed significant movement of the B domain away from the A 
domain, widening the active site.120  The biotinylated Lys residue was not visible in the 
structure and this backbone C" was 40 Å from the active site.  It is unclear if this is a 
biologically relevant conformation as the enzyme complex is about 100 times more 
efficient if partner enzyme carboxytransferase (CT) and acetyl-CoA are present.   
!
Figure 11: Topology plot of ATP Grasp superfamily members with conserved A- and B-domains and 
variant C-domains 
! 30!
The final ATP-Grasp family member that will be discussed is RimK, which is 
responsible for adding as many as 15 Glu residues onto the C-terminus of the ribosomal 
protein S6.118  The biological function of this addition is still unknown.  RimK was 
crystallized in the presence of ATP, Mg2+, and Glu, but only ADP is visible in the active 
site.  When compared to the other ATP-Grasp structures, the active site is very open, 
especially near the #-phosphate of ADP.  This may be the result of suboptimum 
crystallization conditions and resolution, but may also be indicative of the S6 protein 
binding site.  The lack of Mg2+ is also surprising, especially given that the concentration 
in the crystallization solution was 10 mM.   This structure has the highest sequence 
similarity to the microviridin ligases MdnJB and MdnJC according to the delta BLAST 
server, but still only at 17% and 13% respectively.  Therefore homology modeling cannot 
be relied upon and the best alternative given the large size of the proteins involved is X-
ray crystallography.  Many questions remain about these systems.  It remains unclear 
whether the enzymes form an active membrane associated complex.  The peptidase 
responsible for cleaving the leader peptide has not yet been identified.  Given the high 
sequence homology between the ligases, it is unknown why each ligase displays such 
different requirements for peptide processing.  Some clusters contain only the prepeptide 
and ligase while others also contain the genes responsible for further processing and 
export.  Many of these questions could be answered given a full understanding of the 
three dimensional structure of each enzyme or enzyme complex.  There are several issues 
that must be overcome in pursuit of a structure.  In order to screen for optimal crystal 
growth conditions, access to large quantities of pure protein is necessary.  From the data 
shown only as supplemental reports by previous researchers, protein production has been 
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a significant hurdle.  Solving this problem so that the questions regarding the mechanism 
of peptide recognition and macrocyclization by MdnJB and MdnJC can be answered is a 
major goal of this work. 
2.7  Structural Studies into Biosynthesis of Microviridin J 
The genes corresponding to these two proteins were synthesized and initially 
ligated into pET-28a with an N-terminal His6-tag by Dr. Timothy Montavon in our 
laboratory.  This approach led to yields of ~7-8 mg/L of MdnJC and less than 0.5 mg/L 
of MdnJB with most of the protein still located in the insoluble fraction.  These constructs 
were screened for crystallization and several hits were found, but extensive optimization 
failed to improve crystal quality. Higher expression levels shifted the focus mainly to 
MdnJC.  The use of triton X-100 led to improved protein yields, but crystallization was 
not reproducible.  Initial hits were found using commercially available crystal screens.  
More than 500 conditions at both 4 and 20 °C resulted in only two hits in which 
nucleation was rare.  Cleavage of the His6-tag with thrombin was attempted, but no 
cleavage was observed even after 48 hr incubation at 37 °C or in the presence of mild 
denaturants.  Therefore the gene was transferred into a different vector with a very short 
linker, enterokinase cleavage site, and C-terminal His6-tag.  This change resulted in 3-
fold higher protein yields with no protein visible in the insoluble fraction.  This protein 
therefore did not require the use of triton X-100 and crystals were reproducible. 
In order to improve crystal morphology further and to obtain more detailed 
structural information, we set out to crystallize MdnJC in the presence of its peptide 
substrate MdnJA.  The gene corresponding to this peptide was also synthesized and 
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ligated into pET-28a, however as is often the case with short peptides, expression was 
minimal and not consistent from batch to batch.  The highest yields were 50 %g/L, which 
was not sufficient for crystal screening.  The full-length peptide (JA-49) was 
commercially synthesized.  Previously, due to the high cost of peptide synthesis, an 
acetylated 30 amino acid variant was purchased (EZBiolabs, Carmel, IN).  Recently, 
after identification of a core conserved region in the prepeptide a 39 amino acid variant 
was also purchased  (LifeTein, South Plainfield, NJ).  
Code   Sequence 
JA-49   MAYPNDQQGKALPFFARFLSVSKEESSIKSPSPDHEISTRKYPSDWEEW 
JA-39   ALPFFARFLSVSKEESSIKSPSPDHEISTRKYPSDWEEW 
JA-30   Acetyl-SVSKEESSIKSPSPDHEISTRKYPSDWEEW 
Table 1:  Sequences of the MdnJA peptides used in our studies 
Co-crystallization of JA-49 with MdnJC in the presence of AMP-PNP and MgCl2 
resulted in growth of crystals suitable for X-ray diffraction analysis.  More than 50 of 
these crystals were screened before identifying a crystal that diffracted to 2.4 Å resolution 
and belonged to space group P41 with 8 monomers in the asymmetric unit.  
Many homology models were created from all of the ATP-grasp structures known 
in attempts to use molecular replacement to solve the phase problem (Figure 12).  De 
novo/ab initio modeling was also undertaken using Rosetta and Robetta.  However, given 
the low sequence similarity, an alternate approach was taken in parallel.   
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Figure 12:  Representative models used for molecular replacement.  Left=Swiss-Model homology model 
Right=Robetta de novo model. 
Se-Met containing MdnJC was grown and crystallized in a manner analogous to 
that used for the native protein using degassed buffers and addition of DTT to prevent 
oxidation.  This protein crystallized in similar conditions, but the resulting crystals 
suffered from high mosaicity and twinning.  The native sequence of MdnJC contains nine 
methionines, which when substituted with Se-Met may be disrupting crystal packing.  
Therefore, the MdnJC sequence was aligned with homologous ligases and non-conserved 
Met residues were targeted for mutagenesis.  Three mutants were made, two triple 
mutants and one penta-mutant.  One of the triple mutants showed visibly larger, cleaner 
crystals and it was selected for further experiments.  Repeated production of Se-Met 
labeled crystals and screening at synchrotron facilities failed to yield crystals with 
sufficient anomalous signal to solve the phase problem.   
Homologous proteins from related pathways were screened, but yielded extremely 
low expression levels.  Reductive methylation and partial proteolysis techniques were 
used in attempts to improve crystal packing interactions, but did not improve diffraction 
quality.  Since switching the His-tag from the N-terminus to the C-terminus of MdnJC 
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had a drastic effect on the expression and solubility, a similar approach was taken to 
move the tag of MdnJB to the C-terminus.  As expected, the solubility and yield 
improved to about 2 mg/L after purification.  Next the peptide JA-49 was treated with 
MdnJC and ATP to convert it to the substrate for MdnJB and was used in co-
crystallization experiments.  Conditions were found that yielded single crystals with 
smooth, defined edges.  The addition of DMSO and TMAO yielded larger crystals.  Se-
Met derived MdnJB was produced and crystallized and both sets of crystals were 
screened using sychrotron radiation.  The native set diffracted to 2.4 Å and the Se set to 
2.7 Å, with a strong enough anomalous signal to solve the phases.  These crystals 
belonged to space group C2 with only 2 monomers in the asymmetric unit.  Once a 
starting model was built and refined, it was used in molecular replacement to solve the 
phases of the MdnJC native data set. 
!
Figure 13: CLUSTAL alignment of MdnJC and MdnJB *=identical, : = strongly similar, .=weakly similar 
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2.8 High Resolution X-ray Crystal Structure of MdnJB 
 The MdnJB model was built with Phenix.autobuild followed by manual 
rebuilding in Coot and refinement in Phenix.refine (Figure 14).  The overall structure is 
similar to the other ATP-grasp superfamily members in the grasp domains but differs in 
the N-terminal portion (C-Domain).  Three predicted loop regions comprised of residues 
83-96, 173-178, 194-204, and 236-253 are not visible in the density maps.  As of writing 
this manuscript, the model is 90% complete with ~15 residues on each chain built in as 
alanines.  Attempts to co-crystallize both MdnJB and MdnJC with higher concentrations 
of ATP analog or ADP failed to yield crystals.  Therefore soaking was undertaken with 
higher concentrations of ADP and addition of MgCl2, CaCl2, and MnCl2.  Gluteraldehyde 
mediated crosslinking was also attempted in hopes of restricting the movement of the 
loops to obtain higher quality maps.  These crystals were sent to Argonne National Labs 
and high quality diffraction data was obtained.   Many of these crystals diffracted to 
higher resolution then the previous batch, but density corresponding to ADP or any of the 
metal ions still could not be identified. 
! 36!
!
Figure 14:  Three dimensional structure of MdnJB. (A) Left- MdnJB chain A in blue with AMP-PNP 
shown as sticks, Right- RimK in green with ADP shown as sticks, Middle- alignment of the two structures 
highlighting the difference in the helix of the N-terminal domain. (B) Representative views of the dimer 
with the A-Domain colored blue, B-Domain colored wheat, C-Domain colored green, and helix colored 
orange in each.  Left and Middle are ribbon diagrams of each face of the dimer, Right- surface 
representation which shows the two beta sheets of the C-domain (green) inserted into the B-domain 
(wheat). (C) Alignment of MdnJB (blue) with the Rosetta model (wheat). (D) Alignment of the MdnJB 
monomer with that of MdnJC with the additional residues indicated in orange. 
 Two monomers are present in the asymmetric unit.  The interface between the 
monomers buries ~ 455 Å2 and PISA suggests that these two monomers, along with their 
two symmetry mates, make up the predicted tetrameric biological unit.   This tetramer 
can be characterized as a dimer of dimers, where the more prominent interface is formed 
between each chain and its symmetry mate burying a total of about ~1900 Å2.  The 
binding is mediated through insertion of two antiparallel beta sheets from the C-domain 
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into a cleft between one helix from the B-domain and another helix from the A-domain 
so that the sheets form an extended assembly with the beta sheets of the B-domain (figure 
14). The other interface is near the last missing loop region and therefore more surface 
area is probably buried than can be observed in this structure.  Some of the important 
hydrogen bonding interactions at this interface are as follows: A-Asp310-B-His259 and 
B-Gln257, A-Arg309-B-Gln219, A-Arg22-B-Gly291(O), and A-Phe18(NH)-B-
Pro289(O).  
All of the conserved residues that make up the ATP binding pocket of the ATP 
Grasp superfamily are present in this structure (Table 2).  The residues in the first missing 
loop 83-96 are likely involved in dimer formation.  Residues in the region 173-204 that 
are missing or modeled in as alanine may be involved in substrate binding.  The final 
missing loop consisting of residues 236-253 likely is involved in forming a lid to cover 
the ATP binding pocket.  Chain B aligns to the RimK structure with an RMSD of 4.8 Å, 
with the major difference within the N-terminal domain, specifically in the beta sheets, 
which contain residues 47-74 and the helix from residue 97-112.  The ATP analog used 
during crystallization, AMP-PNP (three digit code ANP), was built into the binding 
pocket of both chains and the occupancies refined to 0.7 for chain A and 0.8 for chain B, 
but with high B-factors.  Density in this region is weak and no clear density was apparent 
for any metal ions.  There is additional density adjacent to the ATP binding pocket, 
which corresponds to the predicted substrate binding pocket, but modeling this area was 
complicated because the density may also be part of one of the missing loops.   
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Table 2:  Conserved residues in the ATP Grasp Superfamily and their proposed function !
When comparing this structure to the Robetta model, the N-terminal domain is 
rotated, widening the active site compared to the Robetta model.  The Robetta model 
shows an extra helix in the B-domain that corresponds to a missing loop region in 
MdnJB.  Use of the Robetta model to guide building of these missing loop regions was 
unsuccessful.  The Robetta model also has an extended loop in the N-terminal region 
instead of the beta sheets that are important for dimer formation.  De novo protein 
modeling from a sequence alone has been helpful to others, but in this case the Robetta 
model closes off the active site and may represent a stable conformation in solution in the 
absence of the peptide substrate.  While these is no room for the peptide in the Robetta 
structure, the peptide may be bound in our model, but that it may be too mobile to be seen 
in the electron density maps or only be bound with low occupancy. 
2.9  High Resolution X-ray Crystal Structure of MdnJC  
The MdnJC model was built and refined using Phenix.autobuild, Coot, and 
Phenix.refine as for MdnJB.  There are a total of 8 monomers in the asymmetric unit.  
One of the loops missing in MdnJB is fully defined for MdnJC, but the other two loops 
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are missing as well.  Only minimal density is clear for the ATP analog, Mg ions, and 
substrate peptide that were included during co-crystallization.  Attempts to crystallize this 
protein with higher ADP concentrations failed to produce crystals, however some crystals 
were produced using the conditions optimized for MdnJB.  These crystals require further 
optimization but improved data quality may be obtained if they can also crystallize in the 
C2 space group with only 2 monomers instead of P41 with 8 monomers.   
The MdnJC dimer aligns well with that of MdnJB with an RMSD of 1.3 Å 
(Figure 15); however, there are very few conserved residues between the two proteins.  
The short helix indicated in orange in figure 14 differs significantly so that the surface 
representation of the MdnJC dimer lacks the gap between these helices.  This gap is due 
in part to the pair of hydrogen bonds between Arg101 of one monomer and His123 of the 
other monomer.  In MdnJB, these residues correspond to Ala107 and Asn130 and their 
side chains are more than 5 Å apart.  This interaction brings Asp119 from each monomer 
to within 4.7 Å of each other, perhaps forming a water bridge, and packs His120(C$) 
close to Ala116(C#) to within 4.0 Å.  This Asp is Glu126 in MdnJB and the side chains 
are separated by more than 8 Å.  The His/Ala interaction is replaced with Lys/Ala 
separated by 7 Å.   
Some residues adjacent to the ATP binding site are also conserved for example, 
Trp256/Trp252 (JB/JC), Glu303/Glu299, and Arg80/Arg73.  Others are not and may 
therefore be involved in arrangement of the peptide substrate for activation and 
cyclization.  These residues include Met306/Trp302, Trp82/Arg75, His13/Phe7, 
Gly305/Phe301, Phe18/Glu12, Phe17/Asn11, and Lys129/Asn122.  Further work is 
necessary to determine the role of individual residues. 
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Figure 15:  Comparison of MdnJB and MdnJC.  Top left: surface representation of MdnJB dimer, Top 
right: surface representation of MdnJC dimer. Bottom: alignment of active site with AMP-PNP and 
predicted peptide binding residues shown as sticks. 
2.10  Functional Studies in the Biosynthesis of Microviridin J 
HPLC, LC-MS, and ITC assays showed that only the full-length peptide was 
indeed a substrate for MdnJC. HPLC kinetics assays were performed after verifying 
substrate and product peaks by LC-MS.  The kinetics data yielded a Km of 23.8 %M and 
kcat of 0.47 min-1.  A representative initial rate determination plot and the Michaelis 
Menten plot are shown in figure 16. 
! 41!
!
Figure 16:  Representative initial rate determination from HPLC kinetics assay and the Michaelis Menten 
plot created after initial rates at various substrate concentrations. 
 ITC experiments were performed by titrating JA-49 into a solution containing 
MdnJC-3A6H in the absence of ATP (Figure 17).  A clear binding curve was observed 
and data fitting yielded an average KD of 114 ± 26 nM over 5 independent experiments.  
Titration of JA-49 into N-term His6-MdnJC yielded an average KD of 628 nM from two 
independent experiments.  Experiments to determine the binding constant for ATP were 
attempted, but failed to yield useful data, perhaps due to the acidic character of 
commercially available ATP.  A slight difference in the pH of the ATP solution when 
titrated into the protein could cause local precipitation of the protein itself or just result in 
a change of heat upon dilution. Titration of MdnJB-3A6H with N-term His6-MdnJC 
failed to show any clear binding interaction, however this negative result may be due to 
problems arising from the His6-tag. Further experiments are warranted, but have been 
hampered by the low yields of the expressed proteins and the large amounts of protein 
and substrates required for each run. 
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Figure 17: Representative ITC plots of the interaction between MdnJC and JA-49 
2.11  Conclusions and Future Directions  
 Improved expression constructs were designed, which allowed for the 
heterologous expression of the two ATP Grap ligases, MdnJB and MdnJC, from the 
microviridin J pathway in E. coli.  Protein expression and purification protocols were 
optimized that yielded pure protein suitable for crystallization.  Reproducible 
crystallization conditions that can provide diffraction quality crystals have been 
identified.  Crystals were screened and data was collected on both native and selenium 
containing MdnJB and MdnJC.  The MdnJC crystals belonged to P41 space group, which 
was predicted to contain 8 monomers in the asymmetric unit.  Unfortunately, the 
anomalous data from this protein failed to provide a strong signal for phasing.  MdnJB 
crystals belonged to the C2 space group with only two monomers predicted to be present 
in the asymmetric unit.  Anomalous data for this protein was sufficient to solve the 
phases.  The phases of the MdnJC data could then be solved by molecular replacement 
using the MdnJB model as a starting point.   
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 Though these proteins represent a novel mechanism for peptide cyclization, the 
electron density corresponding to the ATP analog and peptide substrate are too weak to 
establish a clear mechanism.  Hopefully, further soaking experiments will yield a better 
view of the active site configuration.  If not, future work should focus on improving 
crystal quality and minimizing domain motions.  Most screening and optimization of both 
MdnJB and MdnJC were performed with low concentrations of ATP and Mg with only 
one equivalent of peptide substrate.  It may be useful to screen different conditions with 
higher levels of these ligands to identify conditions that support crystal growth with these 
additives.  Other metals including Ca2+ and Mn2+ may also be helpful in this respect.   
 A clearer view of the peptide binding pocket will allow for the design of mutants 
with altered activity or altered substrate specificity.  Testing such mutants would require 
an efficient production of a variety of mutant MdnJA peptides.  Expression of this gene 
as a soluble His6-tagged peptide from pET-28a was not suitable.  An altered construct 
designed for expression as a KSI-fusion protein may provide an improved path to larger 
quantities of the peptides of interest after purification from the inclusion bodies.  This 
method also allows for efficient removal of the KSI tag to yield peptides without excess 
amino acids that could interfere with binding to the ligases.   
 A final question yet to be fully addressed is the possibility that MdnJB and 
MdnJC form some sort of heterodimeric or heterotetrameric structure when natively 
produced.  ITC experiments failed to show any interaction between the two proteins, but 
that may be due to slow dissociation of the homodimer.  The ideal experiment to probe 
this possibility is to co-express both proteins simulataneously and to isolate the resulting 
proteins to determine if a complex forms.  Preliminary cloning has been completed to 
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insert genes for both proteins into the pACYC-Duet1 vector.  MdnJC was inserted into 
the first cloning site with an N-terminal His6-tag and MdnJB was inserted into the second 
cloning site with a C-terminal S-tag; Ni-NTA putification should result in isolation of a 
complex if one is indeed formed.  Initial expression tests showed the protein constructs 
are expressed well in BL21(DE3) cells, but most of the protein was insoluble.  Further 
optimization of the constructs to both contain only short C-terminal tags might allow for 
increased solubility.  If a complex were to be isolated, crystallization and structure 
determination would be the next step.   !
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Materials and Methods 
Expression and Purification of MdnJC from pET-28a 
 All three genes from this pathway were synthesized by Mr. Gene (Regenburg, 
Germany), supplied in pMA vector, and subcloned into pET-28a by Dr. Tim Montavon. 
BL21(DE3)pLysS E. coli cells were transformed with the vector pET-28a-mdnJC and 
plated on LB Agar containing 50 ug/mL kanamycin.  A single colony was used to 
inoculate 6 mL LB broth containing kanamycin and the culture was incubated with 
shaking at 150 rpm at 37 °C overnight.  This culture was then used to inoculate 6 L fresh 
LB/kan, which was grown until OD600 = 0.6.  The temperature was reduced to 18 °C and 
equilibrated, then the cultures were induced with 100 %M IPTG, and expression 
continued for 16 hr.  Cells were harvested by centrifugation at 3,500 rpm in a Beckman-
Coulter Allegra 6R bench-top centrifuge for 20 min.  The supernatant was discarded and 
the pellet resuspended in lysis buffer (20 mM Tris pH 7.5, 500 mM NaCl, 0.1% triton X-
100) and lysed using a Microfluidizer M-110L.  The lysate was clarified by 
centrifugation at 10,000 rpm in the Beckman Coulter Allegra 25 bench-top centrifuge.  
The supernatant was applied to prewashed HisPur Ni-NTA resin (Thermo) and incubated 
with rocking on ice for 45 min.  The flow-through was collected and the resin washed 
with 3 x 30 mL wash buffer (20 mM Trip pH 7.5, 500 mL NaCl, 10 mM imidazole) then 
eluted with 2 x 5 mL elution buffer (20 mM Tris pH 7.5, 500 mM NaCl, 250 mM 
imidazole).  The protein was then concentrated and buffer exchange into 20 mM Tris pH 
7.5, 50 mM NaCl using an Amicon Ultra centrifugal filter with a molecular weight cutoff 
of 10 kDa.  Next the protein was purified further using Mono Q HR 10/10 anion 
exchange column on an AktaPurifier FPLC system with a linear gradient of 50-500 mM 
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NaCl.  The collected fractions were then applied to a HiLoad 16/600 Superdex 200 gel 
filtration column equilibrated with 20mM Tris pH7.5, 50mM NaCl.  Attempts to cleave 
the vector derived His6-tag with thrombin failed even at 37°C or in the presence of mild 
denaturants.  
  
Expression of MdnJA from pET-28a 
 Chemically-competent BL21(DE3)pLysS E. coli cells were transformed with the 
vector pET-28a-mdnJA and plated on LB Agar containing 50 ug/mL kanamycin.  A 
single colony was used to inoculate 6mL LB broth containing kanamycin and the culture 
incubated with shaking at 150 rpm at 37 °C overnight.  This culture was then used to 
inoculate 3 L fresh LB/kan, which was grown until OD600 = 0.6. The cultures were 
induced with 200 %M IPTG, and expression continued for 90 min.  Cells were harvested 
by centrifugation at 3,500 rpm in a Beckman-Coulter Allegra 6R bench-top centrifuge for 
20 min.  The supernatant was discarded and the pellet resuspended in lysis buffer (20 mM 
Tris pH 7.5, 500 mM NaCl, 1 mM PMSF) and lysed using a Microfluidizer M-110L.  
The lysate was clarified by centrifugation at 10,000 rpm in the Beckman Coulter Allegra 
25 bench-top centrifuge.  The supernatant was applied to a prepacked HisTrap HP Ni-
NTA column (GE).  The flow-through was collected and the column washed with 50mL 
lysis buffer (20mM Trip pH 7.5, 500mL NaCl) then eluted with a stepwise gradient of 
increasing imidazole. The peptide was then purified further using on Shimadzu prep 
HPLC equipped with a Vydac C18 column (218TP1022) using the method: 0% B for 5 
minutes, then 0-56.7%B from 5-22min (A=0.1% TFA, B=MeCN).  The peptide, which 
eluted at 15.5 min was collected, concentrated en vacuo, and lyophilized.  The residue 
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was dissolved in ddH2O and quantified using the Expasy predicted extinction coefficient 
!280= 13,980.  The yield at this point was ~70 %g/L of culture.  The large tag encoded by 
the vector was cleaved with 1.0%L 0.01U/%L thrombin (Sigma) at room temp for 24hr 
followed by another round of HPLC using the same method.  The cleaved peptide eluted 
at 15.6 min and cleavage was confirmed by Tris/Tricine PAGE.   
 
Crystallization of MdnJC/MdnJA complex 
 MdnJC was concentrated to 12 mg/mL and mixed with 10 eq. AMP-PNP, and 1 
eq. HPLC purified MdnJA for a final [MdnJC] of 7.4 mg/mL and allowed to equilibrate 
at 4 °C overnight.  The complex was screened against Hampton Research Crystal I and II, 
Peg/Ion, and Index screens.  The best condition was found in Index F7: 100 mM Bis-Tris 
pH 6.5, 200 mM ammounium sulfate, 20% PEG 3,350.  This condition was optimized to 
100mM Bis-Tris pH 5.5, 250mM ammonium sulfate, and 29% PEG 3,350.  After 
obtaining the full length synthetic MdnJA JA-49 (Genscript, Piscataway, NJ), further 
optimization was possible and the ideal complex consisted of 4 mg/mL MdnJC with 1 eq. 
MdnJA, 5 eq. AMP-PNP, and 1.6 eq.  MgCl2.  
 
Figure 18:  SDS-PAGE of MdnJA Ni-NTA purification.  Arrow indicates MdnJA from pET-28a. 
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 HPLC Assays and Kinetics 
 The synthetic MdnJA peptides (JA-49 from Genscript, Piscataway, NJ; JA-39 
from LifeTein, South Plainfield, NJ; and JA-30 from EZBioLabs, Carmel, IN) were 
tested to see whether they were substrates for MdnJC using an HPLC assay.  The reaction 
setup was as described.106  Briefly, various concentrations of MdnJA (8.75-52.5 %M) 
were treated with 100 mM Tris pH 8.0, 10 mM ATP, 10 mM MgCl2, 50 mM KCl, 1.8 
%M MdnJC in a 25 °C water bath and quenched at various time points (2-60 min) with 
equal volumes of 0.5M EDTA and run in triplicate on Shimdazu analytical HPLC 
equipped with an autosampler with method: 30%B for 5min, 30-40% B from 5-11min.  
The JA-49 standard eluted at 8.5min, and the MdnJC product eluted at 9.5min.  LC-MS 
analysis verified that the product was 36Da lighter than the standard, indictating that two 
cyclizations had occurred.  Integration of the starting material and product peaks allowed 
for the determination of the kinetic parameters.   
 
 
ITC Assays of the binding of MdnJC with MdnJA and MdnJB 
 All enzymes and peptides were thoroughly dialyzed into 100 mM HEPES pH 8.0, 
50 mM KCl, and 10 mM MgCl2.  N-term His6-MdnJC was placed in the cell at either 8.0 
%M or 16 %M and titrated with 80 %M MdnJA.  Higher yields of pET-30b-MdnJC 
allowed for higher concentrations to be used and yielded better results.  In this case 40 
%M MdnJC-3A6H was placed in the cell and titrated with 266 %M MdnJA.  All three 
peptide variants were screened for binding to MdnJC, but only the full length JA-49 
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showed appreciable binding. N-term His6-MdnJC was also titrated with MdnJB-3A6H, 
but no binding was apparent. 
 
Subcloning of mdnJC into pET-30b 
 The mdnJC gene was cloned out of pET-28a-mdnJC  using standard PCR 
methods.  Two constructs were designed one with a short C-terminal AAAHHHHHH 
(3A6H) tag and the second with a cleavable tag DDDKAAAHHHHHH (ent-3A6H).  
These modifications were encoded in the C-terminal primers bearing XhoI cleaveage 
sites with the N-terminal primer bearing an NdeI cleavage site(IDT): 3A6H 5’-GA CTC 
GAG TCA GTG ATG ATG ATG ATG ATG AGC AGC AGC GGA GTT CAC CAG 
AAT CTC-3’, ent-3A6H 5’-GA CTC GAG TCA GTG ATG ATG ATG ATG ATG 
AGC AGC AGC CTT GTC GTG GTC GTC GGA GGT CAC CAG AAT CTC-3’, N-
term 5’-GC CAT ATG ACG GTA CTG ATT GTG ACG-3’.  PCR products were 
digested and ligated into pET-30b using T4 DNA ligase (NEB, Ipswich, MA).  Correct 
clones were identified by double digest and verified by DNA sequencing (GENEWIZ, 
South Plainfield, NJ).   
  
Expression of MdnJC-3A6H 
 Chemically-competent BL21(DE3)pLysS E. coli cells were transformed with the 
vector pET-30b-mdnJC and plated on LB Agar containing 50 ug/mL kanamycin.  A 
single colony was used to inoculate 6 mL LB broth containing kanamycin and the culture 
incubated with shaking at 150 rpm at 37 °C overnight.  This culture was then used to 
inoculate 6 L fresh LB/kan, which was grown until OD600 = 0.6.  The temperature was 
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reduced to 18 °C and equilibrated, then the cultures were induced with 100 %M IPTG, 
and expression continued for 16 hr.  Cells were harvested by centrifugation at 3,500 rpm 
in a Beckman-Coulter Allegra 6R bench-top centrifuge for 20 minutes.  The supernatant 
was discarded and the pellet resuspended in lysis buffer (20 mM Tris pH 7.5, 500 mM 
NaCl) and lysed using a Microfluidizer M-110L.  The lysate was clarified by 
centrifugation at 10,000 rpm in the Beckman Coulter Allegra 25 bench-top centrifuge.  
The supernatant was applied to prewashed HisPur Ni-NTA resin (Thermo) and incubated 
with rocking on ice for 45 min.  The flow-through was collected and the resin washed 
with 3 x 30 mL wash buffer (20 mM Tris pH 7.5, 500 mL NaCl, 10 mM imidazole) then 
eluted with 2 x 5 mL elution buffer (20 mM Tris pH 7.5, 500 mM NaCl, 250 mM 
imidazole).  The protein was then concentrated and buffer exchanged into 20 mM Tris 
pH 7.5, 50 mM NaCl using an Amicon Ultra centrifugal filter with a molecular weight 
cutoff of 10 kDa.  For the cleavable construct, 1.0%L enterokinase was added and the 
reaction incubated at 4°C overnight.  Both cleaved and uncleaved protein were purified 
further using MonoQ HR 10/10 anion exchange column on an Aktapurifier FPLC with a 
linear gradient of 50-500 mM NaCl.  The collected fractions were then applied to a 
HiLoad 16/600 Superdex 200 gel filtration column equilibrated with 20 mM Tris pH7.5, 
50 mM NaCl.   !
Crystallization of C-term His6-MdnJC 
 Both MdnJC-3A6H and MdnJC-ent-3A6H (cleaved and uncleaved) were mixed 
with 1 eq MdnJA, 5 eq. AMP-PNP, and 1.6 eq MgCl2 and rescreened.  The cleaved 
protein did not result in any hits in the conditions tested.  MdnJC-3A6H showed hits for 
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the same condition as the N-term tagged version and also in a similar condition where the 
buffer was replaced with 4% tacismate pH 6.0.  The tacismate condition was not as 
consistently reproducible and often yielded only very small crystals.  The best optimized 
condition was 100mM Bis-Tris pH 6.0, 160mM ammonium sulfate, 18% PEG 3,350, and 
5% glycerol.  
 
Se-Met labeling of pET-30b-MdnJC 
 Chemically-competent T7 Express Crystal Competent E. coli (NEB, Ipswich, 
MA) were transformed with the vector pET-30b-mdnJC and plated on LB Agar 
containing 50 ug/mL kanamycin.  A single colony was used to inoculate 6 mL LB broth 
containing kanamycin and the culture incubated with shaking at 150 rpm at 37 °C 
overnight.  This culture was then used to inoculate 6 L fresh M9 media with kanamycin 
and 50 mg/L L-methionine, which was grown until OD600 = 0.6.  Then the cells were 
harvested by centrifugation at 3,500 rpm in a Beckman-Coulter Allegra 6R bench-top 
centrifuge for 20 min and resuspended in fresh M9 media without any methionine source 
and grown for an additional 3 hr at 37 °C.  Next, 50 mg L-selenomethionine was added to 
each liter and, after 30 minutes, the temperature was reduced to 18 °C and equilibrated, 
and the cultures were induced with 100 %M IPTG, and expression continued for 16 hr.  
Cells were harvested by centrifugation at 3,500 rpm for 20 min.  The supernatant was 
discarded and the pellet resuspended in Ar degassed lysis buffer (20 mM Tris pH 7.5, 500 
mM NaCl) and lysed using a Microfluidizer M-110L.  The lysate was clarified by 
centrifugation at 10,000 rpm in the Beckman Coulter Allegra 25 bench-top centrifuge.  
The supernatant was applied to prewashed HisPur Ni-NTA resin (Thermo) and incubated 
! 52!
with rocking on ice for 45 min.  The flow-through was collected and the resin washed 
with 3 x 30 mL Ar degassed wash buffer (20 mM Trip pH 7.5, 500 mL NaCl, 10 mM 
imidazole) then eluted with 2 x 5 mL Ar degassed elution buffer (20 mM Tris pH 7.5, 
500 mM NaCl, 250 mM imidazole).   
!
Figure 19: SDS-PAGE purification of Se-Met MdnJC-3A6H mut 3b 
The protein was then concentrated and buffer exchanged into 20 mM Tris pH 7.5, 
50 mM NaCl, 10 mM DTT using an Amicon Ultra centrifugal filter with a molecular 
weight cutoff of 10 kDa. Se-Met protein was purified further using MonoQ HR 10/10 
anion exchange column on an Aktapurifier FPLC with a linear gradient of 50-500mM 
NaCl (10 mM DTT).  The collected fractions were then applied to a HiLoad 16/600 
Superdex 200 gel filtration column equilibrated with Ar degassed 20 mM Tris pH7.5, 50 
mM NaCl, and 10 mM DTT.  
 
Mutagenesis of Methionines 
 Mutagenesis of non-conserved methionine residues was carried out using the 
Agilent QuikChange Lightning Multi Site-Directed Mutagenesis Kit.  The mutant 
designated #5 contained the following mutations: M24K, M103L, M166L, M180N, and 
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M281I.  Mutant #3a contained the following mutations: M24K, M103L, and M281I.  
Mutant #3b contained the following mutations: M103L, M180N, and M281I.  The 
primers used for each site are listed in the table below with the mutant codon in bold.  
The provided protocol was followed with vector pET-30b-mdnJC-3A6H as the template 
and 0.5%L of the Quik solution in each 25%L reaction.  The mutants were confirmed  by 
DNA sequencing (GENEWIZ, South Plainfield, NJ).  Mutant SeMet labeled protein was 
produced as above and screened for highest quality crystals.  Mutant #3b gave the most 
visibly superior crystals under the following conditions: 100 mM Bis-Tris pH 6.0, 180 
mM ammonium sulfate, and 8 % dioxane 
site Primer 
M24K 5’- GCGATCGAAGCAAAAGGCAAAAAGGCC-3’ 
M103L 5’- GTATTCGTGGCCTGATTGCCTCACTGTC-3’ 
M166L 5’- CGGTATTGTCACTAAACTGCTGTCCCAGTTCG-3’ 
M180N 5’- GGGGATAAACAGGAGGAAAACGTCGTCTTTAC-3’ 
M281I 5’- CGCCATTGATATCATCGTGACCCCG-3’ 
 
Reductive Methylation of SeMet MdnJC3A6H mutant #3b 
 The protein methylation procedure was adapted from a published protocol.121  
Protein for methylation was dialyzed into 50 mM HEPES pH 8.0, 500 mM NaCl, 5 % 
glycerol, and 10 mM #ME and concentrated to 4.37 mg/ml in 0.5 ml total volume.  Stock 
solutions were prepared as described: 1.0 M borane dimethylamine complex (ABC 
complex), 1.0 M formaldehyde, 0.67 M glycine, 1.0 M DTT, and 0.1 M DTT.  The 
protein solution was kept on ice throughout the protocol.  First, 20 %L of the 
formaldehyde was mixed with the protein, followed by 10 %L of the ABC complex.  
After 2hr and 4hr on ice, additional aliquots of formaldehyde and ABC complex were 
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added.  The methylation reaction was kept at 4°C overnight then quenched with 10%L 
glycine and 2.5 %L 1.0M DTT.  LC-MS analysis of the protein at each step showed that 
full dimethylation of each Lys and the N-terminus of MdnJC was complete after 4hr.  
This protein was used in crystal screening.  Many more hits were found than with 
unmethylated protein and every condition contained 20% PEG 3,350.  The remaining 
components are listed in the table below, however the best condition remained similar to 
the non-methylated protein. 
Screen Well Conditions 
Peg/Ion B1 200 mM Sodium thiocyanate pH 6.9 
 C12 200 mM Sodium Tartrate pH 7.3 
 D1 200 mM Potassium Sodium Tartrate pH 7.4 
 E6 200 mM Sodium Malonate pH 6.0 
 F2 8% Tacismate pH 6.0 
 F12 200 mM DL-Malic Acid pH 7.0 
Index F11 100 mM Bis-Tris pH 6.5, 200 mM NaCl 
 F7 100 mM Bis-Tris pH 6.5, 200 mM Ammonium Sulfate 
 G3 100 mM Bis-Tris pH 6.5, 200 mM Lithium Sulfate 
 
Partial Proteolysis 
 Trypsin and "-Chymotrypsin were purchased from Sigma and dissolved in 1.0 
mM HCl, 2.0 mM CaCl2 to create 1.0 mg/ml stock solutions.  These solutions were 
further diluted with 10 mM HEPES pH 7.5, 500 mM NaCl to create 10, 1.0 and 0.1 
%g/mL stocks.  Cleave reactions were performed following a published protocol.122  Small 
scale test cleavage was carried out by mixing 5 %L of 1.5 mg/ml MdnJC with 0.75 %L of 
each trypsin and "-chymotrypsin dilution and incubating at 37 °C for 1 hr followed by 
SDS-PAGE.  Each concentration showed some cleavage of the parent band to a slightly 
smaller band.  The 10 %g/mL stocks showed the cleavage was complete in 1 hr.  This 
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guided large-scale proteolysis where 80 %L of 13 mg/mL MdnJC was mixed with 104 %L 
of 10 %g/mL of each protease.  After incubation at 37 °C for 1 hr, the reactions were 
purified by gel filtration chromatography and subjected to LC-MS analysis to determine 
the cleavage points.  LC-MS showed that both proteases made a single cut on the same 
stretch of amino acids and that both fragments remained tightly bound to each other 
during purification. 
Figure 20: SDS-PAGE of proteolysis test with three dilutions of trypsin and chymotrypsin with impure 
elution (E1) for comparison.!
Subcloning of mdnJB into pET-30b  
 The mdnJB gene was cloned out of pET-28a-mdnJB using standard PCR methods. 
The construct was designed to have the same tag (3A6H) that gave good results for 
MdnJC. The modification was encoded in the C-terminal primer bearing a XhoI 
cleaveage site while the N-terminal primer bears an NdeI cleavage site(IDT): C-term 5’- 
C TAA CTC GAG TCA GTG ATG GTG ATG GTG ATG GGC GGC GGC ACC GAA 
CAC CAG AAA ATC-3’, N-term 5’- GAC CTT CAT ATG AAA GAA TCG CCG 
AAA GTT-3’ .  PCR products were digested and ligated into pET-30b using T4 DNA 
ligase(NEB).  Correct clones were identified by double digest and verified by DNA 
sequencing (GENEWIZ).  
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Expression of MdnJB-3A6H 
 Expression for MdnJB-3A6H was exactly as for MdnJC-3A6H but with 
expression at 20°C. 
!
Figure 21:  Purification of MdnJB-3A6H on Ni-NTA and FPLC.  P=pellet, E1 &E2=elutions, Q=after 
monoQ FPLC, GF=after GF FPLC, MW=Fisher EX-run protein ladder.  Left three lanes show purification 
with triton x-100, next three lanes show purification without triton x-100 
 
Synthesis of Dicyclo-MdnJA 
 Dicyclo-MdnJA was formed in a manner analogous to the HPLC kinetics assays.  
Briefly, 2 mg MdnJA was added to 100 mM Tris pH 8.0, 5 mM ATP, 10 mM MgCl2, 50 
mM KCl, and 1.4 %M MdnJC and allowed to incubated at 37 °C for 5hr.  LC-MS 
analysis showed the reaction had reached completion.  The cyclized peptide was purified 
by FPLC on a HiLoad 16/600 Superdex 200 gel filtration column equilibrated with 
ddH2O.  Fractions containing the peptide were identified by Tris/Tricine SDS-PAGE and 
lyophilized.   
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Crystallization of MdnJB-3A6H with Dicyclo-MdnJA 
 MdnJB-3A6H was concentrated to at least 6 mg/mL and premixed with 1 eq. 
dicyclo-MdnJA, 5 eq. AMP-PNP, and 1.6e q. MgCl2.  The mixture was incubated at 
room temp for 4 hr, and then subjected to the various crystal screens.  A hit was found in 
condition Crystal Screen D4: 100 mM Sodium Citrate pH 5.6, 20 % PEG 4,000, 20 % 2-
propanol.  These conditions were optimized and microseeding gave the best results.  
Small crystals from one drop were removed by first pipetting 25 %L of well solution 
(stabilizing solution) into an eppendorf tube.  Then 5 %L of well solution was pipetted on 
top of the crystal drop.  A glass pipette was used to create a rounded bead that was useful 
for crushing the crystals in the drop.  The crystal solution was pipetted into the 
eppendorf.  An additional 5 %L of well solution was added on top of the drop and then 
transferred to the eppendorf.  This method was repeated until the total volume of crystal 
seed stock was 50 %L.  From this seed stock, dilutions of 1:10, 1:100, and 1:1000 were 
made.  The best crystallization condition was found to be 100 mM Sodium Citrate pH 
5.6, 19 % PEG 4,000, 15 % 2-propanol, and 8 % DMSO.  This tray was setup with 1.3%L 
of well solution, 1.3%L of protein solution, and 0.17%L of the different seed stocks.  
  
Expression of SeMet JB 
 SeMet incorporated MdnJB-3A6H was produced following the exact protocols 
used for the production of SeMet MdnJC-3A6H with expression at 20°C. 
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Crystallization of SeMet MdnJB-3A6H 
 Crystallization of SeMet MdnJB-3A6H was similar to the native protein, but with 
minor differences.  SeMet MdnJB was premixed with 1.1eq dicyclo-MdnJA, 5eq. AMP-
PNP, and 1.6eq MgCl2.  Seeding was also used.  The best condition for crystal growth 
were found to be 100mM Sodium Citrate pH 5.6, 18% PEG 4,000, 15% 2-propanol, and 
8% DMSO.  Using crystals from this conditions and seeding them into conditions where 
DMSO was replaced with TMAO resulted in crystals that were significantly bigger with 
nice edges and more three-dimensional character.  
 
X-ray data collection and processing 
The MdnJC native crystals were sent to Brookhaven National Labs, National 
Sychrotron Light Source, beamline X25 for X-ray diffraction analysis.  All other crystals 
were analyzed at Argonne National Labs, Advanced Photon Source, LS-CAT beamline 
ID-21.  All raw X-ray diffraction data was processed with HKL2000.123  The native 
MdnJC-3A6H data was processed in space group P41 with unit cell parameters 132, 132, 
196.  The Matthews Coefficient for this size unit cell predicts eight MdnJC chains.  
Attempts to solve the phases through molecular replacement were carried out with Phaser 
from Phenix.  Many models were chosen as starting models including the structures from 
D-ala D-ala ligase, biotin carboxylase, lysine biosynthesis enzyme LysX, and RimK, 
along with homology models made by Swiss-Model124 and Robetta.125   None of these 
methods provided a solution.  SeMet derived MdnJC crystals also belonged to P41, but 
were anisotropic and gave a weak anomalous signal.  Both native and SeMet MdnJB 
gave nice diffraction and belonged to space group C2 with 2 monomers predicted.  This 
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small size made solving the phases much easier.  The anomalous diffraction of the SeMet 
derived MdnJB was sufficient to solve the phases using Phenix.Phaser.126  
Phenix.autobuild succeeded in placing 80% of the amino acids.  The rest was built into 
the density maps manually with Coot127 and refinement with Phenix.refine.  The refined 
model of MdnJB was then used as the molecular replacement model to solve the phases 
of the MdnJC data set in Phaser.  Again Phenix.autobuild was able to place about 85 % of 
the model and the rest was built in manually with Coot and refined with Phenix.refine.  
All figures were made with PyMol.128 
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3.1  Introduction to Nonribosomal Peptides 
 
In addition to ribosomally produced and post-translationally modified peptides, 
another class of peptide based natural products are produced through an entirely different 
mechanism.  The nonribosomal peptides (NRPs) are produced by multi-domain, modular 
enzyme assemblies denoted nonribosomal peptide synthetases (NRPSs).1-3  These 
megaenzymes use a thiol-templated system, similar to that used in fatty acid and 
polyketide biosynthesis, to pass building blocks from module to module in a way often 
compared to an assembly line (Figure 1).  Where RiPPs are constrained to the 20 
canonical amino acids and gain most of their structural diversity through tailoring steps, 
NRPs can gain complexity through the use of over 300 distinct building blocks that 
include amino acids and other monomers.  The post assembly tailoring varies between 
systems, with some peptides released from the synthetase in their mature form while 
others require extensive modifications to yield the biologically active product.4   
The core domains that are found in all NRPS pathways are the adenylation (A), 
condensation (C), and peptidyl carrier protein (PCP) domains.5  The first module, often 
denoted the initiation module, requires only the A and PCP domains.  Subsequent 
elongation modules require A, PCP, and C domains.  The final module, termed the  
termination module, usually contains A, PCP, C and thioesterase (TE) domains.6  The 
conserved serine of the PCP domain is modified with a phosphopanthetheine prosthetic 
group derived from coenzyme A by a dedicated phosphopanthetheinyl transferase 
(PPTase).7  This cofactor terminates in a thiol allowing for a thioester templated 
elongation mechanism.  Once this modification has taken place on all PCP domains, the 
synthetase is fully active.  First, the A domains select the proper amino acid or other 
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carboxylate containing monomer and activate it using ATP to form an acyl-adenylate.  
Then the building block is covalently linked as a thioester to the synthetase through the 
PCP phosphopanthetheinyl arm.  Once each arm is loaded, the first and second PCP 
domains orient their substrates in the first C domain for peptide bond formation.8  The 
amino group of the downstream PCP acts as a nucleophile and attacks the carbonyl of the 
thioester resulting in release from the arm.  Now the second PCP domain contains a 
thioester tethered dipeptide that will come together with the third PCP tethered amino 
acid in the second C domain.  This process repeats until the full-length peptide is attached 
to the last PCP domain.  The peptide is often released from the enzyme assembly line by 
the TE domain that is positioned as the last domain in the synthetase.9  The peptide is 
transferred from the PCP to a serine in the TE domain, and then is released either by 
macrocyclization using an internal nucleophile or by hydrolysis using water as the 
nucleophile.   
 
Figure 1:  NRPS Assembly line scheme. The peptidyl carrier protein domain (PCP) has its 
phosphopantetheine prosthetic group with terminal thiol shown as wavy line.  Each adenylation (A) domain 
activates and loads its cognate amino acid onto the PCP domain, then the intervening condensation (C) 
domains catalyze peptide bond formation.  This continues until the full length peptide is cleaved by the 
thioesterase (TE) domain on the termination module. 
These peptides are further modified in two ways.4  The first way is through in cis 
on assembly tailoring by auxiliary domains like epimerization, cyclization, and methyl 
transferase domains located within the NRPS. The second way is through in trans post 
assembly tailoring where additional enzymes act on the free peptide in solution.  These 
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modifications include oxidative crosslinking, halogenation, and glycosylation among 
others.  These modifications help to impart structural rigidity, stability, and biological 
activity.  The result is a wide array of peptide natural products with varied structure and 
function.   
Many NRPs are clinically relevant antibiotics, anticancer agents, surfactants, and 
siderophores.  Vancomycin is a potent antibiotic and is often referred to as the antibiotic 
of last resort due to its activity against resistant strains of S. aureus.10  The vancomycin 
core consists of a heptapeptide scaffold that includes several non-canonical amino acids 
that are extensively modified by tailoring enzymes.11  Typical gene cluster contains more 
than 30 genes that are responsible for the synthesis, immunity, and export.12,13  Total 
syntheses have been completed for vancomycin and related compounds, but they are 
extremely inefficient.14-16  Recently, a derivative of vancomycin was synthesized that can 
bind to both D-ala-D-ala and D-ala-D-lac, circumventing a known resistance mechanism.17  
This further highlights the potential of these and other NRPs to yield important clinically 
relevant compounds. Further research into the biosynthesis of these compounds will aid 
production and enable the engineering of the pathways to yield variants with improved 
pharmacokinetics and therapeutic activity. 
 
2.2  NRPS Core domains 
2.2.1  Peptidyl Carrier Protein (PCP) Domain  
 The PCP domain is a small, highly flexible domain that is usually about 80-100 
amino acids in length.  The PCP domain is structurally homologous to the ACP of fatty 
acid and polyketide biosynthesis.18,19  The nature of NRPS assemblies requires the PCP 
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domain to interact with other synthetase domains as well as the PPTase, which installs 
the phosphopantetheine prosthetic group.7 Due to the small size of this domain, many 
NMR studies have been possible that illustrate changes in conformation upon binding 
with partner enzymes.   
 
Figure 2:  NMR structures of TycC3-PCP (a) A-state (PDB ID: 2GDY)  (b) A/H-state (PDB ID: 2GDW)   
(c) H-state (PDB ID: 2GDX).  Ten residues from the N-terminus that lack secondary structure were 
removed for clarity.  Blue=helix I, Khaki=helix II, Green=helix III, Orange=helix IV. 
The first NMR structure, published in 2000, was of the excised TyrC3-PCP 
domain from the third module of the tyrocidine synthetase (Figure 2).20  This apo-
structure showed a distorted 4-helix bundle (A state) with the active site serine located in 
the loop near the edge of helix II as part of a conserved sequence (I/L)GG(D/H)SL.  After 
conversion to the holo-protein a distinct conformation of the protein was apparent (H 
state).21  A third conformation was identified from weaker signals in both the NMR 
spectra of the apo and holo forms revealing a shared conformation (A/H state).  The helix 
orientation is shared in both the A and A/H state, but in the A state, helix I and helix II 
are mostly uncoiled.  The transition between A/H and H states occurs due to the 
unraveling of helix III which in turn reorients helices II and IV with respect to helix I.  
Titrations of the apo form with the PPTase Sfp in the absense of CoA showed weak 
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binding interaction in the residues closest to the active Ser.  Mutation of the active Ser 
and subsequent titration in the presence of CoA revealed a much stronger interaction 
demonstrating the involvement of CoA in the binding of the two proteins.  NMR peak 
shifts were seen now for the residues in the loop containing the mutant residue and helix 
II.  This allowed for the construction of a model of Sfp/PCP binding using the crystal 
structure of Sfp with the NMR of the complex.  The PCP domain can tuck itself on top of 
CoA in the Sfp active site cleft with the Ser hydroxyl in close proximity to the proper 
phosphate of CoA.  The model also helps to explain the preference of Sfp for binding the 
A state only, as it is much less compact than the A/H state and exposes more of the 
residues important for binding.  Titrations of the holo form with Sfp showed no 
discernable interaction, further indicating that the surface for protein-protein recognition 
had been significantly altered by the attachment of the prosthetic group.   
Subsequent investigations have focused on PCP domain interactions with other 
members of the synthetase and will be discussed later. 
 
2.2.2  Adenylation Domain 
 The adenylation domains of NRPS pathways are related to other stand-alone 
adenylation enzymes like firefly luciferase and acyl-CoA ligases.22,23  A domains are 
responsible for proper amino acid selection, followed by ATP-dependent activation of the 
amino acid as an acyl-adenylate, and finally positioning of the holo-PCP domain for 
nucleophilic attack of the adenylate by the free thiol of the phosphopantetheine arm.  
These three functions are presumed to be performed by rearrangement of the N- and C- 
subdomains.   
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 The first published structure of an A domain was the phenylalanine incorporating 
GrsA of the gramicidin S initiation module (Figure 3).24  Sequence alignment with other 
A domains and mutational analysis revealed 8-10 amino acids within the active site 
which now represent the “adenylation code” that determines the amino acid specificity 
based on primary sequence alone.25,26  Computational studies starting with this structure 
as a model, showed the importance of binding pocket size and hydrophobicity on proper 
amino acid selection.  Further studies in silico designed mutations to this code that would 
allow for a switch in specificity.27  These results were verified by adenylation assays in 
Figure 3: Adenylation domain structures. (a) Surface representation of adenylation and thiolation 
conformations. (b) The same view in cartoon format with ligands shown as sticks. (c) Overlay of the two 
conformations showing the rotation of the C-terminal subdomain. (d) D-Ala-AMP adenylate intermediate. 
!
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vitro showing the successful creation of A domains, which activated Leu, Arg, Glu, Lys, 
and Asp to a higher degree than the native substrate Phe. Additional structural clues to 
A domain chemistry can be seen by D-alanine-D-alaninyl carrier protein ligase, DltA.28  
DltA is responsible for activating and transferring D-Ala onto the carrier protein DltC. 
This loaded CP will then move across the cell wall aided by DltB, and the D-Ala moiety 
will be transferred by DltD to form lipoteichoic acid.   Several high-resolution structures 
have been determined for DltA that provide a view of the three different states required 
for each adenylation cycle.28-30  Structures for each of these states were obtained by 
varying the ligands added to the crystallization conditions.  In the presence of ATP, only 
the open conformation was trapped.  With ATP and D-ala the adenylate conformation 
was achieved.  The addition of DltC yielded the thiolation conformation.  These 
structures reveal that amino acids within the small hinge region between the two 
subdomains exchange hydrogen bonding partners to create two pivot points for domain 
motion.   
Recently, the structure of a fungal A domain responsible for incorporating the 
large non-canonical amino acid cis-AMHO was solved.31  This represents the first 
structure from a fungal NRPS.  Similar hydroxyornithine amino acids are found in many 
fungal siderophore pathways.  The structure revealed a large binding pocket necessary to 
accommodate the substrate, which is lined with a total of 17 amino acids instead of the 8-
10 normally seen in bacterial NRPS A domains.   This structure can help pave the way 
for A domain specificity prediction among eukaryotic NRPS systems just as GrsA did for 
prokaryotic NRPSs.   
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2.2.3  Condensation (C) Domain 
 In general, condensation domains are responsible for peptide bond formation 
between donor and acceptor PCP tethered amino acids.  However, C domains have also 
been shown to catalyze ester bond formation in certain systems.  For example, SgcC5 is a 
stand-alone C domain responsible for the ester bond formation in the enediyne antitumor 
antibiotic C-1027.32  C domains also play an important role in bridging hybrid PKS-
NRPS systems where the upstream carrier protein carries the PK portion and the 
downstream PCP contains the amino nucleophile.  Biochemical studies of the C domains 
of the tyrocidine synthetase have indicated a stronger substrate requirement on acceptor 
site and relaxed specificity on the donor site.33 
 The first C domain structure was the stand-alone VibH domain in the vibriobactin 
pathway (Figure 4).34  VibH catalyzes amide bond formation between DHB-PCP as the 
donor and free norspermidine as the acceptor.  The structure revealed that N- and C- 
subdomains form a V shaped cleft with the active site at the base of the cleft.  The 
consensus sequence in this area HHXXXDG is thought to play a role in amide bond 
formation.  Initially it was imagined that the second H was responsible for deprotonating 
the downstream amino group, but mutational studies suggest that an electrostatic model is 
more probable than simple acid/base catalysis.  Solvent channels on each face that extend 
into the active site should represent the binding sites for the phosphopantetheine arms of 
the acceptor and donor PCPs.   
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Figure 4: From left to right: structure of VibH (PDB ID: 1L5A), CDA-C1 (PDB ID: 4JN3),TycA-E (PDB 
ID: 2XHG) domain showing same overall fold. 
 Recently, the structure for the C domain excised from the initiation module of 
CDA biosynthesis was solved.35  This C domain, CDA-C1, is responsible for condensing 
the FAS derived 2,3-epoxyhexanoyl group with the Ser loaded PCP domain.  This 
structure shares the same overall domain organization as the VibH structure, but in this 
case the N- and C-domains are rotated by about 15° to form a more compact structure.  
CDA-C1 was shown to be catalytically competent in vitro so the researchers postulated 
that this is another low energy conformation present during the catalytic cycle that is 
probably important for interdomain communication.  This group also used their C domain 
structure, mapped on the serinyl-PCP according to the SrfA-C structure, and docked the 
acyl-ACP with the phosphopantetheine arms pointing into the active site.  This gives a 
nice model for designing new chemical probes that could stabilize the multidomain 
complexes for crystallography in mechanistically relevant conformations. 
 
2.2.4  Thioesterase (TE) Domain 
 Thioesterase domains are positioned as the last domain in the final module of 
most NRP assembly lines and are responsible for cleaving the peptide from the 
synthetase, usually through hydrolysis or intramolecular cyclization.6,9  First, the peptide 
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bound to the final PCP domain is transferred to the TE conserved Ser residue.  Then, the 
peptide is positioned around a catalytic triad and subjected to nucleophilic attack either 
by a water molecule or a nucleophile on the peptide itself.  Many studies have shown that 
excised TE domains retain their activity in vitro and have at least some activity with 
alternate peptide-SNACs.36,37   
 The first structure of a TE domain was published in 2002 and verified that TE 
domains belong to the !/"-hydrolase superfamily (Figure 5).38  Residues Ser80, His207, 
and Asp107 make up the catalytic triad.  The protein crystallized as a dimer, though it 
had been characterized as monomeric in solution.   The overall structure is very similar to 
lipases, but with the insertion of a 3-helix “lid” segment.  One monomer was in an open 
state with the 3-helix lid region extended, while the other monomer was in the closed 
state with this lid region covering the active site.  Three residues, K111, R120, and P26  
Figure 5: Structure of SrfTE with catalytic triad colored red and arrow indicating entry of 
phosphopantetheine arm (PBD ID: 1JMK). 
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were found to be essential for promoting cyclization and preventing hydrolysis of the TE 
bound lipoheptapepide.  The structure of the TE domain in the fengycin pathway was 
also determined.39  It was very similar to the SrfTE, but the protein only existed in the 
open conformation and the lid region was 12 amino acids shorter eliminating one of the 
three helices.   
An interesting case of a TE domain located at the start of the initiation module 
instead of at the end of the termination module is given by the phosphinothricin 
synthetase.40  Mutational analysis proved the TE domain was active and necessary for 
mature peptide formation.  The two enzymes that make up the complete pathway must 
form a complex in solution with the terminal PCP domain of the second enzyme in close 
contact with the initial TE domain.   
The in vitro experiments with TE domains prove their potential as tools for regio- 
and stereoselective macrocyclization reactions.  Chemical synthesis of linear peptides is 
straight forward, but proper cyclization can be challenging.   TE domains could be used 
as an efficient way to eliminate this challenge.   
 
2.3  Multidomain Structures 
2.3.1  Tyrocidine Condensation-Peptidyl Carrier Protein Didomain Structure 
 Even given structures of each of the individual domains, there is still little known 
about the how these domains interact to create the natural product.  Early attempts at 
engineering these pathways by A domain swapping were not very successful, hinting that 
interdomain protein-protein recognition is also important.41-44  Structurally characterizing 
multidomain NRPS proteins is difficult for a number of reasons.  First, these systems are 
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very large which makes NMR characterization challenging.  X-ray crystallography is also 
inhibited due to the size of these large proteins which, in general, are more difficult to 
produce as properly folded recombinant proteins.  The flexible nature of these systems 
means the proteins in solution occupy a large number of low energy conformations 
making a crystallization event rare.  Still, interest in this field is high and a few chance 
events have yielded some information about interdomain interactions. 
 The first didomain structure was published in 2007 (Figure 6).  The 5th PCP and 
6th C domain were excised from the tyrocidine synthetase and produced in E. coli as a C-
term His6-fusion protein.45  Inclusion of 10!M Fe(II) in the growth medium was found to 
be necessary to inhibit the action of the endogenous Sfp from the enterobactin pathway.  
This yielded homogenous apo-protein suitable for crystallography.  The structure was 
solved using anomalous methods to 1.8 Å resolution.  The overall fold of the PCP 
domain was shown to align well with the A/H state of excised TyrC3-PCP.  The C 
domain shows a 12° shift between the N- and C-terminal subdomains when compared to 
the VibH structure.  Unfortunately, when taken as a whole, this didomain structure is not 
in a catalytically relevant conformation.  The active site Ser of the PCP and the catalytic 
His of the C domain are 47 Å apart, which is about twice as far as the 
phosphopathetheine arm can reach.  This structure represents just one conformation these 
two domains occupy during the catalytic cycle.  Perhaps this structure represents the 
PCP-C conformation during interaction with the missing A domain.  Either way, this 
highlights the challenges involved in multidomain structure solution and presses the field 
to find a way to obtain catalytically competent conformations.  
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Figure 6: Multidomain NRPS Structures. (a) TycC-PCP-C domain with C domain in blue and PCP domain colored by 
helix and distance between active sites shown(PBD ID:2JGB). (b) Left=EntF-PCPTE NMR structure (PDB ID: 
2ROQ), Right=EntF-PCPTE Xray structure (PDB ID: 3TEJ), Middle=alignment of TE domains. (c) SrfA-C 
termination module colored by domain (left) and showing distances between active sites (PDB ID: 2VSQ). 
2.3.2  Enterobactin Peptidyl Carrier Protein-Thioesterase NMR Structure 
 In 2008, the structure of the PCP-TE didomain from the enterobactin synthetase, 
EntF, was solved by extensive NMR methods.46  In this case, to ensure a homogenous 
protein sample, the active site Ser of the PCP domain was mutated to Ala.  This yielded 
an apo structure with this Ala and the TE active site Ser only 17 Å apart suggesting this is 
!
"
#
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a conformation adopted during catalysis.  The interface includes helix II, loop III, and the 
single turn helix of the PCP, which tuck in underneath the lid region of the TE.  Besides 
this conformation, NMR signals were also detected for a conformation in which the two 
domains show little interaction.  To probe the significance of these conformations, 
partner enzymes Sfp and the excised C domain were titrated in and the NMR spectra 
recorded.  Upon addition of Sfp, clear signals appeared to indicate binding near the active 
site of attachment and the conformation in which the two domains show fewer 
interactions predominated.  This illustrates that large changes in conformation are 
necessary to fulfill the roles of each domain.  Interestingly, when the C domain was 
titrated into the PCP-TE didomain, only small changes in the PCP-TE interface were 
apparent.  Given this apo structure, it would be interesting to see what changes occur 
with the native PCP loaded with its arm as the presence of the arm would lead to 
reorganization of the PCP domain and may alter the interdomain interactions. 
 
2.3.3  Structure of the Entire Termination Module of the Surfactin Synthetase 
 In 2008, the first and only structure of a complete module was published.47  The 
termination module of the surfactin synthetase incorporates the final L-leucine and 
performs macrolactonization to create the mature lipopeptide scaffold.  In this case, the 
PCP active site Ser was also mutated to Ala to ensure homogenous protein was produced.  
The overall structure of the individual domains was similar to the published structures, 
with the C domain also showing the pivot point when compared to the TyrC-PCP-C and 
VibH.  The C and A domains form a close association involving the 32 amino acid linker 
region that includes a helical segment and buries a total of 1,621 Å2 of their surfaces.  
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The PCP domain sits atop the scaffold created by the C and A domains with its active site 
pointed along the acceptor site of the C domain.  The two active sites are 17 Å apart well 
within the range of the phosphopanthetheine arm.   The TE domain is positioned away 
from the C domain and therefore doesn’t make any contacts.  However, part of the C-
terminal tag is visible in the density maps and sits into a grove on the symmetry related 
C domain.  The sequence of the tag has some similarity to the C-terminal portion of 
SrfA-B and may give some insight into how consecutive synthetases recognize each 
other.  This structure provides a snapshot of one of the catalytic conformations necessary 
for assembly line biosynthesis, but with the active sites of the A and TE domains located 
57 Å and 43 Å away, respectively, from the PCP active site, significant changes must 
occur to complete the other steps in one catalytic cycle.  Ideally, snapshots of each step 
would provide a more complete picture of the nature of the rearrangements that must 
occur in these megasynthetases. 
 
2.3.4  Enterobactin Peptidyl Carrier Protein-Thioesterase X-Ray Structure 
 Our group made the first step in establishing these snapshots by publishing the 
first holo didomain structure in 2011.48  Instead of inhibiting the endogenous Sfp or 
mutating the PCP active site, our group instead chose to use the phosphopantetheine 
moiety as a tool to lock the two domains in an active conformation.  This was 
accomplished by synthesizing an !-chloroacetylamide coenzyme A analog that could be 
loaded onto the PCP domain by Sfp.  This CoA analog had already been shown to inhibit 
TE domains by our group.  Within the active site of the TE domain, the catalytic triad 
reacts with the !-chloroacetyl moiety trapping the active conformation.  This structure is 
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quite similar to the EntF-PCP-TE NMR structure discussed previously.  The attachment 
of the phosphopantetheine arm causes rearrangement of the PCP domain to its H-state, 
which orients the arm along the channel to the active site and in doing so creates a wedge 
that pushes the helix turn helix away from the active site to make room for the arm.  
Leu1187, Ile1990, and Val1272 form a hydrophobic lock that holds the arm within the 
active site.  The tip of the arm is solvent exposed and surface views show how the 
enterobactin scaffold could be pieced together.  Given that the full module structure 
shows no interactions of the TE domain with the other domains and the fact that the TE 
domain doesn’t need to interact with other domains it is safe to say that activity of the TE 
domain is modulated by the holo-PCP. 
   
2.3.5  Chimeric Enterobactin Adenylation-Peptidyl Carrier Protein Structure 
 A chimeric didomain protein was created by linking the standalone PCP and A 
domains of the enterobactin pathway together with the linker taken from EntF.49  The 
PCP domain was posttranslationally modified with CoA by the native E. coli PPTase 
after growth in minimal media.  A vinyl sulfonamide adenylate mimic was also used, 
which resulted in a covalent bond between the adenylate and the phosphopantethinyl arm 
or the PCP domain.  Though this experiment is very well designed and yielded diffraction 
quality crystals, the overall structure showed a dimer where the PCP of one monomer 
pointed into the active site of the other monomer’s A domain.  The substrate binding and 
panthetheine tunnel can be easily identified and should represent the general contacts in 
A-PCP domain interactions, however the interface of this A and PCP may not be entirely 
indicative of the native conformation.   In this case, 16 amino acids in the linker between 
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the PCP and A domains form a helix, whereas in the SrfA-C this region is mostly 
flexible, with only a short helical segment.  The interaction between the two standalone 
domains may be weaker and more flexible than when the domains are within an intact 
module and binding must not only be strong enough to form a suitable domain-domain 
interaction, but also to break apart other domain-domain interactions.  This artificial 
didomain may be representative of this interaction, but it does not illustrate the domain 
organization in complete modules.     
 
2.4  Tailoring Enzymes in NRPS pathways 
Epimerization domains are inserted between the PCP domain of one module and 
C domain of the next module.50  These domains allow for a switch in configuration at the 
!-carbon resulting in a net L-to-D conversion.  This change enables greater structural 
variability and also provides some resistance against protease degradation.  Epimerization 
domains can be found in initiation and elongation modules.  In the case of initiation 
module of the gramicidin S synthetase, the preferred substrate for the E domain is the 
PCP tethered amino acid L-Phe, as no inversion of stereochemistry was found with free 
L-Phe.51  In contrast, a separate study of two initiation and two elongation domains found 
that when loaded with aminoacyl- and peptidyl-CoA by the PPTase Sfp, each E domain 
showed some substrate promiscuity.52  The initiation E domains could accept peptidyl 
substrates and elongation E domains supported epimerization of varied and elongated 
peptide-PCP substrates.  The group also showed that each E domain accepted N-
methylated peptidyl-PCP substrates as well, which is in contrast to prior results and 
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shows the potential of E domains to be used in the combinatorial biosynthesis of N-
methylated peptides.   
Cyclization (Cy) domains also have homology to C domains.53,54  Cy domains are 
responsible for heterocyclizing Ser, Thr, and Cys residues to form 5-membered rings.  In 
general, Cy domains appear in place of C domains and catalyze both peptide bond 
formation between donor and acceptor substrates and heterocyclization via the !-
nucleophile of the acceptor and the newly formed amide carboxyl.  Loss of water then 
results in the formation of thiazoline/oxazoline depending on the nucleophile and can 
either be oxidized to thiazole/oxazole as in the epithilone B pathway55 or reduced to 
thiazolidine/oxazolidine as in the pyochelin pathway56,57 with the help of dedicated 
oxidase (Ox) and reductase (R) domains.  No structural evidence of these domains exists. 
However, the OX domain of the epithilone pathway is FMN dependent and the R domain 
in the pyochelin pathway uses NADPH as the hydride source. 
Nitrogen and carbon methylation is a key method to alter the hydrogen bonding 
character and hydrophobicity in NRPs.  Both in cis and in trans domains have been 
discovered in NRP pathways with N-methyltransferases mostly acting on PCP bound 
substrates within the assembly line and C-MTs acting on free substrates before 
incorporation into the NRP.56,58-62  When located within the NRPS assembly line, 
methyltransferase (MT) domains are located between the A and PCP domains.  The MT 
domain uses (S)-adenosyl-methionine (SAM) as the methyl donor and can methylate at 
nitrogen in amides and heterocycles.  In C-MTs, methylation occurs on unactivated 
carbons as in the case of GlmT, which converts "-ketogluterate to (3,R)-3-methyl-2-
oxogluterate in the CDA pathway.63   
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Other modifications that occur on assembly include formylation and halogenation.  
The formylation domain of the gramicidin pathway exists at the N-terminus of the first 
module and is responsible for N-formylation of the PCP-bound valine.  No altered 
substrate was accepted for formylation by this module and formylvaline was not a 
substrate for the A domain showing the great importance of formylation in this 
pathway.64  Halogenation is a very common modification in natural products that often 
imparts increased bioactivity and stability.65  The enzymes responsible for this 
transformation fit into five different classes with two of them responsible for NRP 
halogenation.  Flavin dependent halogenases act on electron rich aromatic or 
heteroaromatic substrates through O2-assisted oxidation of chloride to hypochlorous acid 
followed by transfer of the Cl to an conserved Lys and shuttling to the substrate.66,67 The 
other class is the non-heme iron/!-ketogluterate (!-KG) dependent halogenases that can 
insert halogens at unactivated carbon centers as in the case of syringomycin E.68  In this 
class, !-KG, O2, and Cl- are ligands for the Fe center.   Oxidative decarboxylation of !-
KG yields an Fe(IV)oxo species, which abstracts the hydrogen from the substrate.  
Radical recombination with Cl yields the chlorinated product.   
These and other tailoring steps that occur after release of the NRP from the 
assembly line help to create the bioactive natural product.  Some pathways have minimal 
tailoring while others have extensive modifications, which are absolutely necessary to 
impart bioactivity.  To better illustrate this, a few example pathways will be discussed in 
detail. 
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2.5  Biosynthesis of Enterobactin 
 The siderophore enterobactin (ent) was first isolated from E. coli and S. 
typhimurium in 1970.69,70  Its structure is composed of three repeating DHB-L-Ser units 
that are connected via three depsipeptide bonds to form the cyclic peptide.71-73  The gene 
cluster responsible for this pathway contains only 6 genes.    
Figure 7: Enterobactin NRPS pathway and glucosylation 
 In the first step of the pathway, chorismate is diverted from primary metabolism 
by EntC, which acts as an isochorismate synthase.  The enoylpyruvyl moiety is removed 
by the bifunctional protein EntB acting as an isochorismate lyase (ICL) and then 
oxidative aromatization is completed by the dehydrogenase EntA.  EntD is the dedicated 
PPTase that installs the phosphopanthetheine prosthetic group onto the active site Ser of 
the two carrier protein domains in this pathway, the bifunctional ICL-ArCP EntB and the 
PCP domain of EntF, which is a full termination module.  EntE is a stand alone A domain 
that selects, activates, and loads the newly synthesized DHB onto the ArCP domain of 
EntB (Figure 7).  EntF is is comprised of C, A, PCP, and TE domains and selects and 
 88!
loads L-Ser and condenses it with DHB.   This domain acts in an iterative manner, 
performing three condensation reactions catalyzed by the C domain and three 
lactonization reactions performed by the TE domain to create the mature peptide product. 
 The catecholate scaffold of mature ent is capable of binding ferric iron with a Kd 
of 10-49 M through the three DHB groups.74  This tight binding helps the producing 
organism survive in low iron conditions of their environment and aids in virulence in 
pathogenic strains.  Mechanisms of resistance to ent exist in mammals.  Enterobactin and 
Fe(III)-ent can be bound to the proteins serum albumin and siderocalin, respectively, 
preventing their escape back to the bacteria.  In response, some bacteria have overcome 
this obstacle by utilizing tailoring enzymes to modify the ent scaffold to prevent binding 
to these proteins while maintaining Fe binding efficiency.  An additional gene cluster that 
contains five genes responsible for synthesis and export of modified ent, was identified in 
a pathogenic strain.  An ent derivative, salmochelin S4, was isolated with C-glycosylation 
from UDP-glucose at the C5 position of 2 of the 3 DHB moieties.  Studies of all possible 
glucosylation sites, from mono- to tri-glucosylated cyclic and linear ent, determined that 
Fe affinity was not altered appreciably but that hydrophobic effects were interrupted.  
Therefore it was postulated that addition of sugars aids in export of Fe(III)-ent as the 
native ent is often sequestered in the membrane.   
 Thus, the enterobactin pathway is an example of an iterative NRPS with minimal 
tailoring that results in an easily reconstituted system perfect for engineering efforts to 
modify the pathway. 
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2.6  Biosynthesis of Vancomycin 
 In contrast, the pathway to the vancomycin family of antibiotics requires more 
than 30 genes.12,13 This family of antibiotics is made up of vancomycin, balhimycin, and 
chloroeremomycin, which differ only in their glycosylation patterns.  A total of three 
proteins representing seven NRPS modules are responsible for synthesis of the linear 
peptide backbone.11  Most of the other genes are involved in the biosynthesis of the 
nonproteinogenic amino acids common to this family, are required for immunity, or are 
responsible for tailoring steps.10 The balhimycin and chloroeremomycin gene clusters 
were identified first and therefore much of the biosynthetic investigations have involved 
their genes and proteins (Figure 8).  The vancomycin gene cluster was recently identified 
and was found to be in accordance with the other clusters.   
!
Figure 8:  Genes identified in chloroeremomycin biosynthesis from Amycolatopsis orientalis12 
 The NRPS assembly for creating the linear heptapeptide scaffold uses a 
combination of natural and noncannonical amino acids (Figure 9).  [The dedicated 
biosyntheses of these noncannonical amino acids will be discussed in detail in a later 
chapter.]10  This pathway is said to be linear, as each module is used in sequence to 
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incorporate a single amino acid.  The first NRPS enzyme contains three modules.  The 
first amino acid incorporated is Leu, followed by !-hydroxy-Tyr (!-OH-Tyr), which is 
also epimerized, followed by Asn.  This tripeptide is then passed to the second NRPS, 
which also contains three modules.  The next two modules both incorporate 4-
hydroxyphenylglycine (HPG) with each epimerized to the D-configuration.  The sixth 
module adds another !-OH-Tyr maintaining the configuration at C".  The final NRPS 
enzyme contains a single termination module, which adds the final amino acid 3,5-
dihydroxylphenylglycine and hydrolyzes the peptide from the assembly line. 
!
Figure 9:  NRPS domain organization in vancomycin family pathways with in trans tailoring by OxyA-C 
and glycosylations to yield vancomycin. 
 Cyclization of the peptide scaffold doesn’t occur with the C-terminus by the TE 
domain, but instead is accomplished through one aryl-aryl and two aryl-ether crosslinks 
generated by dedicated P450 oxidases OxyC, OxyA, and OxyB.75  The two !-OH-Tyr 
residues are chlorinated after loading onto the PCP domain.13,76,77  It is still unknown 
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whether the Flavin dependent halogenase BlaA from the balhimycin pathway acts on the 
assembly line tethered amino acid,  tethered heptapeptide prior to release, or free 
cyclizaed peptide in solution.  N-methylation of the N-terminal Leu residue is 
accomplished by the SAM dependent MT Bmt on after release from the NRPS.69  Lastly, 
glycosylations are performed.78-80  All of the vancomycin family members incorporate 
one D-glucose and a unique sugar moiety either vancosamine, 4-epi-vancosamine, or 4-
oxo-vancosamine.  The D-glucose is attached to the hydroxyl of Hpg4.  In vancomycin 
and chloroeremomycin a second sugar, vancosamine or 4-epi-vancosamine, respectively, 
is linked from the glucose.  In balhimycin, no such modification occurs but a second site 
of glycosylation with the !-hydroxyl of !-OH-Tyr6 with 4-oxo-vancosamine for 
balhimycin and 4-epi-vancosamine for chloroeremomycin is found.  These sugar moieties 
increase the potency of these compounds by helping to direct them to the membrane 
where they can bind to the D-ala-D-ala subunit in the cell wall and prevent crosslinking of 
the peptidoglycan layer.   
 Given the extensive biosynthetic steps required for vancomycin production, it is 
clear why the total syntheses of such compounds remain inefficient.  Still a large 
potential exists in engineering the biosynthetic machinery to provide new compounds 
with improved bioavailability and lower toxicity.   
 
2.7  Biosynthesis of Saframycin A 
 From the structure of saframycin A and related natural products it isn’t 
entirely obvious that these compounds are produced by an NRPS assembly line.   These 
compounds are potent antitumor antibiotics with ecteinascidin 743 (ect-743) approved for 
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clinical use.81,82  Ect-743 was isolated from a marine tunicate in yields of only 1 mg of the 
compound per kg of cell mass.  This low yield could never meet our needs, so a 
semisynthetic route to production is currently used since an intermediate can be isolated 
in much higher yields.  Further research into this pathway will help to improve the 
synthetic route to produce more of the drug, which will help to keep the cost of the drug 
down. 
Several gene clusters were found which contain 3 NRPS modules, which select 
Ala, Gly, and a Tyr derivative, but the only two peptide bonds that remain in the product 
are the result of condensation of Ala with a fatty acyl chain and with Gly (Figure 10).83  
The termination module in this pathway contains a terminal reductase domain as opposed 
to the usual terminal TE domain. In vitro characterization of this module revealed seven 
transformations that are accomplished by the single enzyme.  The C-A-PCP-R module 
selects and loads a tyrosine derivative onto the PCP domain.  Instead of the traditional 
peptide bond formation, the downstream acyl-Ala-Gly dipeptide is reductively eliminated 
from the corresponding PCP domain to yield an aldehyde that is then coupled to the 
tyrosyl amine through a Pictet–Spengler reaction.84  Then, the PCP-bound intermediate 
undergoes the second reductive elimination followed by a second Pictet–Spengler 
reaction with another tyrosine derivative.  Finally, the C-A-PCP-R module catalyzes a 
final reductive elimination and intramolecular cyclization. Tailoring enzymes complete 
the transformation of the intermediate into the final natural product.  This termination 
module not only contains a multifunctional reductase, but also a condensation domain 
capable of performing two Pictet–Spengler reactions.  Further investigations of the NRPS 
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and tailoring steps should be invaluable in the pursuit of readily available potent 
anticancer drugs.   
Figure 8:  Unusual Chemistry of C-A-PCP-R module in the pathway to Saframycin A. 
2.8  Biosynthesis of the Fuscachelins 
In 2008, Dr. Eric Dimise from our lab completed the isolation, structure 
elucidation, and proposed biosynthetic pathway to the mixed catecholate-hydroxamate 
siderophores, fuscachelins A-C, from Thermobifida fusca.85  Genome mining lead to the 
discovery of an NRPS cluster that contained a total of six adenylation domains, and 
therefore a hexapeptide product was predicted.  However, NMR analysis of the isolated 
product revealed that two DHB, two Arg, four Gly, one Ser, and one N-hydroxyornithine 
(HO-Orn) were present.  This led to a revised biosynthetic scheme in which the first four 
modules acted iteratively to be consistent with the isolated products.  The biosynthesis 
begins with standalone A and ArCP domains FscC and FscF, which select, activate, and 
load DHB onto the ArCP (Figure 11).  Next, an NRPS enzyme containing three modules, 
FscG, installs an epimerized Arg and two Gly residues.  The next two enzymes, FscH and 
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FscI, each represent a single module and incorporate Ser and HO-Orn.   The hexapeptide 
remains bound to the FscI-PCP, and after synthesis of the tetrapeptide bound to FscG-
PCP3, FscH is bypassed and the two peptides condense and cyclize to form the 10-
membered cyclic depsipeptide natural product fuscachelin A.  The other compounds 
isolated, fuscachelins B and C, are attributed to be degradation products resulting from 
the isolation.   
!
Figure 9: NRPS domain organization in fuscachelin biosynthesis 
 T. fusca is a soil dwelling, moderate thermophile best known for its production of 
extracellular cellulases.  It has been proposed that thermophilic organisms should produce 
proteins that must be thermostable and should therefore be highly amenable to 
crystallization.  For that reason, our lab has set out to use this system as a model for our 
studies of NRPS assembly lines. 
 
 
 
 95!
2.9  Total Synthesis of the Fuscachelins 
 As part of the structure elucidation of the fuscachelins, Dr. Dimise also completed 
the total synthesis of each compound in order to verify the NMR and MS guided structure 
determination.86  A convergent synthetic plan was devised where creating the Ser-HO-
Orn core would then allow for coupling of the tetrapeptide onto each available amine in a 
single step to yield the linear peptide scaffold of fuscachelin B (Figure 12).  Subsequent 
cyclization would then yield the natural product fuscachelin A.   
!
Figure 10:  Retrosynthetic analysis of Fuscachelin A 
The synthesis of the core was completed in a total of six synthetic steps by 
reaction of benzoylamidated Ser and !-bromonorvaline to form the hydroxamate (Figure 
13).  This step often results in N- and O-alkylation and in this case a ratio of 1.2:1 of the 
desired N-alkylated product was achieved by varying the coupling conditions.  
Construction of the tetrapeptide was achieved using standard peptide coupling chemistry 
in high yields.  The coupling of the tetrapeptide to the core required long reaction times, 
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but yielded the fully protected linear peptide as expected.  Global deprotection should 
have been straight forward, but it was found that during the hydrogenolysis reaction, 
partially deprotected product would adhere to the catalyst.  Various catalysts, solvents, 
and additives were screened, but the highest yield that could be achieved was 10% with 
Pd black in 3:1 acetic acid to methanol.   
!
Figure 11:  Total Synthesis of Fuscachelin A 
 Given the issues with core formation, deprotection, and mechanistic views of the 
enzymes involved; we decided to synthesize a fuscachelin analog that would be easier to 
synthesize in high yields and would provide synthetic intermediates to enable 
characterization of the NRPS enzymology.   
 
 
2.10 Total Synthesis of the Fuscachelin Analog 
 An extensive search of the literature failed to yield any hint of issues in 
hydrogenolysis as a deprotection strategy in siderophore pathways.  The octahedral 
hexadentate geometry of Fe(III) siderophore complexes is in contrast to tetrahedral or 
bidentate known Pd(O) complexes.  The hydroxamate functionality was removed for two 
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reasons.  First, removal of this functionality would allow for elimination of 3 steps in the 
synthesis and allow for direct amino acid coupling with the Orn side chain.  Second, 
during NMR, HPLC, and LCMS tracking of the hydrogenolysis reaction the hydroxamate 
benzyl protecting group was still present, hinting that once this group was removed, it 
was then that the material bound to the catalyst.  Ala was chosen to replace Ser.  This 
modification removes the hydroxyl nucleophile involved in macrocyclization by the TE 
domain and so that the resulting peptide could be used as a mechanistic probe of TE 
domain reactivity and substrate binding.86 
!
Figure 12:  Synthesis of fuscachelin analog 
 The initial plan followed the synthesis of the natural fuscachelins with creation of 
an altered core, followed by coupling to the flanking peptides.  However, the removal of 
the Ser hydroxyl and hydroxamate functionality also removed the corresponding 
protecting groups, which enabled simple identification and purification of the products.  
The dipeptide could be synthesized, but deprotection of the amines resulted in insoluble 
material that was not suitable for subsequent coupling to the hydrophobic tetrapeptide.  
As a result, a different approach was used where Ala was coupled directly to the 
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tetrapeptide followed by deprotection and Orn coupling (Figure 14).  In this way, the 
final coupling between the resulting hexapeptide and tetrapeptide proceeded in less time 
than the previous coupling of two tetrapeptides to the core.  Given the modifications, 
global deprotection could now be accomplished using conditions adapted from the initial 
Pmc deprotection of the D-Arg residues to yield pure product in higher yield and in fewer 
steps.   
 
2.11  Conclusions and Future Directions 
 With this fuscachelin analog in hand, methods to install this moiety onto the final 
NRPS module, FscI are underway.  Coupling to the nonhydrolyzable CoA analog, amino-
CoA, failed so instead the peptide was coupled first onto the amino-CoA precursor, 
amino-panthetheine.  Enzymatic processing to install the phosphates and adenosine was 
used to complete the synthesis.  The Pank reaction, which installs the first phosphate, was 
successful as was the PPAT reaction, which adds the adenosine portion.  The last 
phosphorylation reaction by DPCK failed under a variety of conditions.  We have 
obtained an Sfp mutant denoted R4-4 which can load substrates lacking this last 
phosphate, so the focus will be on using this mutant to load our fuscachelin analog-
(dephospho)-amino-CoA onto the full FscI and the FscI-PCPTE didomain, including a 
mutant in which the Ser of the catalytic triad has been removed in hopes to prevent 
hydrolysis of our bound substrate mimic.  The synthetic steps have been verified by LC-
MS and currently a purification strategy is being worked out to obtain the pure 
fuscachelin analog-amino-CoA moiety. 
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 In addition to loading of the full-length fuscachelin analog, construction and 
loading of various other amino-CoA derived peptides is planned.  Our long-term goal for 
this project is to obtain multiple X-ray crystal structures of each module within the 
fuscachelin synthetase.  It would be ideal if we could trap each conformation essential for 
the enzymatic synthesis of the natural product.  This would highlight the important 
interdomain interactions and can be accomplished by designing and synthesizing probes 
to target each domain.   
Dr. Ye Liu had found utility in using !-chloroacetyl-amino-CoA as a probe of TE 
domain chemistry.87  This probe can be used again in this situation to target the PCP-TE 
domain interaction.  This probe is simple to synthesize and load onto PCP domains and 
therefore can be a useful tool in establishing appropriate crystallization conditions and to 
obtain phase information before attempting crystallization with the harder to synthesize 
fuscachelin analog-amino-CoA.  The termination module performs the most steps in 
natural product synthesis and the most information can be learned from this module.  
Additional peptide substrates that must be processed by this module are shown in Figure 
15.  Using these conjugates, as probes should enable trapping of the adenylation, 
thiolation, and condensation conformations as well.  
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Figure 13:  Possible probes of the NRPS module FscI and didomain FscI-PCPTE 
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Materials and Methods 
 
Fuscachelin Analog Synthesis 
 
(D)-2,3-bis(dibenzyloxy)benzoyl(N-h-Pmc-argininyl))glycinylglycinylalanine benzyl 
ester (S6).  (D)-2,3-bis(dibenzyloxy)benzoyl(N-h-Pmc-argininyl))glycinylglycine (7, 
0.348 g, 0.40 mmol), DCC (0.165 g, 0.8 mmol), EDC (0.153g, 0.8 mmol) and HOBt 
(0.245g, 1.6 mmol) were taken up in 5 mL DCM/5 mL THF on ice and the OBt ester was 
allowed to form over 30 min.  At the same time, the (L)-alanine benzyl ester (0.093 g, 
0.52 mmol) was taken up in 5 mL DCM/5 mL THF to which 697 µL of DIPEA was 
added and allowed to stir.  After 30 min, the alanine/DIPEA mixture was transferred to 
the flask containing the tetrapeptide-OBt ester and the reaction was allowed to proceed 
for 16 h at room temperature.  The mixture was then dried in vacuo and a silica column 
run using a stepwise gradient of 0%, 5%, 10%, and 20% MeOH in CHCl3 to give the 
pentapeptide product as a white solid. (yield 0.425 g, theoretical yield 0.412 g). 1H NMR 
(600 MHz, CDCl3) d 8.55 (s, 1H), 7.55 (d, 1H), 7.44 (m, 2H), 7.39 (m, 2H), 7.34 (m, 
2H), 7.28 (m, 6H), 7.19 (d, 1H), 7.15 (d, 1H), 7.10 (t, 1H), 6.98 (s, 1H), 5.22 - 5.01 (m, 
6H), 4.42 (b, 2H), 3.87 (m, 4H), 3.07 (m, 2H), 2.61 (t, 2H), 2.52 (b, 8H), 2.27 (s, 3H), 
2.09 (s, 3H), 1.79 (t, 2H), 1.43 (s, 10H), 1.29 (s, 6H). ESI+ MS calc for C55H65N7NaO11S 
[M + Na]+ 1054.4355, found 1054.4349. 
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(D)-2,3-bis(dibenzyloxy)benzoyl(N-h-Pmc-argininyl))glycinylglycinylalanine (S7). 
(D)-2,3-bis(dibenzyloxy)benzoyl(N-h-Pmc-argininyl))glycinylglycinylalanine benzyl 
ester S6, 0.425 g, 0.41 mmol) was taken up in 14.4 mL MeOH to which 3.6 mL 5.0M 
NaOH was  added.  After 5 hr stirring at room temperature, the mixture was dried in 
vacuo, diluted with 20 mL ddH2O, acidified to pH 2 with 6 N HCl, and extracted with 
3x20 mL EtOAc.  The organic fractions were combined, dried over MgSO4, and 
concentrated in vacuo to yield the pure product as a white solid (0.344 g, 89%). 1H NMR 
(600 MHz, CDCl3) d 8.50 (s, 1H), 7.51 (d, 1H), 7.42 (m, 1H), 7.38 - 7.33 (m, 3H), 7.12 
(d, 1H), 7.08 (m, 1H), 6.98 (s, 1H), 5.11 - 5.01 (m, 4H), 4.28 (m, 2H), 3.88 (m, 4H), 3.04 
- 2.94 (m, 2H), 2.57 (t, 2H), 2.50 (m, 3H), 2.27 (s, 3H), 2.07 (s, 3H), 1.76 (m, 2H), 1.43 
(s, 10H), 1.27 (s, 3H). ESI+ MS calc for C48H59N7NaO11S [M + Na]+ 964.3885, found 
964.3882. 
 
 
D)-2,3-bis(dibenzyloxy)benzoyl(N-h-Pmc-argininyl))glycinylglycinylalaninyl(N-Boc-
ornithine) t-butyl ester (S8). (D)-2,3-bis(dibenzyloxy)benzoyl(N-h-Pmc-
argininyl))glycinylglycinylalanine (S7, 0.344 g, 0.37 mmol), DCC (0.150 g, 0.73 mmol), 
EDC (0.140 g, 0.73 mmol) and HOBt (0.224 g, 1.5 mmol) were taken up in 5 mL DCM/5 
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mL THF, cooled on ice and the OBt ester was allowed to form over 30 min.  At the same 
time, the (L)-N-Boc-ornithine t-butyl ester (0.154 g, 0.47 mmol) was taken up in 5 mL 
DCM/5 mL THF (on ice) to which 636 µL of DIPEA was added and allowed to stir. 
After 30 min, the ornithine/DIPEA mixture was transferred to the flask containing the 
pentapeptide-OBt ester and the reaction was allowed to proceed for 16 h at room 
temperature.  The mixture was then dried in vacuo and a silica column run using a 
stepwise gradient of 0%, 5%, 10%, and 20% MeOH in CHCl3 to give the protected 
hexapeptide product as a white solid (0.370 g, 90%).  1H NMR (600 MHz, CDCl3) d  8.52 
(s, 1H), 7.56 (d, 1H), 7.46 (m, 1H), 7.40 (m, 3H), 7.36 (m, 2H), 7.16 (m, 1H), 7.11 (m, 
1H), 6.98 (s, 1H), 5.15 - 5.01 (m, 4H), 4.40 - 4.29 (m, 2H), 3.87 (m, 4H), 3.75 (t, 1H), 
3.17 - 3.00 (m, 4H), 2.61 (t, 2H), 2.53 (m, 3H), 2.27 (s, 3H), 2.09 (s, 3H), 1.86 (q, 2H), 
1.79 (t, 2H), 1.55 (m, 2H), 1.40 (m, 18H), 1.29 (s, 3H). ESI+ MS calc for C62H85N9NaO14S 
[M + Na]+ 1234.5829, found 1234.5821. 
 
 
(D)-2,3-bis(dibenzyloxy)benzoyl(N-h-Pmc-argininyl))glycinylglycinylalaninyl 
ornithine t-butyl ester (S9). (D)-2,3-bis(dibenzyloxy)benzoyl(N-h-Pmc-
argininyl))glycinylglycinylalaninyl(N-Boc-ornithine) t-butyl ester (S8, 95 mg, 102 mmol) 
was taken up in 4.25 mL DCM and placed in an ice bath with N2 atmosphere.  To this 
mixture was added 0.75 mL TFA dropwise.  After 2 hr stirring on ice, the reaction was 
diluted with chelexed ddH2O and extracted with EtOAc.  The organic layers were 
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combined, dried over MgSO4, and concentrated in vacuo to yield the free hexapeptide as 
the TFA salt, (91 mg, 94%). 1H NMR (500 MHz, CDCl3) d  8.58 (s, 1H), 7.47 (m, 1H), 
7.40 (m, 3H), 7.39 (m, 2H), 7.20 - 6.98 (m, 4H), 5.20 - 5.01 (m, 4H), 4.40 - 4.31 (m, 2H), 
3.95 (m, 4H), 3.19 - 3.06 (m, 4H), 2.60 -  2.54 (m, 6H), 2.27 (s, 3H), 2.09 (s, 3H), 1.79 (t, 
3H), 1.43 (m, 10H), 1.29 (m, 3H). ESI+ MS calc for C57H77N9O12S [M + H]+ 1112.5485, 
found 1112.5493. 
 
 
Fuscachelin analog(tBu)(Pmc)2(Bn)4   (S10). (D)-2,3-bis(dibenzyloxy)benzoyl(N-h-
Pmc-arginin-yl))glycinylglycine (7, 0.124 g, 0.11 mmol), DCC (0.069 g, 0.33 mmol), and 
HOBt (0.051g, 0.33 mmol) were taken up in 1.5 mL ice cold DCM/1.5 mL THF in an ice 
bath and the OBt ester was allowed to form over 30 min.  At the same time, the  (D)-2,3-
bis(dibenzyloxy)benzoyl(N-h-Pmc-argininyl))glycinylglycinylalaninyl(N-Boc-ornithine) 
(S9, 0.117 g, 0.13 mmol) was taken up in 1.5 mL DCM plus 1.5 mL THF to which 233 
µL of DIPEA was added and allowed to stir.  After 30 min, the hexapeptide/DIPEA 
mixture   was  transferred  to  the  flask  containing  the  tetrapeptide-OBt  ester and the 
reaction was allowed to proceed for 16 h at room temperature.  The mixture was then 
dried in vacuo and a silica column run using a stepwise gradient of 0%, 5%, 10%, and 
20% MeOH in CHCl3 to give the pentapeptide product as a white solid  (yield 0.221 g,             
theoretical yield 0.219 g). 1H NMR (600 MHz, CDCl3) d 8.55 (s, 2H), 7.53 (b, 2H), 7.43 
(d, 2H), 7.38 (m, 5H), 7.14 (d, 2H), 7.08 (m, 2H), 6.98 (s, 2H), 5.13 - 5.01 (m, 8H), 4.26 
(m, 4H), 4.00 - 3.78 (m, 8H), 3.09 (b, 6H), 2.59 (b, 2H), 2.56 (m, 2H), 2.49 (b, 6H), 2.27 
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(s, 6H), 2.07 (s, 6H), 1.77 (t, 2H), 1.53 (m, 4H), 1.43 (s, 6H), 1.39 (s, 6H), 1.29 (s, 6H). 
ESI+ MS calc for C102H129N15Na2O21S2 [M + 2Na]2+ 1004.9357, found 1004.9330. 
 
 
Fuscachelin analog  (10) Fuscachelin analog(tBu)(Pmc)2(Bn)4 (S10, 11.9 mg, 6.0 µmol) 
was dissolved in 2.0 mL 90:5:5 TFA:thioanisole:chelexed ddH2O and allowed to stir at 
RT under N2 for 16 hr.  The reaction was then diluted with chelexed ddH2O, flash frozen, 
and lyophilized.  The dry material was taken up in 25% MeOH/chelexed ddH2O and 
purified by RP-HPLC using a linear gradient of 10-100% acetonitrile in water/0.1% TFA 
over 40 minutes.  The product eluted at 18.5 min.  Rotary evaporation of the acetonitrile 
followed by lyophilization gave the product as a white solid (2.5 mg, 25%). 1H NMR 
(600 MHz, D2O) d 7.26 (d, J = 7.7 Hz, 2H), 7.03 (m, 2H), 6.84 (t, J = 8.0 Hz, 2H), 4.54 
(m, 2H), 4.17 (m, 2H), 3.95 (m, 8H), 3.21 (m, 4H), 3.03 (m, 2H), 1.97 (m, 2H), 1.88 (m, 
2H), 1.72 (m, 4H), 1.57 (m, 2H), 1.45 (m, 2H) 1.22 (d, J = 7.2 Hz, 3H).  MALDI-TOF-
MS calc for C42H61N15O15  [M + H]+ 1016.4543, found 1016.4572. 
 
Coupling of 9 to amino-pantetheine and coversion to “amino-CoA”(10) Fuscachelin 
analog was dissolved in DMSO to create a 8.08 mM stock solution.  DCC (3 eq.), HOBt 
(3 eq.), and DIPEA (1 eq.) were added to 0.8 mmol of 9 and 1.0 mmols of amino-
pantetheine and diluted to 400uL with DMSO.  The reaction was allowed to stir at RT 
and was monitored by LC-MS on an Agilent Zorbax SB-C18 column (2.1 x 50 mm and 
1.8!m pore size) using the method: 0-5 min 0% B, 5-18 min 0-25% B, 18-20 min 25-
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100% B with 0.1 % formic acid and buffer B 0.1% formic acid/acetonitrile (method 
COUPLING25.M in /Chem32/Bruner/Condurso).  Once significant progress was 
achieved, an aliquot was added to 50 mM Tris pH 8.0, 20 mM KCl, 10 mM MgCl2, 0.5 
mM MgATP and 5 ug/mL PanK.  After an hour at 37 °C, an aliquot was removed for 
LC-MS analysis which verified phosphorylation.  Next, 0.3 mg PPAT was added.  After 
overnight incubation at 37 °C, the reaction was judged to be complete by LC-MS.  
Addition of the final enzyme DPCK failed to show product after overnight incubation 
and starting material degradation was aparent after 3 days due to impurities in the enzyme 
preparations.  Additionally, the human PPAT-DPCK protein was tested after Pank 
incubation, but failed to show any product formation.  The table below highlights the 
utility of LC-MS for monitoring each step of this reaction without purification.   
 Retention Time (min) Calculated mass Found + ion Found - ion 
analog 17.33 1015.5 1016.5 506.9 
+amino-pant 18.09 1258.6 1259.6 628.3 
+PanK 18.18 1338.6 1339.7 1337.9 
+PPAT 18.13 1667.6 1669.2 1667.1 
Table 1:  Retention times and mass ions for the coupling of the Fuscachelin analog to amino-pantetheine 
and enzymatic processing by PanK and PPAT 
 
Expression and purification of FscI-PCPTE 
 The N-Term His6-tagged FscI-PCPTE construct was created by Dr. Ye Liu using 
PCR methods with the full fscI vector as the template.  This fragment was ligated into 
pET-28a using NdeI and HindIII cloning sites.  The vector pET-28a-fscI-PCPTE was 
transformed into chemically-competent BL21(DE3)pLysS E. coli cells and plated on LB 
Agar containing 50 ug/mL kanamycin.  A single colony was used to inoculate 6 mL LB 
broth containing kanamycin and the culture incubated with shaking at 150 rpm at 37 °C 
overnight.  This culture was then used to inoculate 6 L fresh LB/kan, which was grown 
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until OD600 = 0.6.  The temperature was reduced to 18 °C and equilibrated, then the 
cultures were induced with 150 !M IPTG, and expression continued overnight.  Cells 
were harvested by centrifugation at 3,500 rpm in a Beckman-Coulter Allegra 6R bench-
top centrifuge for 20 minutes.  The supernatant was discarded and the pellet resuspended 
in lysis buffer (20mM Tris pH 7.5, 500mM NaCl, 1mM PMSF) and lysed using a 
Microfluidizer M-110L.  The lysate was clarified by centrifugation at 10,000 rpm in a 
Beckman Coulter Allegra 25 bench-top centrifuge.  The supernatant was applied to 
prewashed HisPur Ni-NTA resin (Thermo) and incubated with rocking on ice for 45 
minutes.  The flow-through was collected and the resin washed with 3 x 30mL wash 
buffer (20 mM Trip pH 7.5, 500 mL NaCl, 10 mM imidazole) then eluted with 2 x 5 mL 
elution buffer (20 mM Tris pH 7.5, 500 mM NaCl, 250 mM imidazole).  The pure 
elutions were then dialyzed into 20 mM Tris pH 7.5, 50 mM NaCl.  Next the protein was 
purified further using MonoQ anion exchange FPLC with a linear gradient of 50-500 mM 
NaCl.  The collected fractions were then applied to a Superdex 200 gel filtration column 
equilibrated with 20 mM Tris pH7.5, 50 mM NaCl.  Pure fractions were concentrated 
using an Amicon Ultra centrifugal filter with a molecular weight cutoff of 10 kDa and 
concentration determined by nanodrop using MW=44,448 , "280=45,380. 
 
Mutagenesis of TE active site Ser1144Ala 
 Previous studies had shown undesired hydrolysis of TE substrates from the 
pantetheine arm, so this residue was targeted for mutagenesis.  Complementary primers 
were designed and purchased form IDT for use in the Agilent QuikChange Lightning 
Site-Directed Mutagenesis kit.  However, only six colonies were obtained all of which 
were sequenced and shown to lack the desired mutation.  The most likely cause of this 
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failure is the extremely high GC content in this gene, which is >75% in the region of 
interest.  Fresh primers with the sequences originally used by Dr. Liu to clone this 
fragment were purchased and standard PCR based methods were used to screen for 
optimal conditions for annealing and extension. 
 
 Primer Sequence (cleave site, mutation site) 
N-term 5’- GCG CAT ATG AAG CTC GAC CGT GCC GCA ATC-3’ 
Mut-for 5’- CC CCC GAA CGC CCA GCC CA-3’ 
C-term 5’-GCG AAG CTT CTA GCT GTG TCC GGA TCG T-3’ 
Mut-rev 5’-TG GGC TGG GCG TTC GGG GG-3’ 
 
PCR was performed on N-term-mut and mut-C-term fragments.  Reaction mixtures 
contained the following: 100 pg of pET-28a-FscI-PCPTE template, 0.2 !M primers, 200 
!M dNTPs, 10% (v/v) DMSO, 1x Pfu Ultra II buffer, and 0.3 !L PfuUltra II DNA 
polymerase in a final volume of 50 !L.  The PCR program was the following:  initial 
denaturing at 95 °C for 2 min, followed by 30 cycles of 95 °C for 30 s, gradient of 50-62 
°C for 30 s, 65 °C for 1 min, then final extension at 65 °C for 5 min.  Under these 
conditions all annealing temperatures resulted in a single bright band when viewed on a 
1% agarose gel stained with ethidium bromide.  Bands were excised and gel purified 
using the Qiagen Gel Extraction Kit.  A second round of PCR was performed as above 
except with 56 °C annealing temp using these “mega primers” and the either the C-term 
or N-term primer.  Both products should represent the intact mutant gene and were 
excised and purified by gel extraction.  The DNA fragments were digested with NdeI and 
HindIII, purified and ligated into pET-28a with T4 DNA ligase, and transformed into 
TOP10 cells.  Plasmid DNA was isolated from several colonies, tested for presence of 
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insert by double digest, and verified by sequencing.  Expression and purification of FscI-
PCPTE-S1144A was performed as for native protein. Pure protein was concentrated 
using an Amicon Ultra centrifugal filter with a molecular weight cutoff of 10 kDa and 
concentration determined by nanodrop using MW=44,432 , !280=45,380. 
 
Expression and purification of Sfp R4-4 mutant 
 The pET-21B-sfpR4-4 plasmid was a gift from Dr. Yin.  This mutant contains a 
total of three mutations of the native B. subtilis Sfp:  K28E, T44E, C77Y, which allow for 
loading of dephospho-CoA based substrates. The vector pET-21B-sfpR4-4 was 
transformed into chemically-competent BL21(DE3)pLysS E. coli cells and plated on LB 
Agar containing 50 "g/mL ampicillin.  A single colony was used to inoculate 6 mL LB 
broth containing ampicillin and the culture incubated with shaking at 150 rpm at 37 °C 
overnight.  This culture was then used to inoculate 6 L fresh LB/amp, which was grown 
until OD600 = 0.6.  The temperature was reduced to 16 °C and equilibrated, then the 
cultures were induced with 250 "M IPTG, and expression continued overnight.  Cells 
were harvested by centrifugation at 3,500 rpm in a Beckman-Coulter Allegra 6R bench-
top centrifuge for 20 minutes.  The supernatant was discarded and the pellet resuspended 
in lysis buffer (20 mM Tris pH 7.5, 500 mM NaCl) and lysed using a Microfluidizer M-
110L.  The lysate was clarified by centrifugation at 10,000 rpm in a Beckman Coulter 
Allegra 25 bench-top centrifuge.  The supernatant was applied to prewashed HisPur Ni-
NTA resin (Thermo) and incubated with rocking on ice for 45 minutes.  The flow-
through was collected and the resin washed with 3 x 30 mL wash buffer (20 mM Trip pH 
7.5, 500 mL NaCl, 10 mM imidazole) then eluted with 2 x 5 mL elution buffer (20 mM 
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Tris pH 7.5, 500 mM NaCl, 250 mM imidazole).  The pure elutions were then dialyzed 
into 20 mM Tris pH 7.5, 50 mM NaCl.  Next the protein was purified further using 
HiTrapQ anion exchange FPLC with a linear gradient of 0-500 mM NaCl. Pure fractions 
were concentrated and buffer exchanged into 10 mM Tris pH 7.5, 1.0 mM EDTA, 10% 
glycerol using an Amicon Ultra centrifugal filter with a molecular weight cutoff of 10 
kDa and concentration determined by nanodrop using MW=27,570 , !280=28,880.  The 
final concentration was 831 "M and 18 nmole aliquots (21.7 "L) were added to 
eppendorf tubes and flash frozen in liquid N2.  The tubes were then moved to the Sfp box 
in the -80 °C freezer.  (The native pET-29a-Sfp vector was obtained from Prof. Michael 
Burkart and can be prepared as above except that this vector confers kanamycin 
resistance instead of ampicillin resistance.) 
 
Loading of FscI-PCPTE-S1144A 
 The one pot conversion and loading method of Burkart was attempted but given 
the PCPTE domain is the least concentrated of the four total enzymes added, it was 
inefficient in producing labeled protein.  However, an interesting phenomenon was seen 
on GF FPLC so it will be discussed since this may be important for future work.  The 
entire 400 "L coupling of the fuscachelin analog to amino-pantetheine was diluted with 
3.12 mL ddH2O and 200 "L 1.0 M potassium phosphate pH 7.0 was added, followed by 
89.3 "L 560 mM ATP, and 50 "L 1.0 M MgCl2.  Next, 24.5 "L of 520 "M PanK was 
added and after 30 min at 37 °C, 19.1 "L of 691 "M PPAT was added and after another 
30 min at 37 °C, 48.1 "L 831 "M Sfp and 44 "L 183 "M FscI-PCPTE-S1144A were 
added.  The reaction was kept at 37 °C overnight then purified on a Superdex 200 gel 
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filtration column equilibrated with 20 mM Tris pH7.5, 50 mM NaCl, 1 mM !ME.  
Unloaded FscI-PCPTE-S1144A had been purified as above as a guide to determine which 
peak to collect.  The unloaded protein eluted in fractions B14 and B13, however the 
loading reaction did not retain this peak.  Instead, peaks were seen in increasing peak area 
centered on fractions B15, B12, B2, and B6.  Since loading would increase the size of the 
protein by more than 1kDa it was assumed that peak B15 would correspond to the desired 
loaded protein, however SDS-PAGE gel analysis after concentration showed that either 
the protein had degraded or that it was PanK.  Further analysis is necessary, but it seems 
likely that loading alters the biological conformation of the protein.  By the elution 
volume on GF it seems that the unloaded protein exists as a dimer possibly similar to the 
EntE-B chimera, but upon loading this interaction may be disrupted in favor of a 
monomeric form.   
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4 Noncanonical chemistry in NRP pathways 
The continued isolation of natural products and the identification of associated 
gene clusters have revealed novel structures and enzymology.1  In NRP pathways, unique 
building blocks, non-traditional synthetase chemistries, and elaborate tailoring strategies 
come together to create an ever-expanding array of complex metabolites with varied 
biological activity.  The progress in this area exposes the remarkable diversity of 
biosynthetic machinery and highlights the potential to exploit these systems for 
bioengineering endeavors.2-4 This chapter will focus on our investigations into a unique 
enzyme involved in creation of an important amino acid found in the vancomycin family 
of antibiotics.   
 
4.1  Building block biosynthesis 
One hallmark of NRPS machinery is the utilization of diverse building blocks 
beyond the twenty common proteinogenic amino acids.5  These moieties can be derived 
from a proteinogenic amino acid, a primary metabolic pathway, or synthesized de novo.  
Enzymatic modifications by epimerases and racemaces that yield D-amino acids, mutases 
that yield !-amino acids, hydroxylases that install OH groups, methylases that modify C-, 
N- and O- positions, and halogenases that install chlorine atoms are all common 
strategies to introduce diversity in NRPS systems (Figure 1).   
The bacterial signaling metabolite, hormaomycin, is a prime example of the wide 
array of amino acids that can be incorporated into NRPs.6  The isolation and structure 
elucidation of this depsipeptide revealed several unique residues.7-9  Additional feeding 
studies, isolation of the gene cluster, and in vivo and in vitro investigations have 
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uncovered the pathways to these unprecedented molecules.6 At least five enzymes are 
required to convert L-Pro to N-hydroxy-5-chloro-2-pyrrole carboxylic acid using a PCP-
tethered approach.  The propenyl-pyrrolidine carboxylic acid is made from L-Tyr through 
a series of transformations homologous to enzymes in the biosynthetic pathways to 
tomaymycin, sibiromycin, and anthramycin.  The particularly unique amino acid 4-
nitrocyclopropyl alanine appears twice in the natural product.  Feeding studies 
established that L-Lys is the biosynthetic precursor,10 but no genes could be attributed to 
the biosynthesis and a supplementary study of the unassigned enzymes from the cluster 
may shed some light on the assembly of this building block. 
!
Figure 1:  NRPs with noncannonical building blocks 
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The pyrrolo[1,4]benzodiazepine, sibiromycin (Figure 1), is an antitumor antibiotic 
which contains a propenyl-pyrrole similar to hormaomycin.11  It also contains a highly 
substituted anthranilic acid moiety for which the biosynthesis has recently been 
elucidated.12,13  Feeding studies showed that L-Trp is the precursor14 that is first 
converted to L-kynurenine through primary metabolism, then hydroxylated by SibC, and 
methylated by SibL.  Next, SibQ is a PLP-dependent kynureninase that yields the 
anthranilic acid and alanine.  The NRPS didomain SibE activates this product forming the 
adenylate, which is then loaded onto the SibE thiolation domain.  The final step to the 
fully decorated anthranilic acid is accomplished by the FAD-dependent hydroxylase SibG 
that acts only on the PCP tethered substrate.  The second NRPS enzyme, SibD, then 
selects, activates, and incorporates the propenyl-pyrrole that is then eliminated from the 
assembly line through reductive elimination, undergoes spontaneous ring closure, and is 
decorated with a unique sugar moiety by SibH to form the mature natural product.12 With 
just two NRPS enzymes and one tailoring enzyme the producing organism is able to 
create a highly active compound thanks to the complexity established by the unique 
building blocks. 
Modifications to PCP-bound amino acid building blocks are a common 
occurrence among NRPS assemblies.15,16  The gene cluster of the GE81112 series (Figure 
1) of tetrapeptide natural products revealed more modules than amino acids present in the 
structure.  In vivo studies showed that all of the synthetases were active and the group 
postulated that the seemingly extra A-PCP didomains were used to regulate building 
block biosynthesis, specifically 3-hydroxy-6-chlorohistidine biosynthesis.  This natural 
product also contains 5-hydroxy-2-aminopentanoic acid for which the biosynthetic genes 
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have not been identified and a hydroxy pipecolic acid derived from L-Lys.17  The timing 
of hydroxylation of these building blocks is not currently known and may happen as the 
building blocks are synthesized or after the peptide is released.18-21  Further studies of this 
pathway should help to assign roles to each of the genes in the cluster. 
Another example of building block biosynthesis utilizing PCP tethering can be 
seen in the pathways to the cyclopropyl containing peptides coronatine and 
kutzneride.22,23,24  Each pathway begins with loading of L-Ile or L-allo-Ile into the 
dedicated PCP domain.  Subsequent chlorination at different positions provides the 
leaving group necessary to promote cyclopropyl ring formation.  Finally, a thioesterase 
cleaves the amino acid from the PCP domain to yield the free amino acids coronamatic 
acid and methylcyclopropylglycine (MeCPGly) that will be used by the NRPS.   
Other NRPs with unusual monomers include: pristinamycin IA, which contains a 
para-dimethylaminophenylalanine residue derived by at least four dedicated enzymes 
from chorismate;25 miraziridine A, which is one of only four natural products known to 
contain the aziridine moiety installed by an as yet unknown mechanism;26 and bacilysin, 
which contains the epoxycarbonyl side chain “warhead” anticapsin.27  With over 500 
known monomers found in NRPs, this discussion could continue for quite a while.  
Instead, the focus will be on the biosynthesis of the nonproteinogenic amino acids in the 
vancomycin family of antibiotics as a good overview of the interesting chemistry and 
enzymology often found in these pathways. 
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4.2  Biosynthesis of aromatic amino acids in the vancomycin family of antibiotics 
 Five of the seven amino acids that comprise the vancomycin core heptapeptide are 
nonproteinogenic amino acids.28  This family of compounds contains two !-hydroxy-Tyr 
(!-OH-Tyr) residues, two 4-hydroxyphenylglycine (HPG) residues, and one 3,5-
dihydroxyphenylglycine (DPG) residue.  All of these aromatic residues are involved in 
the aryl-aryl and aryl-ether crosslinks that impart the cup-like conformation necessary for 
biological activity.   
 
Figure 2:  Biosynthesis of HPG (A) and !-OH-Tyr (B) from vancomycin family 
The HPG residues are all found in the D configuration.29  Feeding studies showed 
that both L and D-HPG could be incorporated into the natural product.  Further feeding 
studies with labeled L-Tyr indicated that the aromatic ring of HPG is derived from Tyr 
and the C" of Tyr becomes the carboxylic carbon in HPG.30,31  Gene cluster analysis of 
the chloroeremomycin pathway revealed four open reading frames (orf) that together 
could convert prephenate to HPG (Figure 2a).32-34  Orf1 encodes a prephenate 
dehydrogenase (PD), which converts prephenate to 4-hydroxyphenylpyruvate.  Next, a  
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4-hydroxymandelate synthase (HmaS) decarboxylates and hydroxylates 4-
hydroxyphenylpyruvate to form S-4-hydroxymandelate utilizing an iron-dependent 
mechanism.34  The !-hydroxyacid of mandelate is converted by an FMN-dependent 4-
hydroxymandelate oxidase (Hmo) to the !-ketoacid of p-hydroxybenzoylformate. The 
final step is accomplished by the promiscuous transaminase HpgT, encoded by orf17, 
which catalyzes the transfer of the amino group of L-Tyr to p-hydroxybenzoylformate to 
yield L-HPG and replenish 4-hydroxyphenylpyruvate.33 
 One could envision formation of the "-OH-Tyr residue by a relatively simple "-
hydroxylation. However, the mechanism of this transformation still requires three 
enzymes (Figure 2b).32  CepK is an A-PCP didomain encoded by orf19 that selects, 
activates, and loads L-Tyr onto the PCP tethered phosphopanthetheine arm.  Next, the 
hemeprotein CepL uses NADPH to hydroxylate at the " position.35-37 Finally, the 
thioesterase CepJ cleaves the amino acid from the PCP domain.37  This three-enzyme 
cassette allows for a small portion of the pool of the L-Tyr to be selectively hydroxylated 
without depleting the stock needed for other bioprocesses.  Chlorination of the "-OH-Tyr 
occurs at while the residue is tethered to the assembly line and before the aryl 
crosslinking events via on assembly tailoring as discussed previously.38-42 
 The final nonproteinogenic amino acid found in the vancomycin family of 
antibiotics is DPG.  Initial feeding experiments showed that DPG was not derived from 
any proteinogenic amino acid, but instead originated from acetate suggesting a polyketide 
synthetase assembly.30,31,43   A gene homologous to the chalcone synthase of plant 
flavonoid biosynthesis was found at orf27 adjacent to three crotonase superfamily 
members (orf28-30).32  Expression of the corresponding proteins in E. coli established 
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orf27 as the type III PKS DpgA, which utilizes four units of malonyl-CoA to create a 
linear polyketide and promote decarboxylation and cyclization.  DpgB and DpgD were 
found to accelerate the rate of formation of 3,5-dihydroyphenylacetyl-CoA (DPA-CoA) 
by 30 fold in an in vitro assay.44,45  DpgC was found to convert this acyl-CoA to 3,5-
dihydroxyphenylglyoxalate, a transformation which necessitates a four electron oxidation 
at the methylene carbon and cleavage of the thioester bond to release CoA.45  The final 
transamination step in DPG biosynthesis is accomplished by HpgT (Figure 3).44,45   
 
4.3  Preliminary biochemical studies of DpgC 
Interestingly, solutions of DpgC failed to show any UV/vis absorbance to indicate 
the presence of a metal or cofactor. Additionally, atomic absorption analysis showed that 
only trace metals (less than 2 mol %) were present, and addition of the metal chelator 
EDTA failed to inhibit the DpgC reaction.  These results pointed to DpgC belonging to a 
very limited group of cofactor independent oxygenases. 45 
 
Figure 3:  Biosynthesis of DPG 
 Anareobic incubations of DpgC with its substrate DPA-CoA showed no product 
formation.45,46  However, MS analysis of the same anaerobic reaction in D2O showed that 
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the both !-protons at the site of oxidation were exchanged with deuterium at rates of 14.2 
min-1 for the first exchange and 3.0 min-1 for the second (Figure 4).46  This result suggests 
that the first step towards oxidation is formation of a resonance stabilized carbanion at the 
C2 position that can be reprotonated in the absence of O2.  The consumption of O2 was 
monitored during the enzymatic reaction using an O2 electrode: one molecule of O2 was 
consumed for every molecule of DPA-CoA that was converted to product.  Additional 
assays in which superoxide dismutase and catalase were added to incubations of DPA-
CoA and DpgC failed to show any leaking of superoxide or hydrogen peroxide during the 
catalytic reaction.46   
 Determination of the origin of the two additional oxygen atoms found in DPGX 
was not trivial.  The !-ketone oxygen of the product would be exchanged with solvent 
due to reversible formation of the corresponding geminal diol.  Incubations of 18O2 
followed by HPLC and incubation in H216O or H218O and ESI-MS analysis indeed showed 
that this oxygen was derived from the solvent.  However, these analyses still showed a 
M+2 mass shift indicating that one of the carboxylate oxygens was also derived from O2.  
This suggested that DpgC was a dioxygenase, which was verified by in situ reduction of 
the ketone with NaBH3CN yielded 80% of a product with a M+4 mass shift and 20% of a 
product with a M+2 mass shift.  The 20% discrepancy was shown to be due to partial 
exchange of the oxygen before reduction and was confirmed by assays with 16O2/H218O 
which showed ~18% of the M+2 product.46  
 Analysis of the primary amino acid sequence of DpgC did not reveal any 
predicted binding sites for metals or cofactors.  DpgC falls into the crotonase 
superfamily, which is diverse, but is not known for oxygenase activity.  Crotonase 
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superfamily members have a conserved repeated !!" motif and a conserved pair of 
backbone amides, which provide an oxyanion “hole” to stabilize enolate intermediates 
formed during an enzymatic reaction.47 
!
Figure 4:  Anaerobic incubations of DpgC in D2O show rapid enzyme mediated exchange of the " protons 
with solvent46 
4.4  Oxygen activation by metals and cofactors 
Very few enzymes have been identified that can utilize molecular oxygen without 
activation by a metal or cofactor.48  None of the known enzymes show any significant 
sequence homology to DpgC.  Typically, oxidases and oxygenases require a metal or 
cofactor to aid in reduction of oxygen to an activated species, which can then react with 
the organic substrate.  Most dioxygenases use either heme or nonheme Fe species for 
oxygen activation.49-53  For example, homoprotocatechuate 2,3-dioxygenase (HPCD) was 
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crystallized in the presence of a weak substrate 4-nitrocatechol (4-NC), which trapped 
different oxidative states of the Fe center in three of the four active sites of the tetramer 
(Figure 5).  This enzyme binds Fe (II) through two His and one Glu residue.  After 
binding of the catechol substrate,  an electron is transferred from the substrate to O2 
through the metal center.  Direct radical recombination from superoxide to the substrate 
results in a peroxo intermediate.  The next step is a proposed Criegee-type rearrangement 
that would result in O-O and C-C bond cleavage and formation of a lactone intermediate.  
The remaining oxygen is bound to the iron center as hydroxide, and can act as a 
nucleophile to break the lactone bond to form the ring cleaved product.54  
!
Figure 5:  Active site geometry of HPCD with 4-NC and O2 bound to the Fe center (A) oxidized 
intermediate bound (B) product bound (C) Proposed mechanism of oxidative ring opening by HPCD (D).54 
 In addition to metals, organic cofactors can also activate molecular oxygen for 
catalysis.55  This is due to the unique properties of these compounds where the fully 
reduced state can readily donate electrons and the fully oxidized state can readily accept 
electrons.  In flavin chemistry, molecular oxygen is activated through the donation of an 
electron from the reduced cofactor, followed by bond formation at the C4 position to 
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yield a peroxyflavin.  This activated species can then attack the substrate at an 
electrophilic position (Figure 6c).56  In most cases, cleavage of the weak O-O bond results 
in formation of a hydroxyflavin species that will eliminate the second oxygen atom as a 
water molecule.   
!
Figure 6:  Overall Structure of MtmOIV with bound FAD and substrate PMB (A) with electron density for 
FAD and PMB shown in green (B) and the proposed mechanism with the role of FAD highlighted in blue.58 
Besides simple hydroxylations, flavin enzymes can also catalyze Baeyer-Villiger 
monoxygenations. MtmOIV is an important enzyme involved in the biosynthesis of the 
polyketide anticancer compound, mithramycin.57 The high-resolution structure MtmOIV 
was recently solved in the presence of its substrate premithramycin B (PMB).58  The 
electron density maps clearly show binding of FAD and PMB poised for the reaction with 
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oxygen (Figure 6).  Despite the hydrophilic character of the substrate, the binding pocket 
contains many hydrophobic residues especially near the site of oxidation.  A few water 
molecules create hydrogen bond bridges between FAD and PMB.  Nucleophilic attack of 
the peroxyflavin on the substrate ketone followed by a Criegee rearrangement leads to the 
PMB-lactone product (Figure 6).57 
!
Figure 7:  Left- Active site configuration of Hod with substrate QND (A) product NAA (B) and chloride 
ion possibly occupying O2 binding site (C). Right- Proposed mechanism of Hod.48 
4.5  Cofactor independent dioxygenation in anthranilate metabolism 
  Of the few cofactor independent oxygenases that have been characterized, two 
represent dioxygenases responsible for anthranilate degradation in bacteria (Figure 7).48 
1H-3-hydroxy-4-oxoquinaldine 2,4-dioxygenase (Hod) and 3-hydroxy-4-(1H)-quinolone 
2,4-dioxygenase (Qdo) share 37% sequence identity and belong to the !/"-hydrolase 
superfamily.  This family is characterized by a conserved catalytic triad of Ser/His/Asp 
that is necessary for hydrolase and serine protease activity.59  In the case of Hod and Qdo, 
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the triad is predicted to play a role in substrate binding, with the Ser possibly stabilizating 
the oxyanion intermediate.  Upon substrate binding, deprotonation results in a resonance-
stabilized anion, which is predicted to donate an electron to molecular oxygen to form the 
caged radical pair.  Radical recombination results in the formation of a peroxy 
intermediate, which can then attack the C2 carbonyl carbon to form a five-membered 
endoperoxide ring.60  Collapse of the weak O-O bond results in the loss of carbon 
monoxide and product formation (Figure 7).61  With little sequence and predicted 
secondary structural similarity among the characterized cofactor independent oxidases 
and oxygenases, it is proposed that each enzyme evolved through independent paths.  The 
sole requirement of these enzymes seems to be binding and stabilization of a substrate 
carbanion.  Additional studies are necessary to identify the determinants of O2 binding. 
 
4.6  Structure determination of apo DpgC 
 Structural investigations of DpgC were initiated in our lab by Dr. Paul Widboom 
and Dr. Elisha Fielding.  First, several DpgC homologs from the various vancomycin and 
teicoplanin producers were expressed, purified, and subjected to high-throughput crystal 
screening.  Each of these homologs shared ~70% identity and 80% sequence similarity 
suggesting that any single structure would represent all of the related proteins.  
Conditions in which the DpgC homolog from the A47934 cluster crystallized where 
identified and optimized.  A native data set in the R3 space group was collected to 2.21Å.  
Initial attempts to solve the phase problem using heavy atom soaking with Hg and Pt 
based salts failed to yield sufficient anomalous signal.    Production of protein containing 
selenomethionine yielded protein that crystallized under the same conditions as the native 
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protein; however, X-ray diffraction analysis revealed poor data quality and possible 
twinning.   This DpgC homolog contained ten total methionines and it was postulated that 
either the large Se atoms or oxidized Se was disrupting proper crystal contacts.  Mutation 
of three non-conserved methionine residues to leucine alleviated this issue.  This resulted 
in crystals with sufficient anomalous signal to solve the phases and build a model into the 
resulting electron density maps.   
 This apo-DpgC structure contained a total of four monomers, each of which forms 
a trimer through symmetry operations.  The C-terminal portion, which had sequence 
homolog to the crotonase superfamily, also had secondary structural similarity.  The N-
terminal third of the protein had no sequence homology to known proteins and contained 
a novel fold.  Two of the four monomers fit well into the electron density maps, with the 
other two showing poorer fitting.  However, even the best fitted monomer could not be 
fully built due to weak electron density surrounding the predicted active site.  Given the 
large size of the CoA tethered substrate, the active site residues could be occupying 
multiple low energy conformations within the crystal thus leading to the weak density 
when averaged.  The inclusion of a substrate mimic was predicted to restrict the motion 
of these residues and result in stronger electron density within the active site. 
 
4.7  Co-crystal structure of DpgC with bound substrate analog 
 About 4% of all enzymes employ CoA tethered substrates.  Dr. Ye Liu in our lab 
set out to create a CoA analog that could be used to study the structure and mechanism of 
DpgC, in addition to the vast array of other CoA utilizing enzymes.62   She used a 
chemoenzymatic approach, which mimics the natural biosynthesis of CoA in E. coli, to 
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replace the terminal thiol of CoA with a primary amine.  This compound is designated 
amino-CoA. Since the publication of the synthesis of amino-CoA in 2007, a CoA 
precursor, pantothenic acid has become commercially available which has simplified this 
synthesis.  The synthesis of this compound and it’s coupling to DPA is shown in Figure 
8.   
!
Figure 8:  Solution phase synthesis of amino-CoA and coupling to DPA 
 Co-crystallizaion of DPA-amino-CoA with DpgC under a new set of conditions 
resulted in crystals that diffracted to 2.4 Å.  The new co-crystal structure belonged to 
space group P21212 and had two trimers in the symmetric unit (figure 9).63 The phases  
!
Figure 9:  Overall structure of DpgC with trimer shown on left and different views of monomer shown 
center and right.  DPA-amino-CoA is shown in red sticks and the C-terminal portion homologous to other 
crotonase members highlighted. 
were solved using the partially complete apo model.  The electron density throughout one 
of the trimers was strong, and the positions of active site residues could be identified 
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thanks to the bound substrate mimic (Figure 10c).  However, density for the second 
trimer could not be interpreted for building.  The DPA-amino-CoA was bound in an 
extended conformation with the adenosine ring bent back so that hydrogen bonding could 
occur between the adenosine N6 and N7 and the amide proton and carbonyl of the 
pantoate portion of CoA.  A similar binding conformation has been seen in other 
crotonase structures.  A buildup of negative charge on the DPA portion of the molecule is 
imparted through hydrogen bonding from the DPA 3-OH to Glu189 and a charge 
interaction from 3-OH to Arg254 (Figure 10a).  Additionally, the 5-OH forms a water 
bridge with Glu255.  No catalytic base was present to abstract the !-proton to form the 
enolate, however, given the buildup of negative charge and the presence of the oxyanion 
hole (Ile235 and Gly296), this proton should be acidified to allow for deprotonation by 
the ordered water network anchored by Gln299.  In the structure, orphan electron density 
was identified adjacent to the site of oxidation that was postulated to be bound molecular 
oxygen.  This density was clearly larger than can be explained by an ordered water and 
was located within a hydrophobic pocket that would exclude any cations that may have 
come from the crystallization solution.   
!
Figure 10:  DPA-amino-CoA binding to DpgC active site residues Arg254, Glu189, and Glu255 (A), 
backbone amides that create oxyanion hole (B), electron density corresponding to DPA-amino-CoA, O2, 
and ordered waters (C), and surface representation of DpgC with DPA-amino-CoA in sticks and O2 as 
spheres (D). 
 Given this structure, a mechanism of dioxygenation was proposed (Figure 11).  
The pro-R !-proton of DPA-CoA is abstracted by the water anchored by Gln299 to form 
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an enolate.  This enolate is stabilized by the backbone amides of Ile235 and Gly296, and 
further negative charge buildup on the aromatic ring allows for single electron transfer 
from the substrate to molecular oxygen.  The substrate radical anion and superoxide can 
then undergo radical recombination at the ! carbon.  This produces a peroxy 
intermediate, which attacks the thioester carbonyl to release CoA and form a 
dioxetanone.  Removal of the remaining !-proton and cleavage of the O-O bond 
completes the DpgC reaction. 
 
Figure 11:  Proposed mechanism of DpgC 
4.8  Structure guided mutagenesis and alternate substrate assays 
 Given the structure and proposed mechanism, a series of mutations were made to 
probe the unique hydrophobic oxygen binding pocket.  The four residues that surround 
the density tentatively assigned as dioxygen were mutated to threonine to maintain the 
side chain size and to impart some hydrophilic character.  The kinetic competence of 
each mutant was then compared to wild type enzyme.  Each of the mutants showed 
significantly lower efficiency, this confirming the necessity for a hydrophobic oxygen 
binding pocket.63 
 The residues near the aromatic ring were mutated to determine which interactions 
were necessary for binding and substrate activation. Arg254 was mutated to Lys to 
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conserve the positive charge stabilization of Arg, but subtly change the binding mode.  
This mutant was found to have a kcat/Km of less than 1% of that of the wild type enzyme, 
which was surprising (table 1).  To verify this result and confirm that a significant 
structural change did not occur to cause this drastically lower efficiency, the Arg254Lys 
mutant was crystallized with DPA-amino-CoA.  The structure had an overall RMSD of 
0.5Å when compared to the WT, and the ammonium of Lys was well suited for hydrogen 
bonding to the 3-OH.  These results indicated that a unique interaction with the wild type 
Arg was important for substrate binding and turnover.  This mutation also resulted in a 
loss of hydrogen bond between Arg254 and Glu189, which may act together in substrate 
activation.  A Glu189Gln mutation lead to a decrease in catalytic efficieny to about 3% of 
that of the WT.  Therefore, Glu189 acts as a hydrogen bond acceptor for both Arg254 and 
the substrate 3-OH.  The mutation of Glu255Gln and Gln299Asn had only modest effects 
on enzymatic efficiency indicating that the most important residues for substrate binding 
are Arg254 and Glu189.64 
 
Table 1:  Kinetic analysis of active site mutants and alternate substrates.64 
 To further probe the role of Glu255 and Gln299, alternate substrates were tested. 
Kinetic constants were determined for phenylacetyl-CoA (PA-CoA) and 3- and 4-
hydroxyphenylacetyl-CoA (HPA-CoA) and the results summarized in Table 1.  As 
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expected, the 3-HPA-CoA was a substrate and had an overall catalytic efficiency of 65%.  
PA-CoA was a poor substrate mostly due to a higher Km of 100 !M.  The 4-HPA-CoA 
had an even higher Km of over 800 !M.64  Co-crystal structures of DpgC with PA-amino-
CoA and 4-HPA-amino-CoA were solved, however the density for the substrate analog 
was not clear, especially surrounding the aromatic ring, suggesting that multiple 
conformations may exist within the active site.  These results further cemented the role of 
residues Arg254 and Glu189 as essential for substrate recognition.  Only a single 
hydroxyl group at the 3 position on the ring is necessary to activate the substrate for 
catalysis.    
 
4.9  Probing the mechanism of DpgC using specially designed inhibitors 
 With a clear view of the catalytically important residues, we sought to create 
mechanistic probes that could trap reaction intermediates.  Previous work had 
demonstrated that the substrate was activated as an enolate prior to electron donation.  
The DPA-amino-CoA substrate mimic was shown to prevent enolization.  Dr. Paul 
Widboom designed a synthesis for an "-Fl substituted DPA-amino-CoA that would have 
a lower pKa for the remaining "-proton.  I assisted Paul in this synthesis to provide 
sufficient material for biochemical and structural characterization of this inhibitor.  The 
details of the synthesis are listed in Figure 12.  We demonstrated that DPA-Fl-amino-
CoA was a competitive inhibitor of DpgC with a Ki of 7.9 !M and an IC50 of 5.3 !M.  
However, an NMR assay in D2O failed to provide evidence for enolate formation. To 
investigate this unexpected result, a DpgC/DPA-Fl-amino-CoA co-crystal structure was 
obtained.  In this structure, the density that we had attributed to molecular oxygen in the 
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native structure was absent.  The lack of molecular oxygen in the binding pocket 
indicates the importance of a strictly hydrophobic environment as a slight perturbation of 
the electrostatics of the substrate resulted in loss of this density. 
!
Figure 12:  Left- Synthesis of Fluoro-DPA-amino-CoA;  Right- Comparison of the active sites of DPA-
amino-CoA bound DpgC (blue) and each of the active sites of the DPA-Fl-amino-CoA bound DpgC trimer. 
 As an alternative approach to lower the pKa of the !-proton without disrupting 
the electronic environment, we set out to create a new CoA analog in which the sulfur of 
the terminal thiol would be replaced with a carbon atom.  When coupled to DPA this 
would yield a ketone functionality that should first allow enolate formation and possible 
initial oxidation, but would not undergo hydrolysis to release CoA.  The configuration of 
CoA made this design quite complicated and required a modification to our synthesis of 
CoA.  Our retrosynthetic plan is displayed in Figure 13. Instead of coupling 1,2-
diaminoethane to pantothenic acid to form amino-panthetheine, we would instead 
proceed directly with the enzymatic steps starting with pantothenic acid. We successfully 
prepared the shorter CoA following the protocol for enzymatic modification of amino-
pantetheine.  However, DPA-amino-ketone portion proved much more difficult to obtain.  
First, 3-bromopropylamine was protected with acteonylacteone following a published 
procedure.  The product was then converted to the corresponding Grignard in the 
presence of Mg turnings and 1,2-dibromoethane.  Separately, methyl-3,5-
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dihydroxylphenylacetate was protected with TBS-Cl and converted to the corresponding 
Weinreb amide with N,O-dimethylhydroxylamine HCl and dimethylaluminum chloride.  
Coupling of the Weinreb amide to the Grignard should have yielded the desired protected 
ketone (Figure 13):  however, no product was isolated.  Extensive investigation into the 
cause failed to reveal the problem.  Reaction of the Weinreb amide with n-BuLi resulted 
in the expected alkylation, and reaction of the Grignard with benzaldehyde was also 
successful. An organolithium reagent was employed in lieu of the Grignard with no 
success.  Protecting groups were modified, but still no product was detected.  We then 
designed an alternative approach.!!
Figure 13:  Retrosynthesis of the ketone inhibitor"!
 In this approach, methyl-3,5-dihydroxylphenylacetate was protected with benzyl 
protecting groups, and a Claisen coupling with N-vinylpyrrolidone in the presence of 
NaH was performed.  While the desired coupling reaction occured, often significant 
amounts of undesired coupling products were also generated. A stepwise protocol was 
adapted in which the vinyl group was removed first with 1% HCl in EtOH, and the 
intermediate purified on silica before treatment with 6 N HCl.  The imine product was 
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induced to undergo selectively ring-openingto yield an amine that was protected with 
pyridine and di-t-butyl dicarbonate.  Only low yields of product were recovered for this 
step despite long reaction times.  Hydrogenolysis using 10% Pd/C in 1:1 MeOH/EtOAc 
successfully removed the benzyl protecting groups.  However, attempts to protect the 
ketone with ethylene glycol under various conditions failed to afford the expected 
product, and degration of the ketone was often apparent.  This carbon based CoA analog 
remains a target for synthesis in our lab.   
 
4.10  Probing the radical mechanism with cyclopropyl DPA analogs 
 To probe the electron transfer steps in DpgC, Dr. Elisha Fielding had designed, 
synthesized, and assayed cyclopropyl-PA-CoA substrates using NMR and HPLC 
methods (Figure 14).  Both assays failed to show the expected cyclopropyl ring opening 
that should have occurred following donation of an electron to O2.  Instead, hydrolysis of 
the thioester bond was apparent.   
!
Figure 14:  NMR and HPLC assays of 4-cyp-DPA-CoA with DpgC 
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To further probe this interesting result, I crystallized 4-cyclopropyl-PA-amino-
CoA with wild type DpgC.  The protein crystallized under conditions identical to the 
native DpgC/DPA-amino-CoA complex; however, after phasing, density modification, 
and refinement no density corresponding to the bound 4-cyp-PA-amino-CoA could be 
identified.  Additional LC-MS analysis of the remaining crystallization solution revealed 
that 4-cyp-PA-amino-CoA was no longer present.  A peak corresponding to amino-CoA 
was identified in addition to a peak for the dephospho version of 4-cyp-PA-amino-CoA. 
Dephospho-amino-CoA is a minor contaminant in all of our amino-CoA samples due to 
incomplete phosphorylation by DPCK and poor resolution of the two compounds by 
HPLC.  These results suggest that 4-cyp-PA-amino-CoA is a substrate for DpgC, but the 
dephospho version is not.  Identification of the product was complicated by the additional 
components present in the solution.  Further detailed MS assays are necessary to verify 
this as a substrate for DpgC and fully characterize the products.  Additional cyclopropyl 
probes including those with hydroxyl groups on the ring may provide a clearer picture of 
the reactivity of DpgC. 
 
4.11  Twinning of DpgC data sets 
 During the course of solving this DpgC structure I was able to consult with a 
colleague, Dr. Art Robbins, who provided ideas about our issues with building in the 
second trimer in the DpgC datasets.  Twinning results when crystal packing interactions 
are uniformly altered as shown in the figure 15.65   This is a rather common occurrence in 
protein crystallography, and as such we had previously tried to process the data with 
consideration for twinning; however, this failed to improve the electron density maps or 
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refinement statistics.  Eventually, we discovered that in addition to in fact being twinned, 
our data had also been consistently misindexed by the data processing software 
HKL2000.66   
!
Figure 15:  Examples of Twinning. (A) In non-merohedral twinning, the different crystal orientations align 
only at single surface and the diffraction patterns which result from each are shown and as the lattices do 
not align, the sum due to the twinned crystal results in a diffraction pattern shown. (B) In meohedral 
twinning, the lattices that result from the different orientations are identical so that the sum due to each 
orientation results in the same diffraction pattern, but with the spot intensity equal to the sum of the 
intensity from each orientation.65 
 According to the manual, when the symmetry dictated by the space group results 
in different indexing parameters, the parameters are chosen randomly.  This means that 
given many crystals and many data sets, if the indexing is not straightforward, then 
multiple unit cells will be given as solutions.  In our case, we consistently obtained 
parameters 140, 156, 171 Å in space group P21212 for all of the holo DpgC data sets.   If 
the data was processed in the lower space group P21, reindexed to 140, 171, 156 Å, and 
refined using the twin law h, -k, -l, then four trimers could be completely built into each 
unit cell (Figure 16).  The large number of atoms present complicated the processing and 
refinement as the files were very large.   I reprocessed each of the data sets, rebuilt, and 
refined to R values that were in line with the predicted values based on the resolution 
(Table 2).  Now that there were 12 total active sites, some minor differences were seen in 
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the density corresponding to bound waters and molecular oxygen simply due to splitting 
of previously averaged reflections. These changes had little effect on the overall trimer 
structure or the active site orientation.  Our previously proposed hypothesis is consistent 
with these revised structures.   !
 
Data Collection 
Resolution (Å) 2.4 2.5 2.5 2.5 2.8 2.9 2.6 2.69
Space group P21212 P21 P21212 P21 P21212 P21 P21212 P 21
Cell dimensions
    a, b, c (Å) 139.9 156.7 171.0 139.5 171.2 156.8 140.0 156.1 171.0 139.8 171.6 156.2 139.2 156.1 171.3 140.0 172.8 156.3 141.1 156.4 171.0  139.7 170.6 155.7
    !, ", # (°)  90, 90, 90 90, 90, 90 90, 90, 120 90, 90.11, 90  90, 90, 120 90, 90, 90 90, 90, 120 90 89.86 90
R merge 0.13 (0.577) 0.115 (0.412) 0.081 (0.324) 0.099 (0.412) 0.138 (0.544) 0.148 (0.895) 0.108 (0.622) 0.109 (0.566)
Redundancy 5.1 (4.4) 3.5 (3.0) 6.1 (5.2) 5.1 (4.8) 7.4 (7.1) 3.7 (3.4) 7.5 (7.3)
Completeness (%) 98.0 (96.7) 98.0 (93.6) 99.2 (96.4) 98.7 (94) 98.9 (98.8) 88.7 (87.3) 100 (100) 99.44 (95.39)
I/$I 15.5 (2.55) 10.16 (2.09) 22.9 (3.4) 13.6 (2.81) 18.2 (4.1) 6.9 (1.10) 15.09 (3.20)
Refinement
No.  reflections 128559 249392 128431 251900 91225 145753 115869 201323
R-work 0.328 0.179 0.336 0.187 0.339 0.169 0.352 0.1698
R-free 0.356 0.229 0.362 0.229 0.344 0.223 0.3763 0.226
No. atoms
    Protein 9797 39100 10154 38952 9846 38632 9520 39112
    ligands 180 708 708 708 172 708
    water 225 2358 675 143 3009
Rms deviations
    bond lengths (Å) 0.008 0.007 0.029 0.008 0.032 0.004 1.509 0.004
    bond angles (°) 1.48 0.97 1.9 1.11 2.1 0.83 0.007 0.86
Native Complex DPA-Fl-amino-CoA Val425Thr Ala319Cys
Table 2:  Crystallography data collection and refinement statistics. 
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4.12  Probing the O2 tunneling paths in DpgC 
 In addition to studying the direct binding of dioxygen to the hydrophobic pocket, 
we sought to identify other residues that are important for allowing oxygen to enter the 
active site.  Modeling of the diffusion of small ligands into protein structure has become a 
useful tool.67-72  In collaboration with the group of Professor Adrian Roitberg at UF, we 
performed molecular dynamics simulations to identify several probable pathways for 
molecular oxygen to enter the active site.   
In order to obtain useful information from these time intensive simulations, we 
had to derive a useful starting model.   DpgC is a large enzyme that forms a hexameric 
structure in solution.63   Simulations with a structure this large would be very time 
intensive.  Therefore, we performed short simulations to identify the minimal unit 
required to identify the oxygen paths.  We used monomer, trimer, and hexamer models 
Figure 16:  Configuration in P21 unit cell of wild type DpgC.  Each monomer in each trimer is colored 
differently to illustrate the symmetry.  On the left, two trimers are stacked to form the hexamer and on the 
right two other trimers create hexamers with their symmetry mates. 
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all derived from the native DpgC crystal structure.  In all of our structures, many of the 
C-terminal residues couldn’t be built in do to weak density. This isn’t an uncommon 
phenomenon in crystal structures, in which often N- and C-terminal residues are too 
mobile to be seen within the electron density maps.  As these residues are close to the 
substrate binding pocket and one of the predicted oxygen paths to the active site, these 
residues were added to our structure and the resulting model was energy minimized.  
Oxygen was placed within the active site and tracked during short MD simulations to see 
the paths oxygen followed to escape to bulk solvent.73,74  Our assumption is that paths of 
entry and exit would be shared.  These simulations indicaed that the hexamer model was 
required to yield reproducible results.  Oxygen was placed within each of the six active 
sites and tracked over 100 ns of MD simulation.  This was repeated five times.  
Additionally, simulations with a high concentration of O2 in the solvent surrounding the 
hexamer were performed for 60 ns and repeated five times.    
!
Figure 17:  Pie charts depicting the frequency of O2 entry and escape by the different tunnels and graphical 
depiction of the tunnels. 
 The longer simulations with the hexamer model and bound substrate revealed four 
pathways of oxygen escape and entry with different frequencies.  As seen in Figure 17, 
the most frequent paths followed along the ligand via paths L1 and L4. Additionally, an 
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upper path (U1) and side path (S1) were identified.   We devised a series of mutants to 
probe each of these paths, and simulations were performed to ensure these mutations 
would not drastically alter the protein structure.  Of all the mutants analyzed, we decided 
to create a total of ten for in vitro testing to verify the computational results.  A summary 
of the mutants can be found in the table 3.  We also chose to create a truncated construct 
of DpgC to reflect only the residues that were built into our structure.  To date, we have 
successfully completed the cloning of 9 of these constructs.  We expressed and purified 
each of the mutants and have begun in vitro characterization.  
!!
Table 3: Summary of O2 tunnel mutants MD simulations. Mutants that were stable and did not change the 
probability of diffusion through other pathways are shown in bold. Mutants that are underlined are stable 
but may display unexpected behavior. 
 To establish that our mutants are active and that the specific mutations we created 
do not disrupt substrate binding, we performed the standard DNTB assay to determine the 
kinetic parameters for each mutant.  We also used ITC as a way to judge substrate 
binding independent of the enzymatic reaction.  To do this, we titrated each of the 
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mutants with DPA-amino-CoA to ensure each mutant could bind this compound.  For this 
approach, we assumed that the binding of the inhibitor would mimic binding of substrate.  
To address oxygen binding within the mutants, we first attempted to use membrane inlet 
MS to monitor oxygen consumption.  However, establishing accurate and stable oxygen 
concentrations in this system was difficult.  We instead used an oxygen sensor, which 
could be used on a sealed cuvette.  Under these conditions, the oxygen concentration 
could be monitored directly and reliably.  These experiments are currently underway.  A 
summary of all of the data collected for each of our mutants is shown in Table 4.  We 
have also identified a few mutants of interest that we will crystallize with the inhibitor in 
order to solve the structure and further validate the biochemical data. 
!
Table 4:  Summary of DpgC mutant DTNB kinetics with DPA-CoA and Kd determination by ITC with 
DPA-amino-CoA. 
4.13  Conclusions and Future Directions 
 Our work on DpgC has provided structural evidence for cofactor independent 
dioxygenation and has allowed for a proposed mechanism involving direct electron 
transfer from the activated substrate to dioxygen.  This enzyme utilizes a hydrophobic 
pocket to bind molecular oxygen near the site of substrate oxidation.  Once superoxide 
has formed, radical recombination creates a peroxide intermediate which attacks the 
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thioester and releases CoA.  Final deprotonation of the remaining !-proton and oxygen-
oxygen bond cleavage results in product formation.   
 We have identified residues important for DPA-CoA and O2 binding and 
enzymatic activity.  We have solved a long standing question about the ‘missing trimer’ 
in our initial P21212 DpgC structures by reprocessing the data in a lower space group 
with reindexing and refinement with twinning.  We are currently studying the various 
solvent channels that allow oxygen into the active site through mutagenesis and kinetic 
assays.  Further work on DpgC should focus on the synthesis and assays of additional 
cyclopropyl substrate mimics to probe the radical mechanism.  Additionally, altered 
substrates may be synthesized, which contain the 3-OH found to be necessary for 
catalysis, but altered substitution at the 5 position to produce analogs that could be 
incorporated to create vancomycin analogs. 
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Materials and Methods 
Preliminary Synthetic Protocol for new CoA analog 
 
Methyl-3,5-dibenzyloxyphenylacetate75 (A) To a solution of methyl-3,5-
dihydroxyphenylacetate (0.98 g, 5.2 mmol) in 25 mL acetone was added 4 eq. K2CO3 
(2.84 g, 20.5 mmol) and 4.5 eq. benzyl bromide (2.80 mL, 23.6 mmol).  The mixture was 
allowed to reflux with stirring overnight.  The reaction was cooled, gravity filtered, and 
washed with ethyl acetate.  The combined organic layers were concentrated and purified 
on silica with 6:4 hexanes: ethyl acetate.  Yield of A 1.67 g, 86 % as fine, white powder. 
1H NMR (CDCl3, 500MHz) ! 7.30-7.37 (m, 10H), 6.52 (s, 3H), 4.95 (s, 4H), 3.61 (s, 3H), 
3,50 (s, 2H). 
13C NMR (126 MHz, CDCl3) ! 171.70, 160.06, 136.87, 136.14, 128.58, 127.99, 127.56, 
108.52, 100.85, 70.02, 52.04, 41.40. 
 
 
3,5-dibenzyloxyphenylacetyl-1-vinylpyrrolidin-2-one (B)76 To 20 mL dry THF was 
added NaH (60 % in mineral oil) (0.26 g, 6.6 mmol) and 1-vinyl-2-pyrrolidinone (518 
"L, 4.9 mmol).  This mixture was brought to reflux then was added 7 "L MeOH in 5 mL 
THF.  The ester A (1.76 g, 4.9 mmol) in 10mL THF was added via addition funnel over 2 
HO
OH
O
O
O
O
OBn
BnO
Chemical Formula: C9H10O4
Exact Mass: 182.0579
Molecular Weight: 182.1733
A: C23H22O4
Exact Mass: 362.1518
Molecular Weight: 362.4184
O
O
OBn
BnO
A: C23H22O4
Exact Mass: 362.1518
Molecular Weight: 362.4184
O
OBn
BnO N
O
B: C28H27NO4
Exact Mass: 441.1940
Molecular Weight: 441.5183
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hr.  The mixture was allowed to reflux with stirring overnight.  The reaction was cooled, 
quenched with 1.34 eq. 20 % acetic acid and allowed to stir for 10 minutes.  The mixture 
was then diluted with brine and extracted with DCM.  The combined organic layers were 
concentrated in vacuo and purified on silica with 1:1 hexanes: ethyl acetate.  Yield B 0.94 
g, 44 %. 
1H NMR (CDCl3, 400MHz) ! 7.30-7.44 (m, 10H), 7.01-7.08 (dd, 1H), 6.54 (s, 3H), 5.03 
(s, 4H), 4.43-4.54 (dd, 2H), 3.95-4.11 (q, 2H), 3.72-3.76 (q, 1H), 3.38-3.57 (m, 2H), 
2.53-2.62 (m, 1H). 1.94-2.02 (m, 1H). 
13C NMR (126 MHz, CDCl3) ! 202.16, 168.28, 160.27, 136.91, 135.87, 129.28, 128.68, 
128.66, 128.07, 127.66, 109.02, 108.19, 101.31, 95.95, 77.41, 77.16, 76.91, 70.20, 70.15, 
53.90, 49.70, 43.16, 19.26. 
ESI-MS [M+H]+ Theoretical 442.19, Experimental 442.19. 
 
 
3,5-dibenzyloxyphenylacetylpyrrolidin-2-one (C)77 Compound B (0.19 g, 0.43 mmol) 
was to 13 mL 1% HCl in EtOH.  The mixture was slowly brought to reflux and allowed 
to reflux with stirring for 4 hr.  The reaction was cooled, concentrated in vacuo, the 
residue dissolved in 10 mL ethyl acetate, and washed with brine.  The organic layer was 
concentrated and purified on silica with 3:1 ethyl acetate: hexanes.  Yield C 0.16 g, 90 %. 
1H NMR (CDCl3, 500MHz) ! 7.29-7.47 (m, 10H), 6.53 (s, 3H), 5.02 (s, 4H), 3.96-4.08 
(dd, 2H), 3.57-3.60 (q, 1H), 3.28-3.43 (m, 2H), 2.58-2.64 (m, 1H), 2.01-2.09 (m, 1H). 
O
OBn
BnO N
O
B: C28H27NO4
Exact Mass: 441.1940
Molecular Weight: 441.5183
O
OBn
BnO NH
O
C: C26H25NO4
Exact Mass: 415.1784
Molecular Weight: 415.4810
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13C NMR (126 MHz, CDCl3) ! 202.93, 173.95, 160.16, 136.85, 128.58, 127.99, 127.59, 
108.97, 101.07, 70.06, 52.52, 49.70, 40.41, 22.52. 
HR-MS [M+H]+ Theoretical 416.1856, Experimental 416.1857.  
 
 
5-(3,5-dibenzyloxybenzyl)-3,4-dihydro-2H-pyrrole (D)76 Compound C (0.062 g, 0.15 
mmol) was added to a clean round bottom flask followed by 6 N HCl.  The mixture was 
slowly brought to reflux and allowed to stir at reflux for 2 hr.  The reaction was then 
cooled, diluted with dH2O, flash frozen with liq. N2, and lyophilized.  Yield D 20.4 mg, 
37 %. 
1H NMR (CD3OD, 500MHz) ! 7.02-7.26 (m, 13H), 6.32 (s, 1H), 3.93-4.04 (m, 2H), 3.53-
3.55 (m, 2H), 2.18-2.21(m, 2H), 1.59-1.63 (m, 2H). 
 
 
tert-butyl (5-(3,5-dibenzyloxy)phenyl)-4-oxopentyl)carbamate (E) In a clean, flame 
dried flask was combined 5 eq.  ditertbutyldicarbonate and 5 mL anhydrous MeOH.  This 
solution was then added dropwise to a solution of 12 eq. pyridine in 5mL anhydrous 
MeOH.  After 10 minutes of stirring at room temperature, a solution of compound D (46 
mg, 0.13 mmol) in 5 mL anhydrous MeOH was added dropwise.  The reaction was 
slowly brought to reflux and allowed to stir at reflux for 2 hr.  The reaction was then 
O
OBn
BnO NH
O
C: C26H25NO4
Exact Mass: 415.1784
Molecular Weight: 415.4810
OBn
BnO
N
D: C25H25NO2
Exact Mass: 371.1885
Molecular Weight: 371.4715
OBn
BnO
N
D: C25H25NO2
Exact Mass: 371.1885
Molecular Weight: 371.4715
O
OBn
BnO
NHBoc
E: C30H35NO5
Exact Mass: 489.2515
Molecular Weight: 489.6026
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cooled, and concentrated in vacuo.  The residue was dissolved in ethyl acetate and 
washed with 5 % HCl.  The organic layer was concentrated and purified on silica with 
3:1 ethyl acetate to hexanes as the elutent.  Yield E  24  mg, 44 %. 
HR-MS [M+Na]+ Theoretical 512.2407, Experimental 512.2421. 
 
 
tert-butyl (5-(3,5-dihydroxy)phenyl)-4-oxopentyl)carbamate (F)75 Compound E was 
dissolved in 5 mL 2:2:1 ethyl acetate: hexanes: acetic acid in a clean round bottom flask.  
A few milligrams of 10 % Pd/C was added and the vessel flushed with nitrogen.  A 
balloon was filled with hydrogen gas and fitted with a small gauge needle to allow for 
slow bubbling of the gas through the reaction mixture.  The vessel was vented to allow 
for a complete hydrogen atmosphere.  The reaction was monitored on normal phase TLC 
with 3:1 ethyl acetate to hexanes and by reverse phase with 1:1 MeOH to H2O as elutents.  
The reaction was complete after 3.5 hr and was then concentrated in vacuo.   
1H NMR (CD3OD, 500MHz) ! 6.15 (s, 3H), 3.54 (s, 2H), 2.98 (t, 2H), 2.50 (t, 2H), 1.66 
(m, 2H), 1.42 (s, 9H). 
 
Synthesis of shortened CoA  
 Calcium Pantothenate (5 mM) was dissolved in 30 mL of 50 mM Tris pH 9.0, 20 
mM KCl, and 10 mM MgCl2.  Then 150 mg (total concentration 10 mM) Mg ATP was 
added with 10 mg purified PanK.  The reaction was incubated at 37 C for 30 min, then an 
additional 150 mg Mg ATP was added with 20 mg purified PPAT.  After incubation at 37 
O
OBn
BnO
NHBoc
E: C30H35NO5
Exact Mass: 489.2515
Molecular Weight: 489.6026
O
OH
HO
NHBoc
F: C16H23NO5
Exact Mass: 309.1576
Molecular Weight: 309.3575
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°C for 30 min, a last round of 150 mg Mg ATP (final concentration 30mM) was added 
with 15 mg purified DPCK.62  The reaction was allowed to continue at 37 °C for one 
hour, then was quenched with 7.5 mL 50 % TCA and set on ice for 10 min.  The 
denatured protein was removed by centrifugation at 3,500 rpm for 5 minutes and the 
supernatant purified by RP-HPLC with the following method: 0-16 min 0%B, 16-35 min 
0-98% B with product eluting at 27.8 min.  (Buffer A 0.1% TFA and buffer B 0.1% 
TFA/MeCN).  
ESI-MS [(M-H+Na)/2]- Theoretical 365.0, Experimental 364.9 
 
DpgC data processing and structure solutions 
 Native DpgC (11.8 mg/mL) was mixed with 10 eq. 4-cyp-PA-amino-CoAand 
allowed to incubate at 20C for 2 hr(final [DpgC] was 10.5 mg/mL).  This mixture was 
used to set up crystallization trials surrounded the optimium condition indentified with 
DPA-amino-CoA: 100 mM Sodium Citrate pH 5.6, 130 mM Ammonium Acetate, 16 % 
Peg 4,000.  Crystals appeared with 3 days and were transferred to cryoprotectant solution 
matching the well solution with 20% glycerol added.  These crystals were then flash 
frozen in liq. N2 and sent to BNL for data collection.  These raw diffraction images and 
those previously collected by Dr. Paul Widboom and Dr. Elisha Fielding were indexed, 
integrated, and scaled using HKL2000.66  Molecular replacement was performed using 
Phenix.phaser with the 2NP9 trimer or 2NP9 chain A as search model.78  Solutions were 
refined with Phenix.refine and rebuilt with Coot.79  All figures were made with 
MacPymol.80 
 
! 159!
Mutagenesis of DpgC O2 tunnels 
 Mutagenesis of DpgC O2 tunnel residues was performed using PCR methods 
(QuikChange Kit was not successful as the GC content in the mutant areas was >70%). 
The primers used for each site are listed in the table below with the mutant codon in bold.  
The protocol following protocol was used with pET-30b-DpgC as the template in each 50 
!L reaction: 10 !L 5X Q5 buffer, 1.0 !L 10 mM dNTPs, 2.0 !L 25 ng/!L template, 1.0 
!L of 100 !M forward and reverse mutant primers, 10 !L 5X Q5 enhancer, and 0.5 !L 
Q5 Hot Start Polymerase (NEB).  The PCR program used was as follows:  initial 
denaturing at 98 °C for 30 s, then 30 cycles of 98 °C for 30 s, 55 °C for 30 s, 72 °C for 
4.5 min, then final extention at 72 °C for 2 min.  Next, 1.0 !L DpnI was added to each 
reaction, mixed well, and incubated at 37 °C for 2hr.  Transformation was performed 
using of 3.7 !L of this mixture in 37.5 !L XL-10 Gold Ultracompetent cells plus 1.66 !L 
"Me solution.  Cells were grown in NZY+ media and plated on LB/kan plates.  Proper 
mutants were identified by DNA sequencing (GENEWIZ).   
Site Primer sequence 
I426AF 5’- GCCACGACGTGGCCGACAAGGTCCG -3’ 
I426AR 5’- CGGACCTTGTCGGCCACGTCGTGGC -3’ 
K428RF 5’- CCACGACGTGATCGACCGTGTCGGCCGATTCGGAG -3’ 
K428RR 5’- CTCCGAATCGGCCGACACGGTCGATCACGTCGTGG -3’ 
K428LF 5’- CCACGACGTGATCGACCTGGTCGGCCGATTCGGAG -3’ 
K428LR 5’- CTCCGAATCGGCCGACCAGGTCGATCACGTCGTGG -3’ 
F432WF 5’- GATCGACAAGGTCGGCCGATGGGGAGGGCGG -3’ 
F432WR 5’- CCGCCCTCCCCATCGGCCGACCTTGTCGATC -3’ 
F432YF 5’- GATCGACAAGGTCGGCCGATACGGAGGGCGG -3’ 
F432YR 5’- CCGCCCTCCGTATCGGCCGACCTTGTCGATC -3’ 
F432LF 5’- GATCGACAAGGTCGGCCGACTGGGAGGGCGG -3’ 
F432LR 5’- CCGCCCTCCCAGTCGGCCGACCTTGTCGATC -3’ 
L317AF 5’- GCCTACTTCAGCGCTCCCGCGGCGAAG -3’ 
L317AR 5’- CTTCGCCGCGGGAGCGCTGAAGTAGGC -3’ 
L361AF 5’- GAACCCGAGGCGCGCGCGCTGGTCGACGAGGTCGTG -3’ 
L361AR 5’- CACGACCTCGTCGACCAGCGCGCGCGCCTCGGGTTC -3’ 
A329LF 5’- CATCATCCCGGGAGCCCTGAACCTGCGGCTC -3’ 
L329AR 5’- GAGCCGCAGGTTCAGGGCTCCCGGGATGATG -3’ 
433TRUNCF 5’- CCGATTCGGATGACGGCCCCCCGCATGA -3’ 
433TRUNCR 5’- TCATGCGGGGGGCCGTCATCCGAATCGG -3’ 
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Expression of DpgC mutants 
 The appropriate vector was transformed into chemically-competent 
BL21(DE3)pLysS E. coli cells and plated on LB Agar containing 50ug/mL kanamycin.  
A single colony was used to inoculate 3 mL LB broth containing kanamycin and the 
culture incubated with shaking at 150 rpm at 37 °C overnight.  This culture was then used 
to inoculate 3 L fresh LB/kan, which was grown until OD600 = 0.6.  The temperature was 
reduced to 18 °C and equilibrated, then the cultures were induced with 100 !M IPTG, 
and expression continued overnight.  Cells were harvested by centrifugation at 3,500 rpm 
in a Beckman-Coulter Allegra 6R bench-top centrifuge for 20 minutes.  The supernatant 
was discarded and the pellet resuspended in lysis buffer (20 mM Tris pH 7.5, 500 mM 
NaCl) and lysed using a Microfluidizer M-110L.  The lysate was clarified by 
centrifugation at 10,000 rpm in the Beckman Coulter Allegra 25 bench-top centrifuge.  
The supernatant was applied to prewashed HisPur Ni-NTA resin (Thermo) and incubated 
with rocking on ice for 45 minutes.  The flow-through was collected and the resin washed 
with 3 x 30mL wash buffer (20 mM Trip pH 7.5, 500 mL NaCl, 10 mM imidazole) then 
eluted with 2 x 5 mL elution buffer (20 mM Tris pH 7.5, 500 mM NaCl, 250 mM 
imidazole).  The protein was then concentrated and buffer exchanged into 20 mM Tris 
pH 7.5, 50 mM NaCl using an Amicon Ultra centrifugal filter with a molecular weight 
cutoff of 10 kDa. Each mutant was purified further using HiTrapQ anion exchange FPLC 
with a linear gradient of 50-500 mM NaCl.  Fractions containing pure protein were 
concentrated to approximately 12 mg/mL and stored at 4 °C. 
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Spectroscopic DTNB assays 
Kinetic analysis for DpgC mutants was performed using the DTNB [5,5’- 
dithiobis(2-nitrobenzoic acid)] reporter assay with one modification: the concentration of 
DpgC mutants were 0.8 !M. To determine the kinetic parameters of DpgC for substrate 
DPA-CoA, a freshly prepared solution of DTNB (1 mM), Tris·HCl (250 mM), and 
increasing concentrations of DPA-CoA (1.0-40 !M) were incubated for 5 minutes and 
monitored in a UV-Vis spectrophotometer at 24 °C (Agilent 8453. Agilent Technologies: 
Santa Clara, CA) at 412 nm to determine the baseline rate.   Next, the enzyme was added, 
mixed, and the monitoring continued for an additional 5 min. The observed initial rate of 
absorbance increase was converted to initial reaction velocity V0 (ε412nm=13,600 M-
1·cm-1).   Concentration of DPA-CoA was plotted against initial rate and fitting was 
performed using Gnuplot to determine the kinetic parameters.   
 
ITC analysis of DpgC mutant binding of DPA-amino-CoA 
 Each DpgC mutant was added to the ITC cell at a concentration of 12.4 !M in 20 
mM Tris pH 7.5, 50 mM NaCl and titrated with a 100 !M solution of DPA-amino-CoA.  
The data was fit using Origin to determine binding parameters.   
 
O2 Depletion Assay using Membrane Inlet Mass Spectroscopy 
 Calibration of the instrument was performed by mixing O2 saturated and He 
degassed buffer solutions and monitoring for 3 min.  To perform assays, 100 !M DPA-
CoA was added to the reaction chamber containing the desired concentration of O2.  The 
mass output was monitored for 2 min, then the reaction was initiated by the addition of 2 
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!M DpgC and monitoring continued for 5 min.  Using this setup it was difficult to 
control the O2 concentration in the solution and above the solution.  Bubbling in O2 was 
attempted, but a consistent baseline could not be achieved.   
 
O2 Depletion Assay using Fluorescent O2 Probe 
 The NeoFox O2 probe was calibrated by mixing various amounts of O2 saturated 
and air equilibrated buffers and monitoring the O2 for 3 min.  DPA-CoA (100 !M) was 
added to the cuvette in buffer containing the desired O2 concentration and sealed.  The 
reaction was initiated by injecting the enzyme via syringe and the change in O2 
concentration monitored for 5 min.   
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